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Introduction - aims of this dissertation 
Adapted from: 
Alwayn IPJ, Buhler L, Basker M, and Cooper DKC. Immunomodulation strategies in 
xenotransplantation. In: Current and Future Immunosuppressive therapies following 
Transplantation. Sayegh M and Remuzzi G (Eds.). In press. 
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l.l THE NEED FOR XENOTRANSPLANTATION 
The outcome of clinical organ transplantation has dramatically improved since the 
introduction of cyclosporine (CyA) in 1979 and of other, more recently introduced, 
immunosuppressive agents such as azathioprine, mycophenolate mofetil, tacrolimus 
and sirolimus. Furthermore, due to more refined surgical techniques and peri operative 
management, prolonged survival of allografts is achieved. Due to its relative success, 
the inclusion criteria for potential organ transplant recipients have been broadened, 
resulting in an even greater shortage of donor organs. The number of patients with 
end-stage organ failure that die awaiting organ transplantation is steadily increasing, 
mainly because of the shortage of appropriate donor organs (1,2,3). Many clinicians 
and investigators believe that strategies directed at expanding the allogeneic donor 
pool will not be sufficient to resolve this problem of organ shortage~ In contrast, 
successful xenotransplantation - the transplantation of tissues and/or organs between 
two different species - has the potential of providing an unlimited supply of donor 
organs that would be available when required (4). However, major immunological 
barriers, as well as other important issues, at present prevent the implementation of 
xenotransplantation clinically (5). 
Concordant xenografts - tissues/organs transplanted between phylogenetically close 
species, i.e., mouse and rat, monkey and baboon, or nonhuman primate and human -
reject more vigorously than allografts. The mechanism of rejection is thought to be 
mediated by a combination of humoral and cellular factors. Conventional 
immunosuppressive therapy carmot guarantee long-term graft survival because of the 
potent induced antibody response in concordant xenotransplantation. However, with 
judicious pharmacological immunosuppressive therapy, the reported sunrival of 
concordant heart grafts in nonhuman primates exceeds 500 days (6). 
Discordant xenotransplantation - xenotransplantation between phylogenetically 
widely disparate species, i.e., guinea pig and rat, pig and baboon, or pig and human -
is characterized by the occurrence of hyperacute rejection (HAR) (7, 8). This type of 
12 
Introduction 
rejection, mediated in primates by preformed (natural) antibodies (directed against the 
Galal-3Gal (a-Gal) epitopes) (9), which activate complement, takes place within 
minutes to hours after transplantation (10). Histological examination of these rejected 
grafts reveals intravascular thrombosis and interstitial hemorrhage (11,12). 
It has recently become possible to overcome HAR through antibody and/or 
complement depletion or by utilizing organs from pigs transgenic for human 
complement regulatory proteins (8, 13, 14, 15). If HAR is successfully prevented, a 
delayed type of rejection termed acute humoral xenograft rejection (AHXR) occurs 
within days. Cellular infiltrates are invariably found throughout the xenograft, 
consisting of macrophages, NK cells, and monocytes (16, 17). Data suggest that this 
type of rejection is most probably antibody-mediated but complement-independent. It 
has thus far not been possible to overcome AHXR in the pig-to-primate modeL 
Survival of xenografts to date has generally been less than 30 days (I8, 19), and has 
not exceeded 99 days (\\t'hite DJG, personal communication). 
These major immunological differences notwithstanding, it is widely thought that the 
pig will be the most appropriate organ source (20, 21), as pigs have a number of 
advantages over nonhuman primates as a potential source of organs for humans 
(Table 1). Furthermore, pigs can be bred in specific pathogen-free environments, thus 
eliminating to a large extent the risk of transfer of disease from pig to human. Certain 
herds of miniature swine have fully documented :MHC antigens, which may facilitate 
certain manipulations aimed at the induction of tolerance in the recipient, and pigs 
may be genetically modified to become less immunogenic to humans. Finally, since 
pigs are currently being bred for human consumption, it is likely that the general 
public will be amenable to using pigs for human organ xenotransplantation. 
Many studies have been directed at attempting to understand the mechanisms of pig-
to-nonhuman primate xenograft rejection. Much progress in this field has been made 
in the last decade, although the pathophysiology of xenograft rejection has not yet 
been fully elucidated. This chapter will briefly summarize our current knowledge of 
the mechanisms involved in discordant xenograft rejection and describe the 
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techniques being explored to prevent rejection from occurring. Emphasis will be 
placed on our experience in the pig-to-nonhuman primate preclinical model. Various 
RELATIVE ADVANTAGES A~D DlSADVA~T AGES OF PIGS AI\D BABOO]'l;S AS 
POTE~TIAL SOURCES OF ORGANS A]'I;O TISSUES. 
Baboon !!g 
Availability Restricted Unlimited 
Breeding potential Poor Good 
Reproductive age 3-5 years 4-8 months 
Length of pregnancy 173-193 days 114 +/. 2 days 
Number of orupring 1-2 5-\2 
Rate of growth Slow Rapid 
Size of adult Qrgaus Inadequate Adequate 
Maintenance cost High Low 
Similarity 
Anatomical Similar Similar 
Physiological Very similar Less similar 
Immunological Close Distant 
Knowledge of tissue typing Limited Considerable 
(in selected herds) 
Expcrience with genetic engineering None Considerable 
Risk of transfer of infection (xenozoonosis) High Low 
Availability of specific pathogen-free animals No y~ 
Public opinion l'v1ixed More favorable 
methods of immunomodulation will be discussed, including i) those that deplete or 
inhibit complement, ii) phannacological immunosuppressive therapy aimed at 
suppression of both T and B cell function, iii) genetic engineering of the donor 
animal, and iv) the induction oftolerance and/or accommodation. 
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1.2 REJECTION OF XENOGRAFTS 
Hyperacute Rejection 
HAR is an antibody-dependant, complement-mediated process that occurs within 
minutes to hours after revascularization of the transplanted discordant xenograft. 
Perper and ~"JJJlan were among the first to describe this process in 1966 in the pig-
to-dog model (7). All nonprimate mammals, including the pig, express terminal 
Galal·3Gal oligosaccharides (aGal) as surface antigens on many ceUs. including the 
vascular endothelium (22, 23). In 1984 Galili et al. reported that humans possess 
natural antibodies with anti-aGal specificity (24), but it was not until 7 years later that 
Good et al. demonstrated that these antibodies (anti·aGal) playa major role in the 
HAR of pig xenografts in primates (9). Anti-aGal are of IgG. IgM. and IgA 
~'·;h:1as':-,.::::- ... l,,! '.'"'-·~)um for m .... 'H: .. :Uil ~j->'; o-F ~irculating natural anti-pig antibody in 
humans and 100% in baboons (24, 25. 26, 27, 28). IgM is thought to be the major 
contributor to HAR (29). Binding of these antibodies to the aGal epitopes on porcine 
tissue results in activation of complement through the classical pathway. This initiates 
a chain-reaction involving multiple complement components and leads to the 
formation of complexes, known as the membrane attack complex of complement, 
which causes lysis and opsonisation of cell membranes, resulting in rapid graft 
destruction. 
Acute Vascular Rejection 
Several methods have been developed to successfully prevent HAR, including 
extracorporeal immunoadsorption (EIA) of anti-aGal antibody, complement depletion 
or inhibition, and/or the use of pigs transgenic for human complement regulatory 
proteins. These approaches are discussed below. Once HAR has been averted, 
however, acute vascular rejection (AHXR) develops, most probably as a result of the 
development of high levels of high-affinity antibody directed against aGal and other 
pig epitopes (30). IgG seems to be the antibody subclass mostly responsible as 
increases in anti-aGal IgG of 100-300-fold have been documented after experimental 
pig organ and bone marrow transplantation in humans and nonhuman primates (31, 
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32). These induced antibodies initiate AHXR by mechanisms that appear to be 
independent of complement, although complement fractions may playa role (17,30). 
Cells, such as macrophages, NK cells, and monocytes are present in the rejected 
xenografts at the time of AHXR, suggesting that they may be important to the 
rejection process (16, 33, 34). Macrophages, in particular, play an important role in 
the production, mobilization, activation, and regulation of immune effector cells. 
They participate in the activation of B and T cells. They process and present antigens, 
secrete various cytokines and chemokines, and phagocytose apoptotic and necrotic 
cells as well as various pathogens. It is not clear, however, if these cells, as well as 
NK cells, playa direct role in mediating or effecting AHXR, or if they migrate to the 
graft as a result of the presence of antibody. 
\Vhatever the mechanism of AHXR, there is growing evidence that it is associated 
with a state of disseminated intravascular coagulation in the recipient, which may 
develop before histopathological evidence of AHXR is advanced (32, 35). This 
phenomenon will de discussed in more detail in chapter 7. 
Immunological Events following Antibody-Mediated Rejection 
Since it has to date not been possible to routinely avert AHXR, discussion of the 
immunological processes following AHXR is mostly hypothetical. However, in vitro 
and in vivo studies involving discordant xenogeneic cells or grafts have shown that 
pig tissues are also rejected by cellular (antibody-independent) mechanisms (36, 37, 
38, 39, 40). The transplantation of pig pancreatic islets may be a useful model in that 
these are transplanted in the absence of a vascular endotheliwn, and therefore do not 
express aGal. Nevertheless, porcine islets are rejected by a cellular mechanism in 
which macrophages and NK cells playa significant role. Although this model cannot 
be fully extrapolated to the transplantation of a vascularized organ, it seems likely 
that, if AHXR is prevented, a cellular form of rejection will take place in the 
vascularized organ. Furthermore, chronic rejection, e.g. graft atherosclerosis, is likely 
to develop early. 
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1.3 MODULATION OF THE XENOGENEIC IMMUNE RESPONSE 
HAR can be prevented by i) depletion/inhibition of anti-aGal, ii) depletion or 
inhibition of components of complement, or iii) the use of organs from pigs transgenic 
for human complement regulatory proteins. To date, it has not been possible to 
prevent AHXR in the pig-to-nonhurnan primate model. Several methods, largely 
aimed at depletion/inhibition of anti-aGal combined with prevention of production of 
induced antibody, are currently being studied. Since non-specific cells, such as 
macrophages and NK cells, appear to be important in the pathogenesis of AHXR. 
agents targeting these cells may also be essential in preventing AHXR. 
Present progress with these various therapeutic modalities are presented and discussed 
in this chapter. The necessity for, and current methods of, depletion and suppression 
of production of anti-aGal antibodies will be discussed in Chapters 3. 
Depletion or Inhibition of Complement 
In the 1960s, cobra venom was important m elucidating the activation of the 
complement pathway (41). Cobra venom factor (CVF) was purified and was found to 
activate the complement system as a functional analogue of C3b (42, 43). Similar to 
C3b, CVF can bind to factor B, but is approximately 5 times more stable than C3bBb 
and is resistant to decay acceleration and proteolytic inactivation (44). The 
administration of CVF therefore leads to continuous complement activation, resulting 
in depletion of one or more complement components. Complement depletion by CVF 
can prolong discordant xenograft survival from minutes to days, but AHXR 
eventually develops by complement-independent mechanisms (14, 45, 46, 47). 
Inhibition of complement activation can be achieved successfully by administering 
human soluble complement receptor 1 (sCR1). This leads to acceleration of the 
proteolytic cleavage of C3!C5-convertases, thus preventing development of MAC and 
proinflammatory cytokines. sCRI does not activate and deplete complement 
components and may therefore be less toxic than CVF. Administered alone, sCRl can 
also prolong discordant cardiac xenograft survival in the guinea pig-to-rat model to 32 
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hours (48) and in the pig-to-primate model to 7 days (49). When combined with CPP, 
cyc1osporine and steroids, survival of pig cardiac xenografts was further prolonged to 
a maximum of 6 weeks (50, 51). 
Genetic Engineering of the Organ-Source Pig 
To date, it has proven rather difficult to maintain depletion of anti-aGal antibodies in 
the recipient primate. A different approach would be to prevent expression of the 
aGal epitope on the vascular endothelial cells of the pig by genetic manipulation. It is 
currently not possible to create an aGal-knockout pig (i.e., to disrupt the 
al,3galactosyl-transferase gene (aGT) by homologous recombination, thereby 
preventing aGal expression) because pig embryonic stem cells are not yet available. 
Furthermore, studies in aGal-knockout mice indicate that the absence of aGal may 
induce expression of underlying 'cryptic' oliogosaccharide epitopes to which humans 
may have antibodies (52). However, several advances have been made in the field of 
genetic engineering and are discussed below. 
Transgenesis for human complement regulatory proteins 
Since complement activation in humans is regulated by membrane bound complement 
regulatory proteins, such as CD46 (membrane cofactor protein, MCP), CD55 (decay 
accelerating factor, DAF), and CD59, inducing expression of these human proteins in 
pigs to inhibit complement activation seems to be a logical approach. Complement 
regulatory proteins are largely species-specific, i.e., complement regulatory proteins 
expressed on porcine tissue do not modulate human complement and vice-versa. The 
creation of pigs transgenic for human complement regulatory proteins therefore seems 
desirable. \Vhite's group in C(lmbridge has successfully created pigs transgenic for 
hDAF. 'When organs from these pigs are transplanted into nonhuman primates, they 
are protected from HAR and, in association with intensive immunosuppressive 
therapy, graft survival of up to 99 days has been reported (White, personal 
communication). Median graft survival of life-supporting pig kidneys transplanted 
into cynomolgus monkeys is approximately 30 days and of pig hearts transplanted 
orthotopically into baboons about 15 days (18,19). Other groups have created pigs 
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transgenic for more than one human complement regulatory protein but with less 
prolonged graft survival (53), probably due to differences in the immunosuppressive 
protocol administered. 
Competitive glycosylation 
As it is not yet possible to create an aGal-knockout pig, alternatives have been 
proposed to decrease the aGal expression on donor pig organs. The introduction of a 
gene that would compete with aGT for its substrate, N-acetyllactosamine, is one such 
approach (54) (Figure 1). In vitro studies by Sandrin et a1. (55, 56) in COS cells 
demonstrated that competition takes place between aGT and a 1 ,2fucosyltransferase 
(aFT) in the Golgi apparatus for this substrate, and that aFT takes precedence, 
thereby resulting in a cell that expresses more H blood group antigen than Gal. COS 
cells simultaneously transfected with cDNA clones encoding for either aGT or aFT 
showed greater expression of the uFT-product (the H epitape) than the uGT-product 
Ct 1 ,3G alactosy Itra 0 sferase 
Gal~I·4GlcNAc-R -----fIt-- Galul-3Galf}I-4GlcNAc-R 
al,2Fucosyitransferase ~! ! ~ aGalactosidase 
Gal~I-4GIcNA~_R Galf}I-4GIcNAc-R 
I 0.1-2 
Figure L 
Natura! biosynthetic pathway for synthesis of the Gal epitope (Galal-3Gal), and methods by which this 
can be modified by transgenic techniques. Galactose is added to the N-acetyllactosamine (GaI131-
4GlcNAc) substrate by the al,3 galactosyltransferase enzyme to fonn Gala J -3Ga1. Gall31-4G1cNAc 
can also fonn the substrate for the H (0) histo-blood group epitope when the gene for the a 1,2 
fucosyltransferase enzyme is transgenically introduced. FurthemlOre, cleavage of Gala 1-3Gal occurs 
when the gene for the a-galactosidase enzyme is introduced. Modification of the natural pathway has 
been demonstrated in cells in culture and in aGal-knockout (aGal-negative) mice by transgenic 
techniques, but has not yet been successfully achieved in pigs. (Modified fTom Sandrin MS, et al. 
(123)). 
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(aGal) (56). Mice transgenic for aFT demonstrated a major decrease in aGal 
expression and reduction of reactivity of these cells when challenged with human 
serum (57). More recently, evidence has been presented that high-level expression of 
the H antigen on porcine cells reduces human monocyte adhesion and activation (58). 
It would be necessary, however, to ensure that all the aGal epitopes are replaced by 
the H epitopes, or the transplanted organ may still be susceptible to HAR or AHXR. 
It has therefore been proposed to add another gene, namely a-galactosidase, to the 
donor pig in addition to that for aFT (59). aGalactosidase removes terminal aGal 
rather than adding it, and would ensure that those aGal epitopes that are not 
competitively replaced with H epitopes by aFT are removed by a-galactosidase. 
Sandrin's group has provided data demonstrating a complete absence of aGal 
expression in cell cultures containing the genes for both aFT and a-galactosidase 
(60). 
Nuclear transfer 
Our knowledge of and ability to genetically manipulate embryonic and adult cells of 
large mammals has greatly increased in the last few years (61). The recent successful 
cloning of pigs by PPL Therapeutics (62) holds considerable potential for the field of 
xenotransplantation. Although the current cloned pigs are genetically unmodified, this 
technology may allow the cloning of pigs that are genetically altered to render their 
organs less susceptible to rejection by humans recipients. The technique by which 
PPL Therapeutics achieved this success, nuclear transfer, had already led to the 
cloning of the umuodified sheep, Dolly, in 1996 (61) and the genetically-modified 
sheep, Polly, in 1997 (63). In Polly, the gene encoding the human clotting factor IX 
had been inserted. 
Nuclear transfer entails the in vitro removal of the nucleus from an unfertilized egg, 
and its replacement with a nucleus removed from another cell of interest. This latter 
cell can be a normal, unmodified embryonic, foetal or adult cell or a cell in which the 
genome has been modified. The newly-created egg is initially cultured for a few days 
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to allow cell division to begin, and the developing embryo is then implanted into the 
uterus of a surrogate mother. The offspring is a (modified or umnodified) clone of the 
pig that donated the original nuclear materiaL The potential benefit for 
xenotransplantation lies in the possibility of deleting or inserting genes of interest in 
the genome before its transfer, and thus create a genetically-modified pig. Advantages 
over other methods of genetic modification are that (i) it does not require embryonic 
stem cells (that to date remain unavailable in pigs), (ii) it allows for the assessment of 
success of the genetic manipulation at an early (cellular) stage, thus negating the 
costly wait until the offspring is born (as is the case with current transgenic 
techniques), and (iii) it has the potential to produce an almost instantaneous herd of 
identical modified swine. 
In xenotransplantation, modification of the genome and nuclear transfer could, for 
example, enable the production of aGal-knockout pigs by deleting the gene for 
al,3galactosyltransferase in the npdeus before transfer, theoretically rendering the 
resulting pig's organs resistant to a human recipient's antibody-mediated immune 
response as discussed above. It remains uncertain, however, whether an aGal-
knockout pig will be viable as so much aGal is present in the pig that some 
authorities have questioned whether it may be essential to sustain life (64). 
Alternatively or additionally, certain protective genes might be inserted, e.g., those for 
one or more complement regulatory proteins, those known to be associated with the 
development of accommodation (65), as discussed below, or those that might promote 
thromboregulation (66), Physiologic barriers could also be surmounted, e.g., by the 
introduction of a gene responsible for the production of a human protein, enzyme or 
honnone (whenever the porcine equivalent is found not to function satisfactorily in 
primates). 
The technique of nuclear transfer will need considerable refinement and testing before 
its implementation into clinical xenotransplantation, but its recent successful 
attainment in pigs brings optimism for the future. 
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Accommodation 
Under certain circumstances, ABO-incompatible allografts or allografts in HLA-
sensitized recipients are able to survive despite the presence of circulating antibodies 
directed against detenninants on the grafted organ (67). This process has been tenned 
accommodation, and can be summarized as the absence of antibody-mediated 
rejection of a primary vascularized organ despite the presence of circulating 
antibodies that are potentially reactive with antigens on the vascular endothelium of 
that graft (68). The phenomenon has not yet been documented to conclusively occur 
in Gal-incompatible large animal models. Possible explanations for the phenomenon 
of accommodation have been proposed by Bach et al. (68) and are briefly reviewed. 
Firstly, the returning antibodies, i.e. the antibodies that are induced post-transplant 
following pre-transplant depletion, may be different in isotype, affinity, and/or 
specificity, and are thus unable to initiate rejection. Secondly, the surface antigens on 
the vascular endothelium may show subtle changes during the absence of natural 
antibodies, thus preventing recognition by the returning, induced antibodies. Finally, 
during the return of antibodies, the endothelial cells may adapt and either respond 
differently to these antibodies or become 'desensitized'. It has been proposed that, 
during accommodation, 'beneficial' genes are upregulated and 'detrimental' genes are 
downregulated (65). 
Induction of Tolerance 
Many investigators believe that the ideal method for avoiding both HAR and AHXR 
is to induce B cell tolerance. Additionally, if T cell tolerance were also induced, the 
subsequent cellular response would be avoided. This would prevent the complications 
associated with long-tenn pharmacological immunosuppressive therapy. Since 
tolerance can be defined as a state of permanent specific unresponsiveness to donor 
antigens (but not to other antigens) by the recipient in the absence of maintenance 
immunosuppressive therapy, immune responses to pathogens would be nonna!. Sachs 
and Sykes have developed tolerance in small and large animal allotransplantation 
models (31, 32, 69, 70). 
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Molecular chimerism 
One approach to the induction of tolerance is by gene therapy in an attempt to induce 
what has been termed molecular chimerism. For example, B cell tolerance might be 
achieved if the primate recipient could be induced to express the Gal epitope on its 
tissues, which might lead to the suppression of production of anti-Gal antibody. 
Autologous transplantation of bone marrow from aGal-knockout mice transduced ex 
vivo with the gene for agalactosyltransferase (aGT, the enzyme that leads to the 
production of the Gal epitopes) resulted in suppression of production of anti-a Gal and 
the achievement of B cell tolerance to aGal (71). Preliminary studies in baboons, 
however, demonstrated only transient expression of aGal following the infusion of 
transduced autologous bone marrow cells. The transduction efficiency of baboon bone 
marrow ceils is currently being optimized with the use of improved vectors and 
culture parameters. 
T cell tolerance might be achieved by the introduction into the recipient of a gene 
encoding a swine MHC (SLA) class II antigen. The presence of a donor-specific class 
II antigen in the recipient (following gene transduction of bone marrow cells) has 
been demonstrated to lead to tolerance to a kidney allograft in miniature swine (72), 
and its importance has been tested in the pig-to-baboon model (73). Ex vivo 
transduction of baboon bone marrow cells with an SLA class II gene of a specific 
MHC-inbred miniature swine genotype was performed. Autologous transplantation of 
these transduced cells led to detection of the transgene in blood and bone marrow, but 
the transcription was transient. Subsequent pig skin or organ grafts (from a pig 
matched to the trans gene ) were rejected within 8 to 22 days from an antibody-
mediated mechanism. In contrast to control baboons, however, the induction of IgG 
against non-a Gal antigens was prevented, suggesting prevention of a T cell response. 
Thymic transplantation 
Zhao et al. demonstrated that the transplantation of fetal pig thymus and liver tissue 
(as a source of hematopoietic cells) under the kidney capsule of thymectomized and T 
and NK cell-depleted mouse recipients can induce donor-specific tolerance and 
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restore immune competence (74). Furthermore, when donor-matched pig skin grafts 
were transplanted to these mice, permanent graft survival was achieved, whereas 
allogeneic skin grafts rejected within 26 days (75). These studies were expanded by 
Wu et a!., who demonstrated in vitro unresponsiveness fo llowing fetal porcine thymic 
tissue grafting in thymectomized, T cell -depleted baboons (76). Further studies are 
underway in this model. 
Figu re 2. 
Microscopic appearance (I OOx) of pig thym ic tissue 3 months after transplantation under the capsule of 
an autologous kidney. Kidney tissue can be seen at the right margin of the figure; nOle the complete 
reorganization of the thymic tissue, which allowed normal thymopoiesis. 
Our center is also involved with the induction of T cell tolerance by the 
transplantation of a vascularized thymic graft from the donor. Yamada et a!. have 
demonstrated in our MHC-inbred herd of pigs that autologous thymic ti ssue, when 
transplanted under the renal capsule, becomes vascularized, regenerates, and functions 
normally (77) (Figure 2). When these "thymo-kidney" composite grafts are 
transplanted across a full y-mismatched allogeneic barrier, in a T cell depleted and 
thymectomized recipient, they are able to induce T cell tolerance (78). If anti-aGal 
could be successfully depleted for a limited period of time, the transplantation of a pig 
thymokidney could potentially induce T cell tolerance in the pig-to-primate model. 
The problem of providing an anti-Gal-free environment that would allow T cell 
to lerance to develop, however, remains unresolved at the present time. 
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Figure 3. 
Thymic irradiation 
Whole body irradiation + 
AntiMthymocyte globulin 
Splenectomy + + Extracorporeal 
immunoadsorption 
-B -7 -6 -s -4 -3 -2 -1 0 
Days 
2 3 
Mycophenolate mofetil +/M 
Cyclosporine ... ---------4~~ Cobra venom factor 
~ 
AntiMCDl54 mAb 
Porcine Ilr3 and 
Porcine Stem cell factor 
Standard nonMmyeloab lative reg imen aimed at inducing immuno logical tol erance. The induction 
therapy fo r baboons cons ists ofa splenectomy on day -8, followed by whole body irradiation 150 cGy 
x2 on days -6 and - 5 to fac il itate engraftment of porcine ce lls. T cell depletion is achieved with 
anti thymocyte globulin on days - 3, -2, and - I and thymic irradiation 700 cGy on day -I. 
Extracorporeal immunoadsorption of antiMuGal Ab is perfonned on days -2, - I, and O. The 
maintenance therapy consists of mycophenolate mofetil at 110 mg/kglday by continuous iv infusion 
from days -6 to 21, complement depletion with cobra venom factor from days - I to 28, costimulatory 
bl ockade with antiMCD 154 mAb from days 0 to 14 at 20 mg/kg on alternate days, either with or without 
cyclosporine at 15 mg/kglday by continuous iv infusion. PBPC are transplanted on days 0, I, and 2 (not 
shown). Porcine growth factors f iLM) 400 JlglkgJday and stem cell factor 2000 Jlg/kg/day) are 
administered from days 0 to 21 by continuous iv infusion to promote engraftment of porcine cells. 
Mixed hematopoietic cell chimerism 
Another approach to inducing tolerance to a transplanted xenogeneic organ would be 
to first induce mixed hematopoietic cell chimerism between pig and primate (32). To 
induce this state in the pigMtoMprimate model, a combination of (at least temporary) (i) 
depletion or inhibi tion of anti-aGal, (ii ) depletion or inhibition of complement, (i ii) T 
cell depletion (and/or costimulatory blockade), and (iv) pig hematopoietic cell 
engraftment, would appear to be necessary. Our laboratory is involved in studies 
aimed at inducing mixed hematopoietic chimerism and thus a state of both B and T 
cell tolerance in this model. We infuse large quantities of cytokine-mobilized 
peripheral blood progenitor cells (approximately 2 - 4 x 10'0 cellslkg), obtained from 
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our MHC-inbred herd of miniature swine, into a pre-conditioned recipient baboon. 
Our current conditioning regimen consists of splenectomy, \VBI, thymic irradiation, 
anti-thymocyte globulin, MMF, CyA, CVF, anti-CDl54 mAb, and multiple EIAs 
(Figure 3). 
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Pig celt chimerism detected by flow cytometry in the blood of a baboon treated with our 
immunomodulatory regimen (see Figure 3) . Porcine PBPC were infused on days 0 - 2, during which 
up to 16% of the white blood cells in the baboon were of pig origin. From days 5 through 15 no pig 
cells could be detected, but on days 16 through 21 a pig monocyte population (stained with markers for 
pig (pan pig), pig CD9 (platelets, early B cells, activated T cells, and basophils), and pig MAC 
(monocytes and granulocytes)) could again be detected, indicative of transient pig cell engraftment in 
the baboon. 
With this regimen, we are able to detect porcine cells by flow cytometry until day 6 
following infusion, and by polymerase chain reaction consistently through day 30 and 
intermittently up to 140 days. Although engraftment of porcine cells, measurable by 
flow cytometry, has been definitively documented only twice, a state of donor-
specific hyporesponsiveness, detected by mixed lymphocyte reaction from day 40 -
80 (Figure 3), has been observed in several cases, indicating that the induction of 
tolerance through mixed hematopoietic chimerism seems feasible if anti-Gal can be 
removed for a sufficient period of time. 
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In our experience, the experiments aimed at inducing immunological tolerance 
through mixed chimerism, have been associated with severe thrombotic 
complications. Most baboons that underwent our tolerance inducing protocols 
developed a thrombotic microangiopathy, resulting in massive bleeding complications 
and even death of several baboons. Although these thrombotic complications appear 
to be quite different than the disseminated intravascular coagulation that is observed 
after solid organ pig-to-baboon xenotransplantation, it is possible that the mechanisms 
that playa role in the etiology of these events may be similar. 
1.4 AIMS OF THIS DISSERTATION 
Xenotransplantation has the potential to change transplantation medicine as it is 
currently known. No longer will patients with organ failure need to wait weeks, 
months or years for an organ as a limitless number of animal organs will be readily 
available. The surgical procedure can be planned electively, during normal working 
hours, while the patient is still in reasonable health. The use of animals as the source 
of organs also presents us with new opportunities to manipulate and/or modify the 
"donor" using techniques such as genetic engineering and nuclear transfer. 
Manipulation of the donor has not been possible in allotransplantation. 
The rejection processes that take place following th~ transplantation of a vascularized 
organ from a pig to a primate present formidable barriers. Much progress has been 
made in the last decade in elucidating the pathophysiology of these phenomena. 
Although major immunological hurdles (such as the prevention of HAR) have been 
overcome, many others remain. It is unlikely that any of the therapeutic modalities 
discussed in this chapter will be successful in preventing rejection when used alone. A 
combination of therapies will almost certainly be necessary, and we believe that the 
successful induction of immunological tolerance will greatly facilitate clinical 
implementation of xenotransplantation. 
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The aims of this dissertation are to discuss the current status of the induction of 
immunological tolerance in pig-to-baboon xenotransplantation through mixed 
hematopoietic chimerism, and to investigate some of the hurdles and complications 
associated with this approach. The author wishes to stress that only immunological 
aspects of xenotransplantation are presented, and that no attempts will be made to 
discuss the equally important issues of infectious hazards, ethical considerations, and 
physiological barriers that are inherent to xenotransplantation, as these latter items fall 
beyond the scope of this dissertation. 
The results obtained from our attempts to induce mixed hematopoietic chimerism by 
depleting, or inhibiting the function of, macrophages in the pig-to-baboon model are 
presented in this thesis (Section II, Chapter 2). 
In order to achieve mixed hematopoietic chimerism, anti-aGal depletion, and 
maintenance of depletion for a significant period of time, possibly several weeks, is 
required. We have summarized current and novel methods of depletion or suppression 
of production of anti-pig antibodies in pig-to-primate xenotransplantation (Chapter 
3). Furthermore, the effect of depletion of B cells by specific immunotherapy on anti-
aGal production in baboons is presented (Chapter 4). 
The potentially lethal thrombotic microangiopathy that is associated with the 
transplantation of large quantities of porcine hematopoietic cells is discussed in 
Section III, Chapter 5, and various etiology is presented. The direct effect of porcine 
cells on baboon platelet aggregation is investigated (Chapter 6), and potential 
beneficial or detrimental aspects of our conditioning regimen aimed at inducing 
mixed chimerism are examined (Chapter 7). Finally, several agents that may prevent 
platelet aggregation in baboons are examined (Chapter 8). 
These data are summarized in Section IV, Chapter 9. 
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ABSTRACT 
Introduction. Attempts to achieve immunological tolerance to porcine tissues in 
nonhuman primates through establishment of mixed hematopoietic chimerism are 
hindered by the rapid clearance of mobilized porcine leukocytes, containing 
progenitor cells (pPBPC), from the circulation. Eighteen hours after infusing 1-2xl01o 
pPBPC/kg into baboons that had been depleted of circulating anti-a Gal and 
complement, these cells are almost undetectable by flow cytometry. The aim of the 
present study Vias to identify mechanisms that contribute to rapid clearance of pPBPC 
in the baboon. This was achieved by depleting, or blocking the Fe-receptors of, cells 
of the mononuclear phagocyte system (MPS) using medronate liposomes (ML) or 
intravenous immunoglobulin (lVIg), respectively. 
:\Iethods. Baboons (Preliminary studies, n=4) were used in a dose-finding and 
toxicity study to assess the effect of ML on macrophage depletion in vivo. 
Furthennore, baboons (n=9) received a non-myeloablative conditioning regimen 
(NMCR) aimed at inducing immunological tolerance, including splenectomy, whole 
body irradiation (300 cGy) or cyclophosphamide (80 mg/kg), thymic irradiation (700 
cGy), T cell depletion, complement depletion with cobra venom factor, 
mycophenolate mofetil, anti-CD154L rnAb, and multiple extracorporeal 
immunoadsorptions of anti-aGal antibodies. Group I (n~5) NMCR + pPBPC Tx. 
Group 2 (n~2) NMCR + ML + pPBPC Tx. Group 3 (n~2) NMCR + IVlg + pPBPC 
Tx. Detection of pig cells in the blood was assessed by FACS and PCR. 
Results. Preliminary studies: ML effectively depleted macro phages from the 
circulation in a dose-dependent manner. Group 1: On average, 14% pig cells were 
detected 2 hours post-infusion of lxlO IO pPBPC/kg. After 18 hours, there were 
generally less than 1.5% pig cells detectable. Group 2: Substantially higher levels of 
pig cell chimerism (55-78%) were detected 2 hours post-infusion, even when a 
smaller number (0.5-lxI010/kg) of pPBPC had been infused, and these levels were 
better sustained 18 hours later (10-52%). Group 3: In one baboon, 4.4% pig cells were 
detected 2 hours after infusion of lxl0 10 pPBPC/kg. After 18 hours, however, 7.4% 
pig cells were detected. A second baboon died 2 hours after infusing 4xlO IO 
pPBPC/kg, with a total white blood cell count of 90,000 of which 70% were pig cells. 
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No differences in microchimerism could be detected bet\.veen the groups as 
determined by PCR. 
Conclusions. This is the first study to report an efficient decrease of phagocytic 
function by depletion of macrophages with ML in a large animal model. Depletion of 
macrophages with ML led to initial higher chimerism and prolonged the survival of 
circulating pig cells in baboons. Blockade of macrophage function with IVIg had a 
more modest effect. Cells of the MPS. therefore, playa major role in clearing pPBPC 
from the circulation in baboons. Depletion or blockade of the MPS may contribute 
towards achieving mixed hematopoietic chimerism and induction of tolerance to a 
discordant xenograft. 
INTRODUCTION 
The induction of stable mixed hematopoietic chimerism has led to transplantation 
tolerance in several models of rodent (1,2,3.4), porcine (5). and primate (6.7) 
allotransplantation, as well as in concordant rodent (8.9) and primate (10) 
xenotransplantation. It has, however. not yet proven possible to achieve stable mixed 
hematopoietic chimerism III the highly relevant pig-to-primate discordant 
xenotransplantation modeL Our laboratory has developed a non-myeloablative 
regimen (NMCR) aimed at inducing mixed hematopoietic chimerism in this model 
that is based on protocols that have previously been successful in the allograft and 
xenograft studies mentioned above. Large numbers of mobilized porcine peripheral 
blood leukocytes, containing progenitors cells (pPBPC). are transplanted into baboons 
pre-conditioned with a NMCR. Most pPBPC are, however. rapidly cleared from the 
circulation of these baboons, as detem1ined by flow cytometric analysis of the 
peripheral blood. As our NMCR includes therapies that deplete and block the function 
of T cells, and deplete complement and circulating xenoreactive natural anti-Gala 1-
3Gal antibodies (anti-aGal Ab). we hypothesized that elements of the innate immune 
system may be responsible for the rapid clearance ofpPBPC. 
It has been well described that macrophages, as well as other cells of the phagocy1ic 
reticulo-endothelial system, are associated with allo- and xenograft rejection 
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(11,12,13). Several groups have reported that depletion of these cells led to increased 
graft survival (14, IS, 16, 17). Van Rooijen et al. have extensively studied the depletion 
of macrophages using liposomes that contain the diphosphonate, clodronate 
(18,19,20). These liposomes have distinct dimensions and properties, that render them 
susceptible to phagocytosis by macrophages. Once phagocytosed, clodronate 
interferes with the cell's metabolism and causes cell death. We have made similar 
observations using liposomes containing medronate (ML), the parent compound of 
clodronate, to which it has similar properties. We have previously demonstrated that 
effective depletion of macrophages from the peripheral blood and other tissues is 
achieved when ML are administered to mice (Cheng J, et al. manuscript in 
preparation). To date, however, ML have not been studied in large animals, including 
nonhuman primates. 
Instead of depleting macrophages, an alternative would be to inhibit the fimction of 
macrophages. Intravenous immunoglobulin (IVIg) is widely used in the treatment of 
various autoimmune diseases, including idiopathic thrombocytopenic purpura (21). 
Although the mechanism of action of IVlg has not been fully elucidated, it is thought 
that one of the mechanisms through which IVIg may act is to bind to the Fc-ganuna 
receptors of macrophages, thus inhibiting their ability to mediate antibody-dependent 
cellular cytotoxicity (22). Furthermore, as IVlg may also inhibit complement activity 
(23), and has been used in the treatment of humoral rejection in allotransplantation 
(24,25), this action could be of additional benefit in xenotransplantation. 
The present study was, therefore, designed to determine (i) whether ML are able to 
deplete macrophages in baboons using a modified in vivo phagocytosis assay (26), 
and (ii) whether the depletion (by ML) or blockade (by IVlg) of the cells of the MPS 
delays the clearance of pPBPC following their transplantation in pre-conditioned 
baboons. 
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MATERIAL & METHODS 
Animals 
Baboons (Papio anubis, n=13, Biomedical Resources Foundation, Houston, TX), of 
known ABO blood group and weighing 9-15 kg, were used to assess the effect of ML 
on macrophage depletion in vivo (n~4), or as recipients of pPBPC (n~9). 
Massachusetts General Hospital MHC-inbred miniature swine (n=6, Charles River 
Laboratories, Wilmington, MA), of blood group 0 and weighing 18-40 kg, served as 
donors of pPBPC. 
All experiments were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals prepared by the National Academy of Sciences and published by 
the National Institutes of Health. Protocols were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care. 
Surgical Procedures 
Details of anesthesia, intravenous (iv) catheter placement in pigs and baboons, and 
intra-arterial line placement, splenectomy, and extracorporeal immunoadsorption of 
anti-aGal antibodies in baboons have been described previously (27,28). 
Non-myeloablative Conditioning Regimen (NMCR) 
This regimen consists of induction therapy with splenectomy, whole body irradiation 
(150 cGy x2), thymic irradiation (700 cGy), anti-thymocyte globulin (50 mg/kg x3, 
Atgarn, Upjohn, Kalamazoo, MI), and multiplc extracorporeal irnrnunoadsorptions of 
anti-aGal antibodies. The maintenance therapy consists of treatment with anti-CD154 
monoc1onal antibody (rnAb) +/- cyc1osporine (Sandirnrnune iv, 15 mg/kg/day by 
continuous iv infusion, generously donated by Novartis Pharmaceuticals, East 
Hanover, NJ), mycophenolate mofetil (Cellcept iv, 110 mg/kg/day by continuous iv 
infusion, generously donated by Roche Laboratories, Nutley, NJ), and cobra venom 
factor (Advanced Research Technologies, San Diego, CAl. Details of this regimen 
can be found in Chapter 1, figure 3. All baboons received cefazolin, 500 mg iv daily, 
as prophylaxis against infection and ranitidine, 12.5 mg iv twice daily (Zantac iv, 
Glaxo-Wellcome, Research Triangle Park, NC). 
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Mobilization and Leukapheresis of pPBPC 
Our methodology has been described previously (29). Briefly, pigs were treated with 
recombinant hematopoietic growth factors before and during the period of collection 
of pPBPC. Leukapheresis was carried out on days 5-9 and 12-16 following 
commencement of growth factor mobilization using a Cobe Spectra apheresis 
machine (Cobe, Lakewood, CO). Plasma was removed from the product by 
centrifugation at 920g for 7 minutes. The collected leukocytes (pPBPC), containing 
progenitor cells, were washed, frozen, and stored until transplantation. 
Preparation and Transplantation of pPBPC 
The pPBPC were thawed by immersion in a 37 - 40° C water bath with gentle shaking 
for 1 - 2 minutes, washed twice with Hanks' balanced salt solution (ca1cium-, 
magnesium-, and phenol red-free) (Mediatech, Herndon, VA), and resuspended in 
Hanks' solution for immediate transplantation through a central systemic iv catheter 
to the recipient baboon. Viability was assessed with trypan blue staining; 
approximately 70-80% of pPBPC remained viable. The baboons received additional 
therapy to prevent thrombotic complications associated with the transplantation of 
pPBPC (30). This consisted of prostaeyelin, 20 ng/kglmin, and heparin, 10 U/kglhour 
by continuous iv infusion, and methylprednisolone, 2 mg/kg iv tv.rice daily for 7 days, 
tapered to daily for a further 7-21 days. 
Preparation of Medronate Liposomes (ML) 
This followed the method described by others (19). Briefly, 75mg phosphotidyl 
choline (Avanti Polar Lipids, Alabaster, AL) and llmg cholesterol (Sigma, St. Louis, 
MO) were dissolved in chloroform and mixed to form a film. After low vacuum 
rotary evaporation at 37° C, the film was dispersed by gentle rotation in lOmI 
phosphate buffered saline in which 2.5 mg medronate was dissolved. The resulting 
liposomes were centrifuged twice at 100,000 g for 30 minutes to remove free, non-
entrapped medronate. The ML were then resuspended in phosphate buffered saline 
and ultrasonicated for 2 minutes before administration (Bransonic 2210, Branson 
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Ultrasonics Corporation, Danbury, CT). Blank liposomes were formed using the same 
protocol with the omission of medronate. 
Preparation of Fluorescent Latex Beads 
Polystyrene latex beads, with a diameter of 2 fim (Polyscience, Warrington, PAl, 
were impregnated with fluorescein isothiocyanate and added to tubes coated with 
bovine serum albumin and rinsed with 70% ethanoL The resulting beads had 
dimensions that made them particularly amenable to phagocytosis by macrophages. 
They were stored in the dark in sterile normal saline at 4° C until use. 
Preparation ofIntravenous Immunoglobulin (IVIg) 
Two preparations of human IVlg were used in these experiments. Pentaglobin 
(Biotest A.G., Dreieich, Germany), consisted of IgG (approximately 76%), IgM 
(approximately 12%), and IgA (approximately 12%). Iveegam (Immuno U.S., 
Rochester, MI), contained IgA (0.2 fig/ml) and IgG (>95%). Both preparations were 
depleted of anti-a Gal Ab by immunoadsorption using synthetic aGal columns 
(Alberta Research Council, Alberta, Canada). 
Flow Cytometric Analysis 
Baboon blood samples were obtained, water lysed, and washed twice. For 
determination of fluorescent latex bead clearance kinetics, the FACScan (Becton 
Dickinson, Franklin Lakes, NJ) was calibrated to sample a fixed volume over a given 
period of time (60fil ± 7fillminute). Freshly prepared fluorescent latex beads were 
used as positive controL For the detection of pig cells, 1 0 ~l human immunoglobulin 
was added to 1 x 106 cells to block non-specific binding of subsequently added 
monoclonal Ab to Fe-receptors. The cells were then stained in 100 IJ-l F ACS medium 
(1 % bovine serum albumin and 0.1 % azide in phosphate-buffered saline) using the 
following conjugated monoclonal antibodies (mAb): W6/32 FITC (mouse anti-
primate MHC Class I, IgG), I030HI-19 PE (pan-pig, mOuse anti-porcine leukocyte, 
IgM), 36-7-5 FITC (mouse anti-mouse MHC Class I, IgG) and 12-2-2 PE (mouse 
anti-mouse MHC class I, IgM), the latter two as isotypic controls. Dead cells were 
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excluded based on propidium iodide staining. Acquisition was performed under hi~ 
flow and samples were analyzed using WinList (Verity Software House, Topsham, 
ME). 
Polymerase chain reaction 
A peR assay that amplifies the porcine cytochrome-B gene was used to detect pig 
microchimerism in baboon samples. An internal PCR standard was created by adding 
the porcine cytochrome-B primer sequence (Cyt-Fl) to either side of a fragment of 
human A-2 phospholipase followed by cloning into a plasmid vector and quantitation 
using limiting dilution PCR. Peripheral blood and BM cells were purified using 
Histopaque 1077 (Sigma). The cells (2 - 10 x 105) were pelleted and frozen at -80°C 
until use. Genomic DNA was extracted using the Qiamp Blood Kit® (Qiagen, 
Valencia, CAl, quantified using Hoechst 33258 dye and a Hoeffer TKO-IOO 
Fluorometer (Hoeffer Scientific Instruments, San Francisco, CA), and denatured. The 
microchimerism assay consisted of 250 ng of sample DNA added to a total PCR 
reaction volume of 100 JlL The final reagent mixture consisted of IX GeneArnp® 
PCR Buffer II, 2.0 mM MgCIz, O.4mM dNTP, and 2.5 units of Amplitaq Gold® 
(Perkin-Elmer, Philadelpllla, PAl. Eighty picomoles each of Cyt-Fl and Cyt-Rl 
primers were added to the reactions. The PCR tubes were placed in a Perkin-Elmer 
GeneAmp 9600 Thermal Cycler. The first denaturing step was 9 minutes at 95°C 
followed by 40 cycles of 96°C for 10 seconds, 59°C for 30 seconds, and noc for 30 
seconds. The program concluded with a 5 minute incubation at 72°C. The internal 
standard was added to PCR reactions along with sample DNA to produce a 240 bp 
product that was compared to the 210 bp product produced by the porcine 
cytochrome-B gene through ethidium bromide-stained agarose gels. Samples that 
produced a cytochrome-B product that was greater than or equal to the product from 5 
copies of the standard were considered to be positive for microchimerism. 
Hematology and Chemistry Parameters 
Serial blood samples were taken for measurement of platelet count, prothrombin time, 
partial thromboplastin time, fibrinogen, and fibrinogen degradation products 
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(Hematology Laboratory, Massachusetts General Hospital). Serum samples were 
obtained for the measurement of lactate dehydrogenase (LDH) and basic renal and 
liver function tests (Chemistry Laboratory, Massachusetts General Hospital). 
Experimental Groups 
All baboons were monitored for toxic side effects, and hematological parameters and 
serum chemistries were measured. 
Preliminary studies (n=4). The effect of ML on macrophages was assessed by 
measuring the clearance kinetics of fluorescent latex beads from the circulation in 
baboons. Fluorescent latex beads (lxI010) were infused iv on day 0 into baboons that 
were either untreated, had received blank liposomes, or had received ML at various 
dosages (200 mg twice daily x 2; 200 mg twice daily x 6; 800 mg once daily x I; or 
800 mg twice daily x 2). Treatment with ML was timed such that the last dose was 
administered on day -1 before bead infusion. In one experiment, when treatment was 
continued for 6 days, ML was administered daily from days -2 to 3. Baboons received 
25mg diphenhydramine prior to ML or blank liposomes administration to prevent 
potential allergic reactions. Blood was drawn at various time points (0,1,5,15,30, 
60, 120 and 240 minutes) after the beads were administered and flow cytometric 
analysis was performed (as described earlier) to determine the number of fluorescent 
latex beads remaining in the circulation. 
Group I (controls, n~5). Baboons underwent the NMCR with transplantation of a 
total of2-4 x 10 10 pPBPClkg on days 0 - 2. No ML or IVlg was administered. 
Group 2 (n~2). Baboons underwent the NMCR with transplantation of a total of 2-4 x 
1010 pPBPC/kg on days 0 - 2 or 0 - 3. Additionally, one baboon (BI30-94) received 
ML at 40 mg/kg on days -2 and -I, followed by 20 mg/kg on days 1,3, and 4, and 40 
mg/kg on day 7. A second baboon (B57-309) received ML at 80 mg/kg on days -2 
and -I. 
43 
Section /1- Chapter 2 
Group 3 (n~2). Baboons underwent the NMCR with transplantation ofa total of2-4 x 
10 '0 pPBPClkg on days 0 - 2 or 0 - 3. Additionally, one baboon (B68-11) received 
IVIg at 500 mg/kg/day from days 0 - 8, with a double dose (total 1000 mglkg) on day 
I. A second baboon (B68-55) received IVIg at 500 mg/kg on days 0 - 2. IVIg was 
administered immediately before pPBPC transplantation on each occasion. 
RESULTS 
Preliminary studies 
Clearance of fluorescent latex beads from the circulation in an untreated baboon and 
in a baboon that had received blank liposomes occurred within 4 hours (Fig. 1). In 
contrast, treatment with ML led to substantially delayed clearance of fluorescent latex 
beads. Four hours foIlowing treatment with one dose of ML at 800 mg, 5% of the 
beads remained in the circulation, but after 24 hours, >99% of the beads had been 
cleared. Administration of ML at 200 mg twice daily x 2 resulted in 6% persistence of 
fluorescent latex beads 4 hours following infusion, and 5% after 24 hours. With this 
regimen, the beads remained in the circulation for 4 days. When ML were infused at 
200 mg twice daily x 6, 7% of the beads could be detected after 4 hours, with 4% 
remaining after 24 hours, and 2% detectable after 5 days. \\!hen ML were 
administered at 800 mg twice daily x 2, 28% of the fluorescent latex beads could be 
detected after 4 hours, 17% after 72 hours, and <1 % at 12 days. 
AIl baboons that received ML developed elevated LDH levels (maximum 
approximately 3000 VII). The increase in LDH closely correlated with the dose and 
duration of treatment of ML. This was probably related to release of LDH by dying 
macrophages. No major changes were observed in renal, liver, or hematological 
parameters. 
These observations demonstrate that fluorescent latex beads are effectively removed 
from the circulation in untreated baboons, and that treatment with ML results in 
delayed clearance. In turn, this indicates a decrease of phagocytic function that is 
most likely due to depletion of macrophages. 
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Figure 1 (Preliminary studies). 
Clearance kinetics of fluorescent latex beads infused into baboons (data are presented in log scales). 
The number of beads in circulation at I minute post infusion is designated as the baseline (100%). In 
untreated baboons, or baboons that received blank liposomes, fluorescent latex beads were cleared 
from circulation within 4 hours. In contrast, all baboons receiving medronate liposomes (ML) 
demonstrated a substantially delayed clearance ofthe beads from the circulation. Treatment with ML at 
200 mg or 800 mg twice daily x2 doses gave the most optimal results, with, respectively, 6% and 28% 
persistence of fluorescent latex beads in the circulation 4 hours following infusion, 2% and 28% 
remaining after 48 hours, and <1 % and 17% remaining after 72 hours. Treatment with 6 doses of ML 
led to 7% persistence of the beads after 4 hours, 1% after 72 hours, and 3% after 72 hours. No beads 
were detectable 5 - 12 days after administration in any baboon receiving ML. 
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Group 1 (controls) 
These baboons received the NMCR with transplantation of a total of 2 - 4 X 1010 
pPBPCikg on days 0 - 3 without ML or IVlg administration. The percentage of 
porcine cell chimerism as detected by flow cytometry is depicted in Figure 2. On 
average, pig cells made up approximately 14% (0.5% - 50%) of circulating cells 2 
hours following transplantation of I x 1010 pPBPC I kg. Eighteen hours after pPBPC 
transplantation, virtually no pig cells could be detected. This pattern was observed 
after each day of pPBPC transplantation. After day 3, no porcine cells could be 
detected. 
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Pig cell chimerism detected by flow cytometry in 5 baboons in Group 2, using a pan-pig leukocyte 
marker. All baboons received the NMR with transplantation of approximately 2 - 4 xlO lo pPBPClkg 
divided equally over days 0, 1, and 2. No medronate liposomes or IVIg was administered. Horizontal 
bars indicate the periods during which pPBPC were infused. Arrows indicate sampling timepoints 2 
hours after transplantation. Two hours after transplantation of pPBPC on day 0, a mean of 14% 
circulating pig cells was detected. Eighteen hours later (marked by timepoint 1), virtually no pig cells 
(1.1%) were detectable. On day 1, 2 hours following transplantation, pig cell chimerism reached 
iO.7%, falling to 0.9% eighteen hours later. On day 2, 17.4% of all cells were of porcine origin 2 hours 
post transplantation, decreasing to near-undetectable levels (1.2%) on day 3. By day 4, no pig cens 
were detectable. 
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Porcine DNA was detected by PCR continuously in the blood for approximately 19 (7 
- 28) days and intermittently up to 263 days. Porcine DNA was detected 
intermittently in the bone marrow in 4 out of 5 baboons between 16 and 365 days. 
All baboons developed a thrombotic microangiopathic state, with elevated LDH 
(>1,500 U/I) and thrombocytopenia «20,000 I~l) necessitating platelet transfusions 
in most instances. This state of microangiopathic thrombosis has been described and 
discussed elsewhere (30). 
These data indicate that, using this NMCR, transplanted pPBPC are rapidly cleared 
from the circulation of baboons. 
Group 2 
In addition to the NMCR, these two baboons received ML before, or during, pPBPC 
transplantation. In B 130-94, 2 hours after the first pPBPC transplantation, pig cells 
made up 49% of the cells detected in the circulation (Fig. 3). The following morning, 
this percentage had increased to 53%. The percentage of pig cells increased to reach a 
maximum of 78% 2 hours after the second pPBPC transplantation (Fig. 4), after 
which pig cell chimerism was slowly lost, despite continued administration of ML. A 
last peak of circulating pig cells was observed on day 4, after the final IxlOlo 
pPBPClkg were transplanted. After day 5, no pig cells were detectable. This baboon 
died of infectious complications on day 12. A similar pattern was observed in B57-
309, where 2 hours after the first transplantation of pPBPC, 30% of circulating cells 
were of porcine origin. The following day, this percentage was sustained at 30%. Two 
hours after the second transplantation, the percentage of pig cells increased to 33% 
and reached a maximum of 55% 18 hours later. After the third, and last, day of 
pPBPC transplantation, however, the percentage of pig cells decreased to 25% and, by 
day 4, no pig cells were detected. 
Porcine DNA was detected continuously for 16 days in the blood of B57-309 and 
intermittently through day 96. No porcine DNA was detected in the bone marrow of 
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this baboon. Porcine DNA was detected in all tissues of B130-94 at autopsy on day 
12. 
Both baboons developed increased LDH levels (7900 VII and >10,000 U/l for B130-
94 and B57-309, respectively), probably limiting any potential increase in the dosage 
of ML. Furthennore, a microangiopathic state similar to that in Group 1 was 
observed, with a marked thrombocytopenia «20,000 I~l), necessitating platelet 
transfusions. 
Treatment with ML, therefore, led to substantially higher initial levels of circulating 
pig cells, and sustained these cells in the circulation for 4 - 5 days. 
Group 3 
These two baboons underwent the NMCR before pPBPC transplantation, and also 
received daily infusions of IVlg. In B68-11 the initial percentage of circulating 
porcine cells (9.3% at 2 hours after the first transplantation ofpPBPC) was equivalent 
to that in the Group 2 baboons (Fig. 5). Two hours after the second transplantation of 
pPBPC (day 1),4.4% of the cells were of porcine origin. Eighteen hours later, this 
percentage had increased to 7.4%. There was, therefore, slightly better maintenance of 
pig cells in this baboon than in the Group 2 baboons. Over the next days, however, 
pig cells were lost from the circulation. In the second baboon (B68-55), the 
percentage of pig cells was also similar to that of the Group 2 baboons during the first 
two days of pPBPC transplantation (2 hours post transplantation, 8% and 12%, 
respectively). Before the third day of pPBPC transplantation, 5% porcine cells 
remained detectable. After the third transplantation of pPBPC, this baboon developed 
a leukocytosis of 90,000 I~l, of which 70% (63,000 I~l) were of porcine origin. The 
baboon died suddenly 2 hours after the third transplantation of pPBPC. Autopsy 
revealed a widespread thrombotic microangiopathy, with thromboses in the 
microvasculature of the heart, lungs, and kidneys. These findings were consistent with 
previous findings when death occurred after high-dose pPBPC transplantation (30). 
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Pig cell chimerism detected by flow cytometry in 2 baboons in Group 3, using a pan-pig leukocyte 
marker. 
B130-94 received the standard NMR with transplantation of approximately 2 - 4 xlOlO pPBPClkg 
divided over days 0, I, 2, and 3. Horizontal bars indicate periods of pPBPC transplantation. Arrows 
indicate sampling timepoints 2 hours after transplantation. B130-94 received medronate liposomes 
(ML) at 40 mgikg on days -2 and -I, followed by 20 mg/kg on days I, 3, and 4, and 40 mg/kg on day 
7. Two hours after pPBPC transplantation on day 0, pig cells made up 49% of the total cells in the 
circulation. Eighteen hours later, this percentage had increased to 53%. Two hours after transplantation 
ofpPBPC on day 1, the pig cell percentage increased to 78% (see Fig. 4). On days 2 and 3, even after 
transplantation of more pPBPC, pig cell chimerism was lost. On day 4, after a further Ix1 010 pPBPCikg 
were transplanted, a final peak of pig cells was observed. These cells were rapidly cleared from the 
circulation and, after day 5, no pig cells were detectable. 
B57-309 underwent the NMR and pPBPC transplantation on days 0, I, and 2 (to a total of 3 xl0 10 
pPBPC/kg) and received ML at 80 mg/kg on days -2 and -\. Two hours after pPBPC transplantation 
on day 0, 30% of cells were of porcine origin. The following day, this percentage was sustained at 30% 
and increased to 33% two hours following pPBPC transplantation on day 1 and to 55% eighteen hours 
later. After pPBPC transplantation on day 2, the percentage of pig cells decreased to 25% and, by day 
4, no pig cells remained. 
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Two-color flow cytomerric analysis of circulating cells in B 130-94 , 2 hours after pPBPC 
transplantation on day 1. Staining was performed for baboon MHC Class I (W6/32 FITC), negative 
isolype control (1 2.2.2 PE, Fig. A), and pan~pig leukocyte (1030HI 19 PE, Fig. B). At this timepoint, 
78% of cells were of porcine origin. 
Porcine DNA was detected in the blood of 868·11 continuously through day 9 and 
intermittently through day 43. [n the bone marrow, porcine DNA was detected only 
on day 14. All tissues ofB68·55 at autopsy on day 2 contained porcine DNA. 
868·11 developed a thrombotic microangiopathic state, with elevated LDH (> 1,500 
U/I) and thrombocytopenia (<20,000 IIlI ) comparable to Group I baboons. 
The addition of IVlg to the NMCR, therefore, led to a marginally delayed rate of 
clearance of pPBPC and. in one case, to a very high level of chimerism (that was 
probably a major factor in the death of the baboon). These differences may be 
explained by differences in the preparations of IVIg used. Alternatively, treatment 
with IVlg in 868·55 may have been more effective in saturating all Fe·gamma 
receptors of the macrophages, thereby preventing opsonization and phagocytosis of 
porcine ce ll s, and leading to higher chimerism. 
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Figure 5. 
Pig cel! chimerism detected by flow cytometry in 2 baboons in Group 4, using a pan*pig leukocyte 
marker. Both baboons received the NMR with transplantation of approximately 2 - 4 xl 010 pPBPClkg 
divided over days 0, 1, and 2. Horizontal bars indicate period of pPBPC transplantation, arrows 
indicate sampling timepoints 2 hours after transplantation. B68-11 received IVlg at 500 mglkglday 
from days 0 - 8, with a double dose (total 1000 mgikg) on day 1. The initial pig cell chimerism 2 hours 
post pPBPC transplantation on day 0 was 9.3%, which decreased J 8 hours later to 1.6%. Two hours 
after pPBPC transplantation on day 1, 4.4% of cells were of porcine origin, with an increase to 7.4% 
eighteen hours later. Pig cell chimerism decreased and became undetectable over the next few days. 
B68-55 received IgM-containing IVlg (Pentaglobin) at 500 mglkg on days 0 - 2. After the first 2 days 
ofpPBPC transplantation, pig cells were detected at 8% and 12%, respectively. On day 2, before the 
last transplantation ofpPBPC, pig cell chimerism was sustained at 5%. Two hours after transplantation 
of pPBPC on this day, the pig cell chimerism was 70%, with a leukocytosis of 90,000 /J.d, at which 
time the baboon died from thrombotic complications. 
DISCUSSION 
The protocols developed at our laboratory aimed at inducing immunological 
tolerance through establishing stable mixed hematopoietic chimerism have not proven 
successful in the discordant pig-to-baboon model (31). Our NMCR, which includes 
non-myeloablative irradiation, T cell depletion, costimulatory blockade, complement 
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depletion, and (temporary) depletion of xenoreactive anti-aGal Ab, has thus far been 
insufficient to allow engraftment of pPBPC in baboons. 
It has been suggested that macrophages may pose barriers to hematopoietic 
engraftment of xenogeneic cells, and that depletion of macrophages can improve 
chimerism in human-to-SCID-mouse xenotransplantation models (14,32). We are the 
first to report successful depletion of macrophages without significant side-effects in a 
large animal model using ML. Furthermore, to assess the negative effect of the MPS 
on the induction of chimerism in the pig-to-baboon model, we tested macrophage 
depletion with ML, or inhibition of the ability of macrophages to opsonize and 
phagocytose particles with IVlg, in our NMCR. 
When ML were added to our protocol, and to a lesser extent when IVlg was added, 
substantially higher initial levels of circulating pig cells were observed, and pig cells 
were sustained in the circulation for longer periods of time. These data indicate that 
macrophages, indeed, play an important role in the clearance of porcine cells from the 
circulation of baboons. This short-term improvement in pig cell survival, however, 
did not lead to engraftment of these cells or to the development of immunological 
tolerance. Experiments in rodents indicate that depletion of macrophages with ML is 
temporary, and that a rebound in the number and/or the activity of macrophages can 
occur within days of discontinuing ML therapy (Cheng J, et aI., manuscript in 
preparation). It is not clear, therefore, whether depletion of macrophages for only a 
limited period of time will be sufficient to establish hematopoietic cell chimerism. 
One may postulate that macrophages will need to be depleted for an extended period 
of time, sufficient to allow the porcine cells to home to and engraft in the recipient 
baboon's bone marrow. 
One of the mechanisms through which baboon macrophages may clear porcine cells is 
through antibody-dependant cellular cytotoxicity. Although anti-aGal Ab can be 
efficiently removed from the circulation (33), continued production of anti-aGal Ab 
cannot be prevented (34). This is illustrated by the observation that, within hours of 
extracorporeal immunoadsorption of antiaGal Ab and pPBPC transplantation, the 
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pPBPC in the circulation are largely coated with anti-aGal IgM and IgG Ab (Awwad 
M, et a!., unpublished data). Coating of pPBPC by anti-aGal IgG may facilitate 
phagocytosis ofpPBPC by cells of the MPS (i.e., by macrophages), thus reducing the 
potential of engraftment. Methods that successfully maintain depletion of anti-a Gal 
Ab, perhaps only for a limited period of time, may, therefore, be of benefit. However, 
it is possible that pPBPC may be phagocytosed by macrophages in the absence of 
coating. 
Depletion of cells of the MPS may, however, be counterproductive, as these cells may 
be required to transport porcine antigen to the thymus if central tolerance is to be 
induced (35). Furthennore, recent data from our laboratory suggest that macrophages 
are essential in maintaining the state of humoral unresponsiveness to porcine antigens 
induced by treatment with anti-CDl54 mAb (BubIer L, et a!., manuscript in 
preparation), and may thereby be associated with the induction of peripheral 
tolerance. Depletion of macrophages resulted in an elicited Ab response to porcine 
antigens following hematopoietic cell transplantation that was previously prevented 
with costimulatory blockade with anti-CD 154 mAb. Sustained depletion of anti-aGal 
Ab, macrophages, and T cells may allow hematopoietic chimerism and 
immunological tolerance to be achieved. 
In addition to the effect IVIg may have on macrophages, other mechanisms of action 
of IVIg may be beneficial in pig-to-primate xenotransplantation. Proposed actions of 
IVIg include reducing complement-mediated injury by modifying the antibody-
antigen ratio (23) and, particularly for IgM-containing IVIg (such as Pentaglobin), by 
'scavenging' of activated complement fragments (36). Furthermore, down-regulation 
of B cells by binding to B cell immunoglobulin, functioning as anti-idiotypic 
antibodies and binding ofxenoreactive antibodies (37,38), or binding to IgG receptors 
on CDS+ T cells, thereby altering T-helper functions (39), have also been detennined. 
In conclusion, it appears that cells of the MPS play an integral role in the clearance of 
porcine cells from the circulation of baboons. Depletion of the cells of the MPS, or 
inhibition of their function, leads to higher levels of chimerism that are better 
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sustained, and may potentially facilitate the induction of mixed hematopoietic 
chimerism and immunological tolerance to porcine antigens in baboons. 
REFERENCES 
1 Sharabi Y and Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced 
by a non~!ethal preparative regimen. J Exp Med 1989; 169: 493 
2 Lee LA, Sergio JJ, Sykes M. Natura! killer ce!!s weakly resist engraftment of allogeneic long~term 
mUltilineage-repopulating hematopoietic stem cells. Transplantation 1996; 61: 125 
3 Wekerle T, Sayegh MH, Hi!! J, et al. Anti-CD 154 or CTLA4Ig obviates the need for thymic 
irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic 
chimerism and tolerance. Transplantation 1999; 68: 1348 
4 Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory 
blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 
2000;6:464 
5 Huang CA, Fuchimoto Y, Scheier-Dolberg R, et al. Stable mixed chimerism and tolerance using a 
nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000; 105:173 
6 Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in 
cynomolgus monkeys. Transplantation 1995; 59: 256 
7 Kimikawa M, Sachs DH, Colvin RB, et al. Modifications ofthe conditioning regimen for achieving 
mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 
709 
8 Sharabi Y, Aksentijevich I, Sundt III TM, et al. Specific tolerance induction across a xenogeneic 
barrier: production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative 
regimen. J Exp Med 1990; 172: 195 
9 Ildstad ST, Wren SM. Cross-species bone marrow transplantation: evidence for tolerance induction, 
stem cell engraftment, and maturation ofT lymphocytes in a xenogeneic stromal environment (rat-> 
mouse). J Exp Med 1991; 174: 67 
10 Ko DS, Bartholomew A, Poncelet AJet al. Demonstration of multiline age chimerism in a nonhuman 
primate concordant xenograft model. Xenotransplantation 1998; 5: 298 
II Alwayn IP, van Bockel HJ, Daha MR, et al. Hyperacute rejection in the guinea pig-to-rat model 
without formation of the membrane attack complex. Transpllmmunol 1999; 7: J 77 
J2 Qian Z, Wasowska BA, Behrens E, et a1. C6 produced by macrophages contributes to cardiac 
allograft rejection. Am J Pathol 1999; 155: 1293 
13 Leonard CT, Soccal PM, Singer L, et al. Dendritic cells and macrophages in lung allografts. A role 
in chronic rejection? Am J Respir Crit Care Med 2000; 161: 1349 
14Terpstra W, Leenen P J, van den Bos C, et al. Facilitated engraftment of human hematopoietic cells 
in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes. 
Leukemia 1997; II: J049 
15 Fox A, Koulmanda M, Mandel TE, et al. Evidence that macrophages are required for T-cell 
infiltration and rejection offetal pig pancreas xenografts in nonobese diabetic mice. Transplantation 
1998; 66: 1407 
16 Wu G, Korsgren 0, van Rooijen N, et al. The effect of macrophage depletion on delayed xenograft 
rejection: studies in the guinea pig-to-C6-deficient rat heart transplantation model. 
Xenotransplantation. 1999 Nov;6(4):262 
17 Feng X, Zheng XX, Yi S, et al. IL-10/Fc inhibits macrophage function and prolongs pancreatic islet 
xenograft survival. Transplantation 1999; 68: 1775 
18 van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous 
injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme~histochemical 
study. Cell Tissue Res 1984; 238: 355 
19 Van Rooijen N, Sanders A. Liposome mediated depletion of macro phages: mechanism of action, 
preparation of liposomes and applications. J Immunol Methods 1994; 174: 83 
20 Van Rooijen N. Minireview: The liposome-mediated macrophage suicide technique. J Immunol 
Methods J 989: 124; 1 
54 
Depletion of macrophages 
21 Fehr J, Hofmann Y, Kappeler U. Transient reversal of thrombocytopenia in idiopathic 
thrombocytopenic purpura by high-dose intravenous gamma globulin. N Eng! J Med 1982; 306: 
1254 
22 Bussel JB. Treatment effects on chronic idiopathic thrombocytopenic purpura. In: Imbach P; ed. 
Immunotherapy with Intravenous Immunoglobulins. San Diego: Academic Press 1991; 253 
23 Dalakkas MC, Illa I, Dambrosia JM, et a1. A controlled trial of high-dose intravenous immune 
globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993 
24 Jordan SC, Quartel A W, Czer LS, et al. Posttransplant therapy using high-dose human 
immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and 
cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800 
25 Furth S, Neu AM, Hart J, et al. Plasmapheresis, intravenous cytomegalovirus-specific 
immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: 
a case report. Pediatr Transplant 1999; 3: 146 
26 Singer JM, Adlersberg L, Hoenig EM, et al. Radiolabeled latex particles in the investigation of 
phagocytosis in vjvo: clearance curves and histological observations. J Reticuloendothel Soc 1969; 
6:561 
27 Kozlowski T, Shimuzu A, Lambrigts 0, et al. Porcine kidney and heart transplantation in baboons 
undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999; 67: 18 
28 Alwayn IPJ, Appel JZ III, Goepfert C, et a1. Inhibition of platelet aggregation in baboons: 
therapeutic implications for xenotransplantation. Xenotransplantation 2000; 7: 247. 
29 Nash K, Chang Q, Watts A, et al. Peripheral blood progenitor cell mobilization and leukapheresis in 
pigs. Lab Anim Sci 1999; 49: 645 
30 Buhler L, Basker M, Alwayn IPJ, et al. Coagulation and thrombotic disorders associated with pig 
organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 
1323. 
31 Kozlowski T, Monroy R, Giovino M, et al. Effect of pig-specific cytokines on mobilization of 
hematopoietic progenitor cells in pigs and on pig bone marrow engraftment in baboons. 
Xenotransplantation 1999; 6: 17 
32 Yerstegen MM, van Hennik PB, Terpstra W, et al. Transplantation of human umbilical cord blood 
cells in macrophage-depleted scm mice: evidence for accessory cell involvement in expansion of 
immature CD34+CD38· cells. Blood 1998; 91: 1966 
33 Watts A, Foley A, Awwad M, et al. Plasma perfusion by apheresis through a Gal immunoaf1mity 
colwnn successfully depletes anti-Gal antibody - experience with 320 aphereses in baboons. 
Xenotransplantation 2000; 7: 181. 
34 Alwayn IP, Basker M, Buhler L, et a!. The problem of anti-pig antibodies in pig-to-primate 
xenografting: current and novel methods of depletion and/or suppression of production of anti-pig 
antibodies. Xenotransplantation 1999; 6: 157 
35 Wekerle T and Sykes M. Mixed Chimerism as an approach for the induction of transplantation 
tolerance. Transplantation 1999; 68: 459 
36 Rieben R, Roos A, Muizert Y, et al. Immunoglobulin M-enriched human intravenous 
immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute 
inflammation. Blood 1999: 93: 942 
37 Dietrich G and Kazatchkine MD. Normal immunoglobulin G (lgG) for therapeutic use (IntTavenous 
Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive 
idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85: 620 
38 Nydegger UE, Sultan Y, Kazatchkine MD. The concept of anti-idiotypic regulation of selected 
autoimmune diseases by intravenous immunoglogulin. Clin Immunol Immunopathol1989; 53:S72 
39 Ruiz de Souza Y, Carreno MP, Cavailon JM, et al. Modulation of cytokine production by 
mmunoglobulins for intravenous use (IYlg). F ASEB J 1984; 8: 1238 
55 
Section 11- Chapter 2 
56 
III 
The importance of snppressing xenoreactive antibody production 

3 
Curreut and novel methods of depletion andlor suppression of anti-
pig antibodies 
Adaptedfrom: 
Alwayn IPJ, Basker M, Buhler L, and Cooper DKC. The problem of anti-pig antibodies in 
pig-to-primate xenografting: current and novel methods of depletion and/or suppression of 
production of anti-pig antibodies. Xenotransplantation 1999;6: 157-68 
Section 111 - Chapter 3 
ABSTRACT 
The role of antibodies directed against Galal-3Gal (aGal) epitopes in porcine-to-
primate xenotransplantation has been widely studied during the past few years. These 
antibodies (anti-aGal) have been associated with both hyperacute rejection and acute 
vascular rejection of vascularized organs. Depletion and (temporary or pennanent) 
suppression of production of anti-aGal seems essential for obtaining long-tenn 
survival of these organs, even when the ultimate aim is the achievement of 
accommodation or tolerance. Although greater than 95% depletion of anti-aGal can 
be realized by the use of immunoaffinity column technology, to date no regimen has 
been successful in preventing the return of anti-aGal from continuing production. In 
this review, we discuss current and novel methods for achieving depletion or 
inhibition (i.e., extracorporeal immunoadsorption, anti-idiotypic antibodies, the 
intravenous infusion of immunoglobulin or oligosaccharides) and suppression of 
production (i.e., irradiation, pharmacologic agents, specific monoclonal antibodies, 
immunotoxins) of anti-aGal antibodies. 
INTRODUCTION 
In 1966, Perper and Najarian were among the first to recognize that both antibodies 
and complement were involved in the hyperacute rejection (HAR) of organs 
transplanted berureen widely disparate species, such as pig-to-dog (1). It has been 
knO\vn for more than 10 years that pigs and other nonprimate mammals express 
tenninal Galal-3Gal oligosaccharides (aGal) as surface antigens on many cells, 
including the vascular endothelium (2). Galili et a1. showed in 1984 that humans 
possess antibodies that have anti-a Gal specificity (3), and that its IgG component 
comprises 1 % of circulating IgG in human serum. It was not until 1991, however, that 
Good et al. demonstrated that these natural antibodies (anti-aGal) playa major role in 
the HAR of pig xenografts in primates (4-6). Furthermore, they determined that anti-
aGal accounts for more than 85% of circulating natural anti-pig antibody in humans 
and that these antibodies are primarily of IgG and IgM subclasses (4-8). Galili and 
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coworkers have postulated that anti-aGal develop soon after birth, similar to ABO 
antibodies in humans, due to exposure to colonizing microorganisms in the 
gastrointestinal tract that express aGal surface antigens (9). There is now clear 
evidence that anti-aGal are responsible for complement-mediated HAR of porcine 
vascularized organs transplanted into human or nonhuman primate recipients (4-
6,10,11). 
Even if complement activation is inhibited (e.g. by the use of complement regulatory 
agents or porcine organs transgenic for human complement regulatory proteins), anti-
aGal still plays a major role in a delayed rejection response, variously termed delayed 
xenograft rejection or acute vascular rejection (AVR), which is most probably 
complement-independent (12,13). Since it is now widely accepted that pigs (that 
express Gal epitopes in abundance) are the most likely animals to provide organs for 
xenotransplantation in humans (who have high levels of anti-aGal), the importance of 
the aGal antigen-anti-aGal antibody complex in xenotransplantation cannot be 
overemphasized. 
In this chapter, current knowledge of anti-aGal and its importance in the rejection of 
vascularized organs in the pig-to-primate model is discussed. We summarize various 
methods being explored of achieving depletion or inhibition of anti-aGal and, 
furthermore, of suppressing production. 
Anti-aGal Antibodies 
Oriol et al. have presented detailed data on the presence of aGal epitopes in different 
porcine tissues (14) and have demonstrated that aGal is expressed unifonnly on 
vascular endothelium of all pig breeds (15). This contrasts with humans, who express 
ABO blood group epitopes rather than aGal, even though both humans and pigs 
express N-acetyllactosamine and a sialic acid on their vascular endothelium (Chapter 
1, Table 1) (16). It has long been considered that anti-aGal and anti-A and anti-B 
blood group antibodies are members of the same family of natural antibodies (17), 
and further evidence to this effect has recently been presented by Parker et al (18). 
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The concentration of aGal on most pig cells approximates 107 epitopes per cell (2). 
The IgM subclass of anti-aGal is of special importance in BAR since IgM is often 
found to be deposited on graft endothelium before, and sometimes in the absence of, 
IgG (10,19), In addition, depletion of anti-aGal IgM eliminates complement-mediated 
cytotoxicity of human serum on porcine endothelial cells (20). However, evidence has 
also been presented that IgG can playa role in HAR as well as in A VR (11,21), 
Humans and nonhuman primates (with the exception of New World monkeys) have a 
nonfunctional a-galactosyltransferase pseudogene, hence lack the encoded al,3-
galactosyltransferase enzyme, and therefore do not make aGal (22). In the absence of 
aGal, primates develop anti-aGal. It has been suggested that nonhuman primates 
were exposed to an aGal-expressing pathogen at an evolutionary stage after the 
divergence of New from Old World monkeys, and that the survival of Old World 
primates depended on adapting by suppressing aGal expression and producing anti-
aGaI antibody (23), Since aGaI epitopes have been fonnd on the surface of certain 
parasites, bacteria, and viruses (reviewed in 6), anti-aGal may playa role in defense 
mechanisms against these organisms in humans and nonhuman primates. These 
observations suggest that anti-aGal may be essential to primates in providing natural 
immunity to a wide variety of pathogens. 
Anti-aGal Antibodies: Role in Hyperacute Rejection 
'When vascularized organs are transplanted between pigs and primates, HAR almost 
nniformly occurs (24), The development ofHAR in the pig-to-primate model depends 
on the activation of complement, mostly, if not entirely, through the classical 
pathway, Activation of this pathway is initiated by the binding of anti-aGal to the 
corresponding antigens (Le, aGal) (19,25). When anti-aGal is depleted from 
xenograft recipients, prolongation of graft survival is seen (26-29). \\'hen porcine 
hearts are transplanted into newborn baboons (that lack anti-aGal), HAR does not 
occur (30). The importance of the aGal antigen-anti-aGal antibody system was 
confirmed by Collins et ai, who demonstrated that HAR occurred when an organ from 
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a New World monkey (expressing aGal) was transplanted into a baboon (that 
produces anti-aGal) (31). 
Anti-aGal Antibodies: Role in Acute Vascular Rejection 
HAR can be prevented by antibody depletion or inhibition (26-29), complement 
depletion or inbibition (32,33), or by transplanting organs from pigs transgenic for 
human complement regulatory proteins (34-37). However, a delayed rejection 
phenomenon (AVR) occurs and leads to destruction of the xenograft (13). It has been 
proposed that this destruction results from the development of high levels of high 
affinity antibody, largely IgG, directed against aGal and possibly also new pig 
epitopes (12). This response occurs despite high doses of immunosuppressive therapy. 
Increases in anti-aGal IgG of 100-300-fold have been documented after experimental 
organ and bone marrow transplantation (38,39) and after clinical pancreatic islet cell 
transplants (40). Even after the transplantation of relatively avascular porcine 
meniscus cartilage to cynomolgus monkeys, anti-a Gal titers (IgM and IgG) rose 10-
fold (41). These induced antibodies appear to be the major cause of A VR (42,43). 
Accommodation 
It has been described that ABO- or human leukocyte antigen (HLA)-incompatible 
allografts are able to survive despite the presence of circulating antibodies directed 
against these determinants (44-46). This process has been termed accommodation, 
and can be applied to any system in which antibodies exist that are potentially reactive 
with antigens on the endothelium of a primarily vascularized organ graft and yet 
where antibody-mediated rejection does not occur (47,48). The phenomenon has not 
yet been documented to occur in Gal-incompatible large animal models. Several 
possible explanations for the phenomenon of accommodation have been proposed 
(47). Firstly. the returning antibodies may be different in isotype, affinity, and/or 
specificity, and are thus unable to initiate rejection. Secondly, the surface antigens on 
the vascular endothelium may show subtle changes during the absence of natural 
antibodies. Finally, the endothelial cells may adapt during the return of antibodies and 
respond differently or become 'desensitized'. Bach et al have presented evidence that 
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changes occur in the endothelial cells, with upregulation of -·beneficial' genes and 
downregulation of 'detrimental' genes (48). 
Tolerance 
Perhaps the ultimate method for avoiding HAR and A VR would be to induce B cell 
tolerance. 1fT cell tolerance were also induced, the subsequent cellular response (and 
the complications associated with long-term high-dose immunosuppression) would 
also be avoided. This option is being studied at our center, and involves the induction 
of mixed hematopoietic cell chimerism between pig and primate (38,39,49). 
Tolerance is achieved when there is permanent specific unresponsiveness to donor 
antigens (but not to other antigens) in the absence of maintenance immunosuppressive 
therapy. To induce this state in the pig-to-primate model, a combination of (at least 
temporary) (i) anti-aGal depletion or inbibition, (ii) depletion or inhibition of 
complement, (iii) T cell depletion (and/or costimulatory blockade), and (iv) pig 
hematopoietic cell engrafiment, would appear to be necessary. The use of organs from 
genetically engineered pigs transgenic for human complement regulatory proteins 
may also prove an advantage, although this remains uncertain. 
'Whether accommodation is to be achieved or tolerance is to be induced, however, it 
seems essential to devise strategies that lead to the depletion of anti-aGal and to the 
suppression of production of anti-aGal for a period of time. 
METHODS OF DEPLETION OR INHIBITION OF ANTI-aGAL 
ANTIBODIES 
Initial experiments III the 60s and 70s directed against removing xenoreactive 
antibodies were performed by perfusion of the recipient's blood or plasma through a 
donor-specific organ, such as a pig kidney or liver (50-53). Antibodies were adsorbed 
by the perfused organ's vascular endothelium, thus temporarily depleting the anti-
species antibody and enabling modestly prolonged survival of a subsequently 
transplanted organ. Initial experiments in the pig-to-non-human primate model 
(26,54) showed the pig liver to be a better immunoadsorbent than the kidney, a 
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finding confirmed recently by Azimzadeh et al (55). Evidence has also been presented 
that perfusion of human blood through pig lungs is more effective in removing anti-
pig antibody tlmn perfusion through pig liver or spleen (56). Other methods for 
depleting anti-aGal include (i) plasma exchange, (ii) plasma perfusion through non-
specific immunoadsorbants (e.g., protein columns), and (iii) plasma perfusion 
through specific antibody sorbents (e.g., synthetic aGal immunoaffinity columns). 
Plasma Exchange 
Plasma exchange - the (complete) removal of the subject's plasma (with replacement 
of volume by other fluids) - is utilized as a treatment for numerous conditions, such as 
myasthenia gravis, thrombotic microangiopathies, and cryoglobulinemias. All or most 
circulating antibodies, including anti-a Gal, are removed. Because of this temporary 
state of agammaglobulinemia, the patient is at risk for infection. Furthermore, the 
patient may be depleted of plasma proteins important to the coagulation cascade. 
Alexandre and coworkers were successful in using repeated plasma exchange to 
remove circulating anti-A and anti-B blood group antibodies from potential kidney 
transplant recipients (45), and demonstrated that the phenomenon of accommodation 
could result. This technique was also moderately successful in depleting xenoreactive 
natural antibodies from baboons in a pig-to-baboon kidney transplant model (27) but, 
although the porcine grafts functioned for up to 22 days, accommodation did not 
occur, and the grafts were lost to A YR. 
Nonspecific Antibody Sorbents 
Nonspecific antibody adsorption differs from plasma exchange in that the plasma is 
passed through an immunoaffinity column containing proteins that remove 
immunoglobulins from the plasma. The remaining plasma is then returned to the 
patient, reducing the need for replacement fluids. The proteins (such as 
staphylococcal protein A or protein G) are efficient in removing antibody by binding 
to the Fc portion of the antibody. Since the proteins are non-specific, all antibodies 
are removed, resulting again in hypogammaglobulinemia and predisposition for 
infectious complications. Palmer et al. reported some success in the use of protein A 
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columns to deplete anti-HLA antibodies in potential renal transplant recipients (46), 
and this technique has been used by several groups in xenotransplantation studies. 
Specific Antibody Sorbents 
Specific antibody sorbents for anti-a Gal utilize columns that remove anti-aGal from 
plasma by binding them to natural or synthetic aGal oligosaccharides. Significant 
hypogammaglobulinemia does not occur. Initial studies were by Ye et al. (57), who 
demonstrated that extracorporeal immunoadsorption (EIA, Figure 1) of baboon 
plasma, utilizing immunoaffinity columns of melibiose on 4 consecutive days, could 
reduce cytotoxicity to pig kidney (PKI5) cells to 20%. 
Anti-
alpha-Gal 
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coagulan 
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elements 
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Figure I. 
Diagram of extracorporeal immunoadsorption circuit, with access through the internal jugular vein and 
return through the saphenous vein. 
Vlhen more specific aGal oligosaccharides became available, a course of EIA 
resulted in successful depletion of anti-aGal for 4-5 days after which anti-aGal 
returned and led to rejection of a transplanted porcine organ (28,29,58,59). Kozlowski 
et al. (60) provided evidence indicating that EIAs should be carried out approximately 
24 - 48 hours apart in order to enable equilibration of anti-aGal between the intra-
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and extravascular spaces to occur. Although (lGal immunoaffinity columns are 
efficient in depleting anti-aGal, in order to maintain depletion, other therapeutic 
modalities need to be employed, such as inhibiting the production of anti-aGar. This 
has proved much more difficult, and is perhaps the major barrier to successful 
xenotransplantation facing us at the present time (see below). 
Antiidiotypic Antibodies 
An alternative approach to using a synthetic oligosaccharide column is the use of 
antiidiotypic antibodies (AlA) directed against idiotypes expressed on anti~aGal 
antibodies. AlAs recognize specific idiotypes that are antigenic determinants within 
the variable regions of immunoglobulins. AlAs are also directed against the B 
lymphocyte subpopulations that bear the same idiotypes as surface receptors. Koren et 
al. (61) produced AlAs in mice by the injection into the mouse of human anti~pig 
antibodies (eluted from pig organs after repeated petfusion with human plasma) and 
by the subsequent creation of hybridomas. Several of these AlAs, when incubated 
with human serum, had a major inhibitory effect on serum cytotoxicity towards pig 
PK15 cells in vitro. The AlAs could be made up as an immunoaffinity column or 
could be infused intravenously into the recipient (to be bound by anti~aGal, thus 
inhibiting binding of anti~aGal to a transplanted organ). \\Then infused into baboons, 
serum cytotoxicity was markedly reduced (to approximately 10%). Recently. we have 
produced a pig polyclonal AlA by immunizing a pig with human anti-aGal 
antibodies. The purified final preparation contained 1~2 % AlA. After repeated 
administration to a baboon (following repeated EIA of anti-aGa!), a delayed return of 
anti-a Gal and reduced cytotoxicity to pig cells was observed. Furthermore, at this 
time point, the baboon serum was able to partially inhibit the cytotoxicity of other 
highly cytotoxic sera. 
Intravenous Infusion of Immunoglobulin 
The intravenous (i. v.) infusion of concentrated human immunoglobulin (IVIG) has 
been used successfully in the treatment of certain autoimmune disorders, e.g., 
idiopathic thrombocytopenic purpura (62), and more recently as therapy to reduce 
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anti-HLA antibodies in highly-sensitized patients awaiting organ transplantation (63). 
Magee et al. (20) demonstrated that the Lv. infusion ofinununoglobulin could prevent 
the HAR of pig organs transplanted into baboons. Different hypotheses have been 
proposed to explain the mechanism of action of IVIG, including the presence of AlAs 
or complement inhibition. Recent studies suggest that IVIG accelerates the 
physiological catabolism of IgG by saturating specific intracellular receptors, 
allowing degradation of IgG in proportion to its plasma concentration (65). If IVIG 
depleted of anti-aGal is repeatedly infused, the level of anti-aGal should steadily fall. 
Our preliminary data using IVIG (depleted of anti-a Gal) in experiments involving the 
i.v. infusion of porcine peripheral blood progenitor cells into baboons indicate that 
significantly greater hematopoietic cell chimerism can be obtained than when IVIG is 
not administered (see Section II, Chapter 2). We believe this beneficial effect is 
brought about, at least in part, by inhibition of macrophage function. 
Intravenous Infusion of Oligosaccbarides 
Yet another approach to 'neutralize' anti-aGal is to administer a large quantity of 
soluble antigen, thus blocking anti-aGal in vivo. It has been demonstrated that many 
oligo saccharides terminating in aGalal can inhibit the action of anti-aGal (4-
6,57,66-68). Ye et aI. (57) demonstrated that the i.v. infusion of melibiose and/or 
arabinogalactan in a very high concentration was effective in (partially) eliminating 
cytotoxicity of the serum to PKI5 cells in baboons. Infusion of such high 
concentrations, however, resulted in severe toxicity. More recently, i.v. administration 
of different oligosaccharides has proved non-toxic and also inhibited anti-a Gal 
activity. HAR was delayed, but not abolished (67,68). 
METHODS OF SUPPRESSION OF PRODUCTION OF ANTI-aGAL 
ANTIBODIES 
Antibodies are produced by B lymphocytes and plasma cells. If it were possible to 
suppress selectively the cells responsible for the production of anti-aGal, a major step 
would have been taken in achieving long-term xenograft acceptance. As this is not yet 
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a reality, present studies at our center are directed towards temporarily destroying or 
suppressing all B cells andlor plasma cells by means of (i) irradiation, (ii) 
conventional or novel phannacologic agents, (iii) anti-B cell or plasma cell 
monoclonal antibodies, or (iv) immunotoxins. 
Whole Body Irradiation (WBI) 
Irradiation causes death preferentially of rapidly dividing cells, such as malignant 
cells and cells involved in hematopoiesis, and is currently being used as an element in 
the conditioning regimen for bone marrow transplantation (69). It has therefore been 
included in some protocols aimed at achieving mixed hematopoeitic chimerism and 
the induction of tolerance (39,49), WBI of 300cGy (which is a non-lethal dose from 
which the bone marrow can spontaneously recover) leads to the temporary ablation of 
B cells (but not plasma cells (70)) (Figs. 2A & 2B), but is associated with only a small 
and temporary reduction in the production of antibody, including anti-aGal 
(38,39,49,70). B cell recovery is fairly rapid (Figure 2C). WBI, therefore, although 
creating "space" in the bone marrow to facilitate engraftment of transplanted 
hematopoietic cells, has only a minimal and transient effect on antibody production. 
Pharmacologic Agents 
Phannacologic immunosuppressive therapy combined with EIA in the depletion and 
suppression of production of anti-a Gal has been investigated by Lambrigts et al. (72). 
Without immunosuppressive therapy, anti-aGal returned to pre-EIA levels within 48 
hours after the last of 3 consecutive EIA procedures. Various combinations of agents 
were administered in an effort to slow the rate of recovery of anti-a Gal, but none 
suppressed anti-a Gal production to a level of clinical relevance. However, rebound of 
anti-aGal to levels greater than or equal to pre-treatment levels was successfully 
prevented. Of the agents investigated, mycophenolate mofetil was judged to provide 
most suppression of antibody production in the absence of toxic side effects. We have 
continued this investigation in baboons by assessing the efficacy of other agents, such 
as zidovudine, methotrexate and cladribine (see below). Some agents are worthy of 
further discussion. 
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Figure 2. 
Photomicrographs of baboon LNs at various timepoints pre and post WBI (300 cGy) 
immunohistochemically stained with the mouse anti-human monoclonal antibody oceD20. 
A. LN before WBI showing nonnal distribution ofB cells in the follic les. 
B. LN 5 days after WBJ. Note the near complete depletion of B cells . 
c. LN 15 days after WBI. Recovery ofB cells can be seen, beginning at the periphery of the follicles. 
Cyclophosphamide 
Cyclophosphamide, an alkylating metabolite, has been associated with suppression of 
both T and B lymphocytes. lts administration in large doses results in a significant 
reduction in the rate of return of anti-a Gal after EIA (72). White and coworkers have 
used cyclophosphamide extensively, along with cyclosporine and steroids, in their 
hDAF transgenic pig-to-primate heart and kidney transplant models (36,37), Its use 
has been associated with significant prolongation of xenograft function for up to 
several weeks, although A VR remained difficult to prevent. It is a difficult drug to use 
long-term as it can result in severe leukopenia and other side effects which contribute 
to morbidity. 
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Mycophenolate mofeti! (MMF) 
MMF is an inhibitor of purine synthesis that inhibits T and B cell proliferation and 
antibody production. It reduced anti-a Gal return after EIA to a comparable extent to 
that obtained by cyclophosphamide, when this latter drug was given in moderate and 
safe dosage (72). Minanov et al. (73) described modestly prolonged graft survival of 
pig-to-newborn heart transplants treated with a combination of MMF, cyclosporine, 
and methylprednisolone (from 3.6 to 6.2 days). 
Melphalan 
This alkylating agent has been used as mainstay treatment for multiple myeloma, 
often in combination with steroids. It would appear to be a promising drug for use in 
xenotransplantation in view of its effect on plasma cells, which are almost certainly 
the major source of anti-aGal production. However, Lambrigts et al. found it rather 
less effective in depleting anti-a Gal than cyclophosphamide or MMF (72), although 
there would appear to be a delayed effect on antibody production that may be 
important. Our impression is that prolonged therapy with melphalan (over several 
weeks) combined with intermittent courses of EIA may slowly reduce the number of 
anti-a Gal antibody-producing cells. 
Zidovudine (AZT) 
Zidovudine is a purine analogue used in the treatment of HIV infection (74). It 
inhibits viral reverse transcriptase, but also inhibits the manunalian DNA-polymerase 
that is responsible for DNA synthesis of mitochondria. Our hypothesis was that, since 
antibody production by B and plasma cells is a highly energy-dependant process, 
depletion of cellular mitochondria might prevent antibody from being produced. We 
have administered zidovudine to baboons while depleting anti-a Gal by EIA. There 
was significant reduction of anti-aGal, particularly of IgG, suggesting some 
suppressive effect of the drug (Fig. 3). However, this reduction would not have been 
sufficient by itself to be of clinical impact. 
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Zidovudine 1200 mg/day OayOto28 
Figure 3. 
Graph depicting the anti-a Gal IgG and JgM profiles in a naIve baboon receiving zidovudine from day 0 
through day 28. EIA was performed on the days indicated by short arrows. Following successful 
removal of anti-aGal by repeated ElA, the rate of return of antibody was slow, but return to pre-
treatment level was not significantly prevented. 
A1ethotrexate 
Methotrexate is a dihydrofolate reductase inhibitor, and is another drug that has been 
used in the treatment of malignant lymphoid tumors. It has also been used as 
adjunctive therapy following organ transplantation in patients with steroid-resistant or 
recurrent acute rejection (75). We have assessed its effect on anti-cx.Gal production in 
baboons. Although it had no apparent myelosuppressive effect (in contrast to its effect 
in humans), anti-aGallevels remained low after EIA for more than 2 weeks. 
Cladribine (Leustatin) 
Cladribine (leustatin) IS a novel antineoplastic drug used for therapy III 
lymphoproliferative malignancies. It is being explored in experimental transplantation 
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as an immunosuppressive agent in both small and large animal models (76). Unlike 
other chemotherapeutic agents affecting purine metabolism, it is not only toxic to 
actively dividing lymphocytes but also to quiescent lymphocytes and monocytes, in 
which it induces apoptosis. In our studies, its efficacy as a suppressor of antibody 
production is at least equal to that of most of the other agents tested. Following EIA, 
baboons receiving c1adribine maintained a decrease in anti-aGal levels of 
approximately 50% - 80% for approximately 2 weeks. 
Anti-B Cell Monoclonal Antibodies (mAbs) 
B cells can be targeted with mAbs directed against B cell-specific surface antigens. 
Several such mAbs have proven successful in reducing the mass of B cell lymphomas 
in in vitro, preclinical, and clinical studies (76-81). Following coating by mAb, the 
lymphoma cells are cleared mainly through antibody-dependant cell-mediated 
cytotoxicity. Such mAbs may prove useful in depleting nonnal B cells and thus 
perhaps lead to reduced antibody production. CD20, expressed on the surface of 
normal B cells, is targeted by the human-mouse chimeric antibody IDEC-C2B8. This 
mAb is effective in depleting malignant B cells in the blood of patients with B cell 
lymphoma; tumor regression has been documented (77-81). In our laboratory, 
baboons have been treated with a 4 week course (xl weekly) of anti-CD20 mAb, after 
which no B cells could be detected in the blood or bone marrow for up to 3 months. 
Lymph nodes showed an 80% decrease in B cells 5 weeks after the initial dose, with 
recovery beginning by week 6. After a course of EIAs, anti-a Gal levels remained 
reduced for 3-4 weeks but the reduction was relatively modest when compared with 
the extent of B cell deletion. 
Immunotoxins 
Some anti-B cell mAbs can be conjugated to toxins, such as ricin A or sapporin, and 
become more efficient in depleting B cells (82,83). CD22 is involved with the 
generation of mature B cells within the bone marrow, blood, and marginal zoneS of 
lymphoid tissues. An anti-CD22 mAb has been successful in the treatment of non-
Hodgkin lymphoma (84). An anti-CD22 mAb was conjugated to the ricin A chain 
(kindly provided by Ellen Vitetta) and administered to a baboon. Its administration 
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led to a rapid reduction of B cells in the blood, bone marrow and lymph nodes, but its 
prolonged effect was impaired by the development of anti-murine and anti-ricin 
antibodies. It was therefore difficult to assess its true effect on anti-aGal antibody 
levels but, even with impairment of its efficacy by the development of antibodies, its 
immediate effect looked encouraging. 
Prevention of Induced Antibodies 
Induced anti-aGal IgG, and possibly antibody directed against new porcine (non-aGal) 
antigenic determinants, are considered to playa major role in A VR. These newly-
synthesized antibodies are ahnost certainly produced by a T cell-dependent mechanism. 
Prevention of this induced reponse may therefore prove to be a major step in the 
prevention of A YR. The costimulatory pathway of CD40 and the T cell ligand, CD40L 
(or CD154), is crucial for effective activation of T cells to antigen (85) and plays an 
important role in establishing T cell-dependent B cell activity (86). Blockade of this 
pathway alone or in combination with blockade of the B7/CD28 pathway effectively 
prolongs survival of skin and organ allografts in rodents (87) and of kidney allografts in 
monkeys (88). At our center, costimulatory blockade has been shown to facilitate the 
establishment of mixed chimerism and tolerance to skin allografts in rodents when 
combined with a nonmyeloablative regimen (89). In xenotransplantation, costimulatory 
blockade has allowed prolonged survival of rat-to-mouse skin and heart grafts, as well as 
pig-to-mouse skin grafts (90). Recently, we have incorporated murine anti-human 
CD40L mAb therapy in a regimen aimed towards the induction of mixed hematopoietic 
chimerism in baboons (91). Without anti-CD40L mAb, high doses of porcine blood 
progenitor cells transplanted into baboons lead to sensitization to aGal (with a IOO-fold 
increase in anti-aGal IgG) and the development of antibody to new (non-aGal) epitopes 
Fig. 4). 
"When anti-CD40L mAb was added to the regimen, sensitization to all pig antigens, 
including aGal, was prevented (Fig. 5). Although there was a return of aGal-reactive 
IgM and IgG to pretransplant levels, there was no increase of either immunoglobulin 
above those levels. The development of antibody to other pig antigens was also 
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prevented. These data suggest that anti-CD40L rnAb may be of great value in preventing 
A VR in pig-to-primate xenotransplantation. 
CONCLUSIONS I FUTURE INVESTIGATIONS 
Anti-aGal plays a major role in complementMmediated HAR of a porcine vascularized 
organ. If this is avoi.ded, the development of A VR would appear to be related to 
induced high affinity antiMaGal IgG and antibody to non-aGal porcine detenninants. 
Unless accommodation develops, or tolerance is achieved during a window when 
there is no antibody being produced, it would appear to be necessary to suppress anti-
aGal production permanently, which would clearly be difficult, if not impossible. If 
tolerance is the goal, it would at least appear to be necessary to suppress anti-aGal 
production for a period of time sufficient to allow for apoptosis of aGal-reactive 
B/plasma cells by the presence of pig cells expressing the aGal epitope. 
Several strategies have been developed for depletion and maintenance of depletion of 
anti-aGal. EIA with an aGalMspecific immunoaffinity column is currently effective in 
depleting anti-aGal, of both IgG and IgM subclasses. Our experience with almost 300 
EIAs in baboons indicates that a course of 3 EIAs results in 99% and 97% reductions in 
IgG and IgM. respectively. Unfortunately, depletion cannot be maintained without 
repeated EIA. 
The combination of EIA with agents such as cyclophosphamide, :MM:F, zidovudine, 
metphalan, and cladribine have contributed to a reduced rate of return of anti-a Gal, but 
not to the extent to be clinically relevant. In the absence of an effective anti-plasma cell 
rnAb, current attention is directed towards B cells. The normal life-span of human 
plasma cells remains uncertain but, if B cells could be eliminated, no new plasma cells 
would be produced. Following the death of existing plasma cells, a state of 
hypogammaglobulinemia might be reached. During this period, newly-developing aGal-
reactive B cells could be tolerized by successful porcine hematopoietic cell 
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transplantation. Although this temporary state of hypogammaglobulinemia would not be 
without risk to the subject, steps could be taken to limit this risk. 
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Figure 4. 
Anti-aGal IgG and IgM (left) and non-aGal-reactive antibody (right) responses as median fluorescence 
intensity (MFI) following porcine peripheral blood progenitor cell (PBPC) transplantation in 
representative baboons receiving a tolerance inducing regimen without anti-CD40L mAb. The arrows 
(left) indicate the first day of porcine PBPC transplantation, which was administered after the third and 
final EIA (day 0). In (right), column 1 represents the anti-pig antibody level, column 2 represents the 
same serum after immunoadsorption of anti-aGal antibody, and column 3 represents this serum 
depleted of both aGal-reactive and non-a Gal-reactive antibodies. The difference between columns 1 
and 2 therefore indicates the amount of anti-a Gal antibody, and the difference between columns 2 and 
3 indicates the amount of anti-nona Gal antibody. 
Left. A rise in both anti-aGal IgG and IgM occurred by day 10, indicating sensitization 
to the Gal detenninants on the PBPe. 
Right. Antibody directed to porcine nonaGal detenninants on the PBPC developed within 
20 days. 
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Anti-aGal IgG and IgM (left) and non-aGal-reactive antibody (right) responses as meOian I1uorescence 
intensity (MFI) following porcine peripheral blood progenitor cell (PBPC) transplantation in 
representative baboons receiving a tolerance inducing regimen with anti-CD40L mAb. 
Left. No rise in anti-aGal IgG or IgM over baseline occurred. 
Right. Antibody directed to porcine nonaGal determinants on the PBPC did not develop 
With regard to current progress, however, the ability of anti-CD40L mAb to prevent the 
induced antibody response to pig cells represents a significant step in overcoming the 
immunologic barriers to xenotransplantation, and will undoubtedly facilitate the survival 
of transplanted pig organs in primates and the induction of tolerance. 
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Effects of specific anti-B and/or anti-plasma cell immunotherapy on 
xenoreactive antibody production in baboons 
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ABSTRACT 
Background. Anti-Galal-3Gal antibodies (anti-aGal Ab) are a major barrier to 
clinical xenotransplantation as they are believed to initiate both hyperacute and acute 
humoral rejection. Extracorporeal immunoadsorption (EIA) with aGal 
oligosaccharide columns temporarily depletes anti-aGal Ab, but their return is 
ultimately associated with graft destruction. We, therefore, assessed the ability of two 
immunotoxins (IT) and two monoclonal antibodies (mAb) to deplete B and/or plasma 
cells both in vivo and in vitro in baboons, and to observe the rate of return of anti-
aGal Ab following EIA. 
Methods. The effects of the mouse anti·human IT anti-CD22·ricin A (ocCD22·IT. 
directed against a B cell determinant) and anti·CD38-ricin A (ocCD38-IT. Band 
plasma cell determinant) and the mouse anti-human anti-CD38 mAb (ocCD38 mAb) 
and mouselhuman chimeric anti-human anti-CD20 mAb (ocCD20 mAb. Rituximab. B 
cell determinant) on B and plasma cell depletion and anti-aGal Ab production were 
assessed in vivo in baboons (n=9) that had previously undergone splenectomy. For 
comparison, two baboons received nonmyeloablative whole body irradiation (WBI) 
(300 cGy). and one received myeloablative WBI (900 cGy). Five baboons were 
administered either ocCD22-IT (at 0.125 - 0.19 mg/kg x 4 doses; n~2) or ocCD38·IT 
(0.1 - 0.6 mg/kg x 14 doses; n~3). One baboon received xCD38 mAb at OJ mg/kg x 
21 doses. Three baboons received ocCD20 mAb at 20 mg/kg x 4 doses, either with 
(n~l) or without (n~2) WBI (150 cGY). Depletion ofB cells was monitored by flow 
cytometry of blood, bone marrow (BM) and lymph nodes (LN), and by histology of 
LN. EIA was carried out after the therapy and anti-aGal Ab levels were measured 
daily. These agents were further analyzed in vitro. 
Results. In vivo, WBI (300 or 900 cGy) resulted in 100% B cell depletion in blood 
and BM, > 80% depletion in LN, with substantial recovery of B cells after 21 days 
and only transient reduction in anti-aGal Ab after EIA. The effect of both murine ITs 
was in part limited by the development of ccmurine andlor ocricin antibodies. 
However, ocCD22-IT depleted B cells by >97% in blood and BM, and by 60% in LN. 
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but a rebouud of B cells was observed after 14 and 62 days in LN and blood, 
respectively. At 7 days, serum anti-aGal IgG and IgM Ab levels were reduced by a 
maximum of 40 - 45% followed by a rebouud to levels up to 12-fold that of baseline 
anti-aGal Ab by day 83 in one baboon. The results obtained with ocCD38-IT were 
inconclusive. This may have been, in part, due to inadequate conjugation of the toxin. 
Cell coating was 100% with ocCD38 mAb, but no changes in anti-aGal Ab production 
were observed. ocCD20 mAb resulted in 100% depletion of B cells in blood and BM, 
and 80% in LN, with recovery of B cells starting at day 42. Adding 150cGy WBI at 
this time led to 100% depletion of B cells in the BM and LN. Although B cell 
depletion in blood and BM persisted for> 3 months, the reduction of serum anti-a Gal 
IgG or IgM Ab levels was not sustained beyond 2 days. In vitro, ocCD22-IT inhibited 
protein synthesis in the human Daudi B cell line more effectively than ocCD38-IT. 
Upon differentiation of B cells into plasma cells, however, less inhibition of protein 
synthesis after ocCD22-IT treatment was observed. Depleting CD20-positive cells in 
vitro from a baboon spleen cell population already depleted of granulocytes, 
monocytes, and T cells led to a relative enrichment of CD20-negative cells, i.e., 
plasma cells, and consequently resulted in a significant increase in anti-a Gal Ab 
production by the remaining cells, whereas depleting CD38-positive cells resulted in a 
significant decrease in anti-aGal Ab production. 
Conclusions. ocCD20 mAb + WBI totally and efficiently depleted B cells in blood, 
BM, and LN for >3 months in vivo, but there was no sustained clinically significant 
reduction in serum anti-aGal Ab. The majority of antibody secretors are CD38-
positive cells, but targeting these cells in vitro or in vivo with ocCD38-IT was not very 
effective. These observations suggest that B cells are not the major source of anti-
aGal Ab production. Future efforts will be directed towards suppression of plasma 
cell function. 
INTRODUCTION 
Xenotransplantation of porcine organs is viewed by many clinicians and investigators 
as a possible solution to the increasing shortage of donor organs for transplantation 
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(1,2,3). Although many advances have been made in understanding the immunologic 
and inflammatory phenomena associated with xenograft rejection (4,5,6), porcine 
vascularized xenografts do not survive beyond a median of approximately one month 
in nonhuman primate recipients (7,8). There is clear evidence that primate antibodies 
directed against tenninal Galal-3Gal oligosaccharides (anti-aGal Ab) on porcine 
vascular endothelium (9,10,11,12) are responsible for complement-mediated 
hyperacute rejection of porcine organs (13). Furthennore, even if hyperacute rejection 
is averted by depletion of anti-aGal Ab, the use of complement regulatory agents or 
of porcine organs transgenic for human complement regulatory proteins, anti-aGal 
Ab still plays a major role in a delayed rejection response, known variously as acute 
vascular rejection, delayed xenograft rejection, or acute humoral xenograft rejection, 
which is possibly complement-independent (14). 
Specific depletion of anti-aGal Ab by extracorporeal immunoadsorption (ElA) of 
baboon plasma through columns containing synthetic aGal oligosaccharides (15,16) 
has resulted in prolonged xenograft survival (17,18,19). However, extended survival 
is limited by the return of anti-a Gal Ab and by the development of antibodies directed 
against other porcine (non-aGal) determinants (19,20). These develop despite 
intensive pharmacologic immunosuppressive therapy. Specific therapies that result in 
a sustained depletion of anti-aGal Ab and other antibodies will almost certainly prove 
beneficial in overcoming acute vascular rejection. 
Since antibodies are produced by B and plasma cells, depleting (or inhibiting the 
function of) these cells should result in diminished antibody production. Several 
pharmacologic agents targeting B cells were assessed for their ability to suppress 
production of anti-aGal Ab without significant success (6,21). Fuelled by the 
advances made in the treatment of B cell neoplasias using immunotherapy 
(22,23,24,25), the effects of specific anti-B and/or plasma cell immunotherapy on B 
cell depletion and anti-aGal Ab production in vivo and in vitro in baboons were 
investigated. These effects were compared to those achieved in baboons receiving 
myeloablative or nomnyeloablative whole body irradiation (WBI), as this has been 
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shown to deplete the majority of B cells in blood, bone marrow (BM), and lymph 
nodes (LN) (6) by inducing apoptosis in rapidly dividing cells such as lymphocytes 
(26). 
We selected deglycosylated (dg) ricin A (RTA) for the construction of specific anti-B 
and/or plasma cell immunotoxins (IT). The dgRTA chain inhibits protein synthesis by 
destroying 60S ribosomal RNA. dgRTA is not efficiently internalized without the 
ricin B chain but, once conjugated to a desired monoclonal antibody (mAb), 
internalization can be facilitated and specific cell toxicity achieved. Other criteria 
used to select effective ITs include: (i) high affinity of the antibody for antigen; (ii) 
limited distribution of the targeting antigen in order to avoid non-specific toxicity; 
(iii) inhibition of protein synthesis by the toxin at relatively low concentrations due to 
effective internalization and intracellular routing. 
Four agents were tested in vivo and/or in vitro in baboons. 
I. A mouse anti-human CD22 monoclonal antibody (RFB4) conjugated to dgRTA 
(ocCD22-IT) was prepared as described previously (27). This IT can inhibit 
protein synthesis and antibody production in vitro and give multi-log depletion of 
human B cell lymphomas in vivo (28). CD22 is expressed in the cytoplasm of all 
B cells and as surface antigen on mature B cells (29). The CD22 antigen is present 
on lymphoplasmacytoid cells and is expressed in most B cell lymphomas; but is 
diminished on the fully-differentiated plasma cell (29). 
2. The unconjugated mouse anti-human CD38 mAb (ocCD38 mAb, OKTlO, 
American Type Culture Collection, Manassas, V A). CD38 is expressed on all pre-
B and B cells, plasma cells, and thymocytes and is also present on activated T 
cells, natural killer cells, myeloblasts, erythroblasts, and BM cells (30). 
3. The ocCD38 mAb was conjugated to dgRTA (ocCD38-IT) as described previously 
(27). The purity of the IT was assessed by sodium dodecylsulphate-
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polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions 
(31). The preparation contained approximately 60% unconjugated mAb. 
4. A chimeric mouse-human mAb directed at the human CD20 surface antigen 
(ocCD20 mAb, Rituximab, kindly provided by IDEC Pharmaceuticals, San Diego, 
CAl, CD20 is expressed on both resting and activated B cells, but is down-
regulated on plasma cells (32). CD20 may also be expressed on follicular 
dendritic cells in germinal centers (33). 
MATERIAL AND METHODS 
In Vivo Experiments 
Animals 
Baboons (Papio anubis, n~12), of both sexes and weighing approximately 9 - 15 kg, 
were obtained from Biomedical Resources Foundation, Houston, TX. In view of the 
shortage and expense of nonhuman primates, five of the 12 baboons had been used 
previously (>2 months) for other experiments, but recovery of all study parameters 
(i.e., B cell counts and anti-aGal Ab levels) had occurred .. All experiments were 
performed in accordance with the Guide for the Care and Use of Laboratory Animals 
prepared by the National Academy of Sciences and published by the National 
Institutes of Health. Protocols were approved by the Massachusetts General Hospital 
Subcommittee on Research Animal Care. 
Surgical procedures 
Splenectomy, intravenous (iv) and intra-arterial catheterization, and EIA were carried 
out under inhalation anesthesia. A splenectomy is routinely performed in Oll baboons 
because there is evidence that this leads to prolonged survival of xenografts (34, 35) 
and, furthermore, we have found that spleens contain a large number of anti-aGal Ab-
secreting cells (Xu Y, et al. unpublished data). Baboons were premedicated with 
atropine (0,05 mg/kg im) and ketarnine (10 mg/kg im) prior to surgery and were 
intubated and ventilated through a closed circuit with oxygen (l - 2 L/min), nitrous 
oxide (2 - 4 Llmin), and isoflurane (0,5 - 3,0 %), Splenectomy was perfonned as 
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described previously (I7). Catheters were inserted in the internal and external jugular 
veins and carotid artery. The catheters were tunneled subcutaneously to the back, and 
brought out through a jacket and tethering system allowing monitoring of arterial 
blood pressure, access to blood withdrawal, and continuous or intermittent iv 
administration of fluids and/or drugs. Cefazolin (500 mg iv daily) was given as 
prophylaxis against infection. 
EXlracorporeal immunoadsorption (EIA) of anti-aGal Ab 
EIA was performed using an immunoaffinity column (Alberta Research Council, 
Alberta, Canada) containing synthetic aGal trisaccharide type VI as previously 
described (19,36). Briefly, using a COBE-Spectra apheresis unit (Gambro BCT 
International, Lakewood, CO), 3 plasma volrnnes were immunoadsorbed through an 
aGal immunoaffinity column at an average perfusion rate of 20 ml/min. 
Anticoagulation was achieved with citrate phosphate dextrose adenine, and 
hemodynamic stability maintained by volume replacement +1- phenylephrine 
infusion. The anti-aGal Ab-depleted plasma was returned to the baboon. Three 
consecutive daily EIAs were performed at the time of optimal B cell and/or plasma 
cell depletion. 
Whole body irradiation (WBI) 
Baboons received nonmyeloablative WEI 2xl50 cGy (n~2) or myeloablative WEI 
2x450 cGy (n~l) using a Cobalt 60 teletherapy unit (Therapy Services Inc., Frederick, 
MD) without specific anti-B and/or anti-plasma cell immunotherapy. Furthermore, 
one baboon received 150 cGy WEI 20 days after treatment with ocCD20 mAb (see 
below). 
Administration of experimental agents in vivo 
Treatment with ITs I mAbs was preceded by the iv infusion of 25 mg 
diphenhydramine to prevent potential anaphylactic reactions. Commencing on day 0, 
the ITs / mAb were administered as bolus iv infusions to baboons. We selected the 
dosages for ocCD22-IT (37) and ocCD20 mAb (38) based on maximum tolerated 
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doses from previous clinical studies. The dose of the ocCD38 mAb and the ocCD38-IT 
we had were extrapolated from the maximum tolerated dose used for the ocCD22-IT, 
since there was no previous clinical experience with this agent. 
ocCD22-IT (n:2) at 0.125 - 0.19 mg/kg every other day x 4 doses. 
ocCD38 mAb (n:l) at 0.3 mg/kg/day x 21 doses. 
ocCD38-IT (n:3) at 0.1 - 0.6 mg/kg/day x 14 doses. 
ocCD20 mAb (Rituximab) (n:3) at 20 mglkg/week x 4 doses. 
In Vitro Assays 
Tissue and cel! preparation 
Baboon spleen cells were surgically obtained by splenectomy as described above. Cells 
were harvested in RPMI (Gibco BRL, Grand Island, NY), homogenized, and filtered 
sequentially through a flow-mesh FM-IOO (PGL Scientifics, Frederick, MD). 
Peripheral blood mononuclear cells were prepared from heparinized peripheral blood 
obtained from healthy baboons. BM cells were obtained and prepared as described 
previously (39). Cells were additionally purified by separation over a Ficoll density 
gradient (Histopaque, Sigma, St.Louis, MO). 
B cell enrichment 
Red blood cells from cell preparations were lysed with ACK buffer (0.15 M NH4Cl, 
10 mM KHC03, 0.1 mM Na2EDTA.2H20). Cells were washed and resuspended in 
RPMI containing 10% fetal calf serum and gentamicin (Gibco BRL). The average 
total yield per spleen was 3-5 x 109 cells. Monocytes were depleted by adherence at 
37'C with 5% CO2 in RPMI with 10% fetal calf serum overnight. T cells were 
depleted by E-rosetting using AET- (Sigma) treated sheep red blood cells (Cocalico 
Biologicals, Inc., Reamstown, PA) following standard procedures. Granulocytes were 
removed during the E-rosetting procedure. Alternatively, T cells were depleted with 
anti-CD2 (Leu5b, Becton Dickinson, San Jose, CAl followed by goat anti-mouse IgG 
magnetic beads (Dynal, Lake Success, NY). B cells were enriched from an initial 
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average of 25-50% to 80-90%, as was assessed by flow cytometry (described below), 
The final preparation contained approximately 10% CD2-positive cells. 
In vitro activation / differentiation of plasma cells 
B cells (2x106 cells/ml in cell suspension medium) were activated with 0.04% 
Pansorbin (fixed Staphylococcus Aureus, Calbiochem-Novabiochem Corp., La Jolla, 
CAl and 2.5 ng/ml of IL2 (R&D Systems, Minneapolis, MN) for 2 - 3 days at 37'C 
with 5% CO,. Cells were washed and subsequently cultured in 2.5 ng/ml IL-2 and 
100 ng/ml IL-IO (R&D Systems) for up to 8 days, according to a modified protocol 
(40). These cells were then maintained in hybridoma medium (IMDM medium with 
10% fetal calf serum, 5 mglL bovine insulin, 10 mg/L bovine transferrin, 17.3 I-lg/L 
sodium selenite, and 5.5 x10-5M 2ME) for up to 30 days. Plasma cell morphology 
was confinned by cytospin (differential staining and intracellular immunoglobulin), 
ELISPOT and flow cytometry (both described below). Plasma cells at different stages 
of differentiation were harvested for further study. 
3H-Leucine (H-Leu) incorporation assay to measure total protein synthesis after IT 
treatment 
A total of 105 cells/well were incubated with ocCD22-IT, ocCD38-IT, or ocCD25-IT 
(as a control) at concentrations from 10-13M to 1O-8M for 1 hour at 4°C. Cells were 
washed and cultured overnight in RPMI with 10% fetal calf serum for B cells or with 
addition of 2.5 ng/ml IL-2 and 100 ng/ml IL-IO for plasma cells at 37'C with 5% 
C02. Cells were washed again, and pulsed in Leucine-free RPMI with 5 fICi/well 3H_ 
Leu for 5hr (for Daudi cells) or 18 hours (for B and plasma cells) at 37'C. 'H-Leu 
incorporation was examined by harvesting cells on to filters and counting the 
radioactivity by beta-counter (Wallac, Gathersburg, MD). 
ELISPOT for detection of onti-aGol Ab and total immunoglobulin production 
For detection of anti-aGal Ab production, 96-well MultiScreen-HA plates (MAHAS 
4510 mixed cellulose esters, Millipore, Bedford, MA) were coated with 100 fII/well (5 
fIg/ml in PBS) of aGal-BSA or control BSA (Alberta Research Council) at 4'C 
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overnight. For detection of total IgM or IgG production, goat anti-human IgM or IgG 
(Southern Biotech, Birmingham, AL) were used as coating reagents with goat anti-
mouse IgM or IgG as negative controls. Plates were washed with PBS and blocked 
with IMDM and 0.4% BSA for I hr at 37'C. A total of Ixl06 cells/well, with a serial 
5-fold dilution, were cultured overnight in a modified hybridoma medium (10% fetal 
calf serum replaced by 0.4% BSA) at 37°C with 5% CO,. The plates were then 
washed with PBS and PBS plus 0.1 % Tween-20. Antibody production was detected 
with 100 J.tl goat anti-human IgM or IgG conjugated to HRP (Southern Biotech) at 
1:1000 dilution in PBS with 1% BSA and 0.5% Tween at 4'C for I hour. Plates were 
washed with PBS plus 0.1 % Tween and PBS. Spots were visualized with substrate 
ABC or 4CN (Sigma) under a stereomicroscope (Nikon SM2-U) equipped with a 
vertical white light. Data were presented as spot forming units (SFU) per 106 cells. 
Flow cytometry 
Flow cytometry to detect B and T cells was performed on blood, BM (aspirates 
obtained from the iliac crests), and LN (biopsies obtained from either inguinal or 
axillary regions). The direct conjugated antibodies anti-CD3 FITC (FNIS, kindly 
provided by Dr. David Neville, Bethesda, MD) and anti-CD2 PE (Leu-5b, Becton 
Dickinson) were used as T cell markers, and anti-CD20 FITC (Leu-I 6, Becton 
Dickinson) and anti-CD22 PE (Clone RFB4, Caltag Laboratories, Burlingame, CAl as 
B cell markers. Blood and BM were incubated at 4° C, lysed at room temperature with 
ACK-Iysing buffer (Bio-Whittaker, Walkersville, MD), and washed and resuspended 
in 500 J.lI FACS Medium (1% BSA and 0.1% azide in phosphate-buffered saline). 
LNs were mashed, filtered, and resuspended in 500 J.lI FACS medium. Cell count was 
approximately 1 x 106 / 100 III in all samples. The samples were stained using the 
aforementioned T and B cell-specific antibodies. Acquisition was perfonned under hi-
flow using the F ACScan (Becton Dickinson), and samples were analyzed using 
WinList (Verity Software House, Inc., Topsham, ME). 
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Cell depletion using magnetic beads 
One million cells (106/ml) were incubated with 10 fig mAb (targeting the cells that 
were to be depleted) at 4°C for 1 hour. Cells were then washed and incubated with 
secondary goat-anti-mouse IgG magnetic beads following the manufacturer's protocol 
(Dynal). The cells that bound to the mAb were removed, and the remaining cells were 
assessed by flow cytometry and for antibody production by ELISPOT. 
Measurement of anti-aGal antibody (anti-aGal Ab) by ELISA 
Daily serum samples were obtained and anti-a Gal Ab levels were measured by 
ELISA (19). This consisted of loading a 0.016%-2% concentration of baboon serum 
on Maxisorb plates (Nunc, Naperville, IL, USA) coated with 5 flg/mL of aGal-BSA 
(Alberta Research Council). Bound antibodies were detected using polyclonal donkey 
anti-human IgG (Accurate, Westbury, NY) or rabbit anti-human IgM (DAKO, 
Copenhagen, Denmark) conjugated to horseradish peroxidase. Color development 
was achieved by using o-phenylenediamine dihydrochloride (Sigma) as a substrate at 
0.9mg/mL in PBS with urea hydrogen peroxide (Sigma). Absorbance at 490 run was 
determined by a THERMOmax plate reader (Molecular Devices, Menlo Park, CAl 
after blocking the reaction with 2N H2S04. 
Immunohistochemistry 
For in vitro experiments, a total of 100,000 cells in 200 fll PBS was centrifuged onto 
slides by Cytospin. The slides were either immediately stained with Giemsa or fixed 
overnight in 0.25% paraformaldehyde at 4° C for intracellular immunoglobulin 
staining. Goat anti-human IgM and/or IgG conjugated to peroxidase (Southern 
Biotech) at 1: 1000 was added to the slides after which they were incubated at room 
temperature for 1 hour in a humidified chamber. After slides were washed, a DAB 
substrate kit (Vector Laboratories, Burlingame, CA) was used to visualize the 
staining. 
For in vivo experiments, depletion of CD20 positive cells in LNs was assessed using 
the anti-CD22 anti-human mAb (Caltag) as primary antibody on frozen samples in a 
standard immunohistochemical assay. Depletion of CD22-positive cells was 
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examined in paraffin-embedded tissue using the anti-CD20 anti-human mAb (DAKO, 
Carpinteria, CAl. 
RESULTS 
In vivo experiments 
Effect oJWBI on B cell depletion and anti-a(}al Ab production 
Administration of 2xl50 cGy WEI led to rapid and complete B cell depletion as 
detected by flow cytometric analysis of blood and BM by day 2, with recovery 
starting by day 28 in the blood and BM (data not shown). B cell depletion in the LN 
was 75 - 100% between days 7 and 14, with recovery by day IS (data not shown). 
This finding was confinned by immunohistochemistry, where complete depletion of 
B cells in the LN was observed at day 9, with recovery starting at day IS in the 
periphery of the follicles (See Chapter 3, Figure 2). In these baboons, a 
thrombocytopenia «20,000/f!1) was noted between days 6 and 13, and a 
leukocytopenia « 1000/f!1) between days 13 and 17, most probably due to BM 
depression. The anti-aGal Ab levels in these baboons remained unchanged, in nonnal 
ranges (data not shown), although no EIAs were performed. When EIAs were 
performed after myeloablative WEI (900 cGy), the rate of recovery of anti-aGal Ab 
was unchanged when compared to EIA treatment alone (data not shown). These data 
confirm that B cells are readily depleted by WEI in blood and BM for 28 days, and in 
LN for 15 days, but that this depletion is not associated with a significant decrease in 
anti-a Gal Ab production. 
Effect oJthe a:CD22-IT on B cell depletion and anti-a(}al Ab production 
At the doses given, ocCD22-IT was efficient in depleting B cells in blood and BM 
(86-99% (Fig. 1 - top) and 80-97%, respectively) between days 6 and 8. B cell 
depletion in LN was less marked, the maximum percentage of depletion ranging 
between 50 and 58% on days 7-12 (data not shown). T cell counts in blood, BM, and 
LN remained unchanged. However, the recovery of B cells was swift. In blood, 
evidence of recovery was observed at.day 12 in both baboons, with increases up to 6-
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fold baseline levels between days 62 and 85 (Fig I - top). In BM, recovery was first 
observed between days 12 - 15, with recovery to baseline levels by day 62 (Data not 
shown). 
Figure 1. 
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The effect of ccCD22-IT in vivo on B cell depletion and anti-aGal Ab production in a baboon. 
Top. Bar chart demonstrating the depletion of CD20-positive B cells in blood (as absolute cell count) 
before, during, and after treatment with four iv doses of 0.19 mg/kg every other day of ccCD22-IT 
commencing on day O. Complete depletion ofB cells was seen immediately following treatment at day 
Bottom. Anti-aGal Ab profile of this baboon. EIAs were performed at time of maximum B cell 
depletion (days 8, 9, and 10). Note the complete depletion of anti-aGal IgG and IgM Ab following 
each consecutive EIA. The maximum depletion was 40% and 45% 7 days following ElA for IgG and 
IgM, respectively. Rebound of anti-aGal IgG and IgM Ab to levels 12- and 9-fold higher than baseline, 
respectively, was observed by day 83. 
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A rebound of B cells to numbers higher than baseline was also observed in LN in one 
baboon by day 22 (2-fold), while in a second baboon return to baseline levels was 
seen after 18 days (data not shown). Immunohistochemistry of LN correlated well 
with the flow cytometry data (data not shown). In one baboon, the initial anti-aGal 
Ab profiles were encouraging with depletion of IgG and IgM 48 hours post EIA 
sustained at 70 and 100%, respectively. However, by day 7, the depletion of IgG and 
IgM was 17 and 34%, respectively (data not shown). In the second baboon, the 
maximum depletion of anti-aGal Ab was 40 - 45% at 7 days, with rebound above 
baseline levels by day 55 (Fig 1 - bottom). Both baboons developed anti-murine 
antibodies and one baboon developed anti-ricin A chain antibodies, as determined by 
ELISA (data not shown). No changes in platelet or white cell count were observed. 
These data indicate that although the ocCD22-IT was effective in the short-term 
depletion of B cells from blood, BM, and LN, this was not associated with a 
significant decrease in the rate of return of anti-aGal Ab. Furthermore, treatment with 
this IT led to the development of anti-murine and anti-ricin antibodies. 
Effect of the cx:CD38 mAb on B cell depletion and anti-aGal Ab production 
Cell coating with the ocCD38 mAb was 100% throughout the treatment in the one 
baboon studied. However, no substantial changes occurred in anti-aGal Ab levels 
following EIA (data not shown). Although blood levels of anti-CD38 mAb 
approximated 1000 ng/ml, no sensitization to the murine component of the 
monoclonal antibody occurred. Conjugation to the ricin A toxin would, therefore, 
seem necessary to successfully deplete B cells and plasma cells in vivo. 
Effect of the cx:CD38-IT on B cell depletion and anti-aGal Ab production 
ocCD38-IT was first tried in a baboon which, 18 months before, had received 
myeloablative \VBI and had undergone treatment with melphalan for several weeks. 
However, by the time of treatment with the ocCD38-IT, anti-aGal Ab levels, as well 
as T and B cell counts, had returned to baseline levels (i.e., pre WEI). Following 
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depletion by EIA, anti-aGal IgG and IgM Ab remained at undetectable levels for I 
week. After an additional EIA on day 26, anti-aGal IgM Ab was undetectable for 10 
days while the IgG returned to baseline values by day 4 (Fig. 2). In a second, 
previously untreated baboon, anti-aGal IgO Ab increased to levels greater than 
baseline within 48 hours after the last of 3 consecutive EIAs (data not shoVvn). 
Coating ofCD38-positive cells with ocCD38-IT was 100% in both cases. Sensitization 
occurred in both baboons, with the development of anti-murine and anti-ricin 
antibodies. Treatment with the ocCD38-IT in a third baboon did not result in coating 
of CD38-positive cells and sUbtherapeutic plasma levels of ocCD38 were measured 
(data not shovm). The reasons for failure in this animal were unclear. 
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Figure 2. 
Anti-aGal Ab profile in baboon receiving ocCD38-IT. During iv treatment with ocCD38-IT (0. J 
mg/kg/day for 14 days commencing on day 0), 3 consecutive EIA were performed, effectively 
removing all anti-aGal IgG and IgM Ab from circulation. Levels of anti-a Gal Ab remained 
undetectable for 7 days after which recovery of both IgO and IgM occurred, with rebound above 
baseline of IgG. After a fourth EIA was performed on day 26. IgM was again undetectable for 10 days. 
whereas IgO returned to previous levels after 6 days. 
97 
Section 111- Chapler 4 
These results indicate that in one experiment ocCD38-IT may have been effective in 
depleting antibody-producing cells, as the levels of anti-aGal Ab remained at low 
levels following EIA. The reason for our failure to duplicate these results in 
subsequent baboons are unclear. It is possible that the development of anti-murine 
and/or anti-ricin A chain antibodies played a role. Alternatively, it is possible that the 
positive effect observed with ocCD38-IT in one baboon may have been associated 
with previous treatment (which includes melphalan), even though the drug has been 
discontinued> 2 months previously. 
Effect of ocCD20 mAb and/or WBI on B cell depletion and anti-aGal Ab production 
Following the first dose of ocCD20 mAb, B cells were rapidly depleted from the blood 
in all baboons, and remained at low levels through day 112 (Fig. 3 - top). Depletion of 
B cells in BM increased following each dose of ocCD20 mAb, with a maximum 
depletion of 92% at day 40 in one baboon, after which recovery was observed (data 
not shown). The effect of ocCD20 mAb on B cell depletion in LN was less impressive, 
with a maximum depletion of 70% B cells/gram LN at day 35, and recovery to 
baseline values by day 57. In one baboon, because some return of B cells in BM was 
observed at day 35, 150 cGy WEI was administered at day 42. Complete depletion of 
B cells in BM was achieved until day 105, with 40% recovery at day 287. The 
depletion in LN was complete until day 70, with recovery by day 105 (data not 
shown). Although EIA resulted in complete depletion of anti-aGal IgG and IgM Ab, 
recovery of anti-a Gal Ab could be observed within 72 hours following the last EIA 
(Fig. 3 - bottom). Three days following EIA, the reduction in anti-aGal IgG Ab levels 
was 80%, with recovery to 75% of pre-treatment levels within 2 days thereafter. The 
reduction in anti-aGal IgM Ab levels was less marked (60% 3 days following EIA), 
with recovery to pre-treatment levels within 1 day, and increase above baseline levels 
(1-2 fold) within 5 days. 
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In vitro experiments 
Morphology of B and plasma cells in culture 
The anti-human ocCD20 mAb, ocCD22 mAb, surface immunoglobulin, and ocCD38 
mAb exhibited good cross-reactivity in binding to baboon spleen B cells when 
compared with binding to human spleen B cells (data not shown). During plasma cell 
differentiation, C020, C022, and surface immunoglobulin were down~modulated 
whereas CD38 expression remained high (Fig. SA). Morphologically, plasma cells 
could readily be distinguished from B cells by size and cell-cell interactions (Fig. SB). 
Furthermore, plasma cells secreted immunoglobulin, as was confirmed by 
intracellular immunoglobulin staining (data not shown). 
These results indicate that the anti-human ITs and rnAb used in these studies cross-
react with baboon cells, and that efficient CD38 targeting may be effective in 
depleting both B and plasma cells. 
Inhibition of protein synthesis 
The ability of ocCD22-IT and ocCD38-IT, along with the negative control ricin A-
conjugated anti-CD2S mAb (ocCD2S-IT), to inhibit protein synthesis using the human 
Burkitt's lymphoma, Daudi, cell line was evaluated. Flow cytometric analysis of 
Daudi cells demonstrated that they are positive for both CD22 (RFB4, 66%) and 
CD38 (OKTlO, 74%), and that CD38 stains brighter than CD22 (data not shown). 
Using the 3H-Leucine incorporation assay, 100% inhibition of protein synthesis was 
achieved with ocCD22-IT at 10,9 - 10'8 M, whereas ocCD38-IT led to a maximum of 
60% inhibition of protein synthesis at 10'8 M (Fig. 4). Furthermore, the slope of the 
curve for ocCD38-IT is much less steep than that for ocCD22-IT. This suggests that 
ocCD38-IT has either a slow rate of internalization and intracellular routing, or slow 
kinetics, leading to less effective inhibition of protein synthesis. 
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Figure 3. 
The effect of <xCD20 mAb in vivo on B cell depletion and anti-aGal Ab production in a baboon. 
Top. Bar chart demonstrating the depletion of CD22-positive B cells in blood (as absolute cel! count) 
before, during, and after treatment with four iv doses of20 mg/kg of <xCD20 mAb, at weekly intervals 
commencing on day O. Almost total depletion of B cells was seen immediately after initiating the 
course of <xCD20 mAb therapy. As some return of B cells was seen in the BM by day 35, WBI (150 
cGy) was administered - this led to almost complete depletion of B cells> 3 months. 
Bottom. Anti-aGal Ab profile in this baboon. EIAs were perfonned at time of maximum B cell 
depletion. Note the complete depletion of anti-aGal Ab following each consecutive ElA. Return of 
anti-a.Gal Ab was not significantly inhibited following treatment with <xCD20 mAb, with anti-aGal 
IgG Ab returning to baseline values, and anti-aGal IgM Ab increasing to levels above baseline. The 
maximum reduction in anti-aGal IgG Ab was 80% 72 hours following EIA, with recovery to 75% of 
pre-treatment levels within 2 days. The maximum reduction in anti-ctGal IgM Ab was less marked, 
reaching 60% 72 hours following EIA, with recovery to pre-treatment levels within 1 day, and increase 
above baseline levels (1-2 fold) within 5 days. 
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Activated B cells andlor early plasma cells had high levels of protein synthesis (in 
contrast to resting B cells). Protein synthesis was efficiently inhibited by the ocCD22-
IT by approximately 60% at 10-10 M in suspensions containing 80% CD22-positive 
cells (Fig. 5). This inhibition was less marked than that observed with the ocCD22-IT 
on human Daudi cells, presumably due to the presence of a CD22-negative population 
in the baboon cell preparation. Plasma cells down-modulated surface CD22 
expression during differentiation. Consequently, at day 8 (22% CD22-positive cells) 
and day 15 (6% CD22-positive cells) of in vitro differentiation, protein synthesis was 
not inhibited by the ocCD22-IT. 
These data suggest that ocCD22-IT is more effective than ocCD38-IT in inhibiting 
protein (e.g., antibody) synthesis in vitro, but, as predicted, that it is not effective in 
inhibiting protein synthesis of differentiated B cells (e.g., plasma cells). 
Anli-aGol Ab production by baboon spleen cells after depleting CD20-, CD22-, or 
CD38-positive cells 
Baboon spleen cells, depleted of T cells, monocytes, and granulocytes, were used in 
this assay. Removal of CD20-positive B cells from baboon spleen cells with magnetic 
beads resulted in an increased frequency of anti-aGal IgM Ab and total 
immunoglobulin secretors (Fig. 6A). This effect was also seen when CD22-positive 
cells were depleted (data not shown). Depletion ofCD38 cells by magnetic beads led 
to a significant decreased frequency of anti-a Gal Ab and total immunoglobulin 
secretors (Fig. 6B). Flow cytometry confirmed the efficient removal ofCD20-, CD22-
,or CD38-positive cells (data not shown). 
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Figure 4. 
--'>- oc CD22-IT 
--D- oc CD38-IT 
--- oc CD25-IT 
Protein synthesis by human Daudi cells in the presence of ocCD22-IT, :x:C038-IT, and the negative 
control :x:CD25-IT. Data are presented as percentage protein synthesis ( i.e., eH-Leu incorporation by 
cells treated with IT j 3H_Leu incorporation by cells treated with unconjugated mAb) x 100%). 
The negative control ocCD25-IT demonstrates a maximum and stable 75% protein synthesis at all 
concentrations of antibody. Treatment with ocCD22-IT leads to an efficient decrease in protein 
synthesis, approaching 0% at concentrations between IO-lO_IO-sM, whereas treatment with ocCD38-IT 
is not as efficient. The minimum protein synthesis is 40% at a concentration of ! O·sM. 
These data indicate that enrichment for plasma cells (by depleting CD20- or CD22-
positive cells) leads to a relative increase in the frequency of anti-aGal Ab and total 
immunoglobulin producing cells, aud that depletion of CD38-positive cells (i.e., B 
cell blasts and plasma cells) removes auti-aGal Ab aud total immunoglobulin 
secretors. Plasma cells and B cell blasts therefore appear to be responsible for the 
majority of anti-aGal Ab production in baboon spleens. 
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Figure 5. 
Protein synthesis by baboon spleen cells in the presence of ocCD22, ocCD22-IT, on days 3, 8, and 15 
after in vitro activation and differentiation as measured by 3H_Leu incorporation. Data are presented as 
percentage protein synthesis ( i.e., eH-Leu incorporation by cells treated with ocCD22-IT ! 3H-Leu 
incorporation by cells treated with xCD22) x 100%). The minimum percentage protein synthesis was 
achieved at day 3 after in vitro differentiation, correlating with 80% CD22-positive cells. At days 8 and 
15 after in vitro differentiation, protein synthesis was not significantly changed. At these timepoints, 
only 22% and 6% CD22-positive cells, respectively, were measured. 
DISCUSSION 
It is well recognized that anti-aGal Ab are the major barriers to clinical 
implementation of xenotransplantation. Anti-aGal Ab are believed to be responsible 
for both hyperacute and acute vascular rejection of vascularized, discordant 
xenografts (9,14), Although it is possible to remove anti-aGal Ab from the circulation 
of nonhuman primates, either by perfusing the recipient's blood through porcine 
organs or through an extracorporeal immunoaffinity column specific for anti-aGal 
Ab, sustained depletion of anti-a Gal Ab has not been achieved due to ongoing 
antibody production (6). Treatment modalities aimed at reducing the production of 
anti-aGal Ab have to date been unsuccessful. Various pharmacologic agents, 
including brequinar sodium, methotrexate, melphalan, cladribine, zidovudine, 
cyclophosphamide, and mycophenolate mofetil, have been evaluated in our laboratory 
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without clinically significant reduction of antibody production (6,21). In our pig-to-
primate model aimed at inducing immunological tolerance, we have recently 
demonstrated that the anti-CDl54 mAb effectively prevents the induced (T cell-
dependent) antibody response to porcine antigens, but the return to baseline levels of 
(T cell-independent) anti-aGal Ab, in particular anti-aGal IgM Ab, is not prevented 
(6,20). Following depletion, the return of anti-aGal Ab in vascularized organ 
transplant models is invariably associated with destruction of the transplanted graft 
(18,19,41). 
Our center has been interested in studying the cellular origin of anti-aGal Ab. We 
have examined numerous tissues obtained from naIve baboons and baboons 
previously exposed to porcine tissue to determine whether anti-aGal Ab-producing 
cells are specific for, or restricted to, certain anatomical regions of the body. 
ELISPOT analyses of these tissues were performed and we observed the highest 
frequencies of anti-aGal Ab (predominantly IgM) secretors in naIve baboons in the 
spleen, tonsils, BM, and LN. Anti-aGal IgG was primarily found in the LN, whereas 
anti-aGal IgA was mostly seen in the small intestine in Peyer's patches. In 
splenectomized baboons sensitized to porcine antigens, however, these secretors 
(especially IgM and IgG) were primarily observed in the BM (Xu Y et aI., 
unpublished data). We believe that, although treatment aimed specifically at cells 
producing anti-a Gal Ab is highly desirable, the technology to do this is not yet 
available. Attention was, therefore, directed at less specific therapies targeting all 
antibody-producing cells. 
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ELiSPOT assay demonstrating the number of spot fanning units (SFU) / 106 cells of anti-aGal IgM 
Ab, and total 19O and 19M in baboon spleens after depletion of CD20- or CD38-positive cells by 
magnetic beads. 
A. Depletion of C020-positive cells resulted in an approximate 30-fold increase of anti-aGal IgM Ab 
production over baseline, and a 5-9 fold increase of total IgG and IgM. This increase indicated that the 
non-depleted (C020-negative) cells were responsible for the majority of antibody production. 
B. Depletion of CD38-positive cells led to an 88% decrease of anti-aGal IgM Ab, and a 96-98% 
decrease of total IgG and IgM production, respectively. These data suggest that CD38-positive cells are 
mainly responsible for antibody production. 
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Recently, significant progress has been made in the treatment of several hematologic 
malignancies. Several in vitro and in vivo pre-clinical and clinical studies have shovm 
promising data using specific anti-B and/or plasma cell mAbs to reduce the tumor 
load of B cell malignancies (22,23,24,25,42), We, therefore, assessed the capacity of 
several of these mAbs and ITs to deplete nonnal (non-malignant) B and/or plasma 
cells and to reduce production of anti-aGal Ab in baboons. 
Both treatment with the ocCD22-IT in vivo and \VBl led to a complete, but transient, 
depletion of CD22- and CD20-positive cells in blood and BM, Furthennore, there was 
no substantially reduced anti-aGal Ab production following EIA. In fact, after the 
ocCD22-IT treatment, as ocmurine antibodies developed, the levels of anti-aGal Ab 
increased significantly above baseline. It is not clear if this was due to sensitization to 
murine-a Gal, or a rebound phenomenon after depletion of B cells. The latter seems 
more likely as the amount of total inununoglobulin also increased. 
Sustained B cell depletion was achieved when ocCD20 mAb was combined with 150 
cOy \VEL B cells were virtually undetectable in the circulation for> 3 months, and 
were almost completely depleted from BM and LN for at least 70 days. Recovery in 
the blood and BM had not yet reached 25 and 40 % baseline, respectively, at day 216. 
Despite this medium-term, near-complete depletion of B cells, reduction of anti-aOal 
Ab levels was not sustained. The maximum depletion of anti-aGal IgG and IgM Ab 
following 72 hours following EIA was 80% and 60%, respectively, and was sustained 
for only 2 days, after which there was a return to baseline levels of IgM. Levels of 
IgO, however, remained at 66% of those pretreatment. Since depletion of B cells with 
the ocCD22-IT was not as effective as that obtained with the ocCD20 mAb, we did not 
combine the ocCD22-IT with WEI. 
These findings suggest that CD20- or CD22-positive B cells are not the major source 
of anti-aGal Ab production, and that other cells, presumably plasma cells or B cell 
blasts, are mainly responsible for antibody production. These observations are also in 
keeping with data presented by other groups, suggesting that antibody-producing cells 
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are long-lived (43,44) and radiation-resistant (45). Unfortunately. in vivo treatment of 
baboons with ocCD38-IT, reportedly targeting plasma cells, did not yield reproducible 
results. Only in one of 3 baboons was treatment with ocCD38-IT followed by reduced 
production of anti-a Gal Ab. It is lU1clear, however, whether this reduction in 
production of anti-aGal Ab was due solely to the treatment with cx:CD38-IT, or to 
some extent due to a late effect of extensive prior inunlU10suppressive treatment. In 
two other cases, when naiVe baboons were used, no effect on antibody production was 
observed. One potential explanation is that the ocCD38 mAb interaction with the 
CD38 molecule expressed on the cell surface did not efficiently mediate 
internalization of the mAb - receptor complex, which is required for effective killing 
by dgR T A. Furthermore, as CD38 is also expressed on cells other than B or plasma 
cells (e.g., activated T cells, natural killer cells, and BM cells), this could interfere 
with the specific binding of ocCD38-IT to B cells and plasma cells, reducing its 
efficacy. However, this explanation is not likely, since all cells were coated with 
ocCD38. In these experiments, higher doses of ocCD38-IT may have been more 
effective by providing greater cross-linking of receptors which could lead to increased 
internalization of the IT. 
The results of these in vivo studies prompted us to carry out further in vitro 
investigations. We first demonstrated that expression of CD20, CD22, and CD38 by 
baboon B cells is highly dependent on the state of differentiation I maturation of the 
cells. Most B cells express immunoglobulin, CD20, CD22, and CD38 on their 
surface. Plasma cells, however, have down-modulated surface immunoglobulin, 
CD20, and CD22 expression, although expression of CD38 is maintained on baboon 
plasma cells. This suggests that mAbs or ITs directed against CD20 or CD22 will 
potentially deplete B cells but, if both B- and plasma cells are to be depleted, a mAb 
or IT specific for a plasma cell marker, such as CD38, would be necessary. 
We confinned this in our subsequent experiments. Removal of CD38-positive cells 
from baboon spleen B lineage cells by magnetic beads led to a greatly diminished 
frequency of anti-aGal IgM Ab and total immunoglobulin secretors. In contrast, 
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depletion of CD20- or CD22-positive cells from baboon spleen B lineage cells led to 
an effective enricbment of CD20- or CD22-negative cells and to an increased 
frequency of anti-aGal IgM Ab and total immunoglobulin secretors. 'When the 
inbibition of protein synthesis by human Daudi cells with ocCD38-IT was compared 
to the inbibition obtained with ocCD22-IT, however, we found that ocCD38-IT was 
less effective than ocCD22-IT. These data may correlate with our inconsistent in vivo 
experience with ocCD38-IT. It appears that, although ocCD38-IT targets the desired 
population of (plasma) cells, it is not particularly efficient at killing those cells, 
possibly due to low affinity interaction of ocCD38 mAb or slower internalization of 
the CD38 receptor. Unfortunately, we have not been able to find other anti-human 
anti-CD38 rnAb that cross-react with baboons. In contrast, ocCD22-IT is very 
effective at killing CD22-positive cells but, unfortunately, these cells are not the 
major secretors of antibody, including anti-aGal Ab. 
In none of the in vivo experiments described above, where administration of anti-B 
cell agents combined with EIA +/- \VBI was the only therapy, were any infections 
noted. In one case (not included in this study), treatment with xCD20 mAb was 
incorporated in our protocol aimed at inducing immunological tolerance (20,41,46). 
This protocol consists of induction therapy with splenectomy, \VBI 300 cGy, ATG, 
and EIAs, and maintenance therapy with anti-CDl54 mAb +1- CyA, mycophenolate 
mofetil, corticosteroids, and cobra venom factor. Although this is an intensive 
protocol that renders the baboon severely immunosuppressed, viral infections have 
rarely been observed. However, when pretreatment with ocCD20 rnAb was added, a 
viral hepatitis (confirmed by inclusion bodies on histology) resulted in death of the 
baboon within 20 days. It is conceivable that pretreatment with ocCD20 mAb reduced 
the ability of the baboon to mount a humoral response to the viral antigen load. Close 
monitoring would, therefore, be necessary if ocCD20 rnAb therapy were to be 
combined with other intensive immunosuppressive therapies. 
More recently, several groups have demonstrated that combining anti-B ITs, e.g., anti-
CD19 and anti-CD22 (47), or combining anti-B cell and anti-plasma cell ITs, e.g., 
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anti-CD19, anti-CD22, and anti-CD38 (48), can cure B cell neoplasias in a mouse 
tumor xenograft model, while the individual ITs are unable to do so alone. This 
treatment could overcome the heterogeneity of surface antigen expression on B cells 
and plasma cells and prove valuable in our goals to deplete antibody-producing cells. 
An interesting observation was also recently made by Treon et al (49). They found 
that treatment with interferon-gamma caused significant upregulation of CD20-
expression on plasma cells of patients with mUltiple myeloma. This approach (i.e., 
pretreatment with interferon-gamma) could, therefore, render some plasma cells more 
susceptible to treatment with ocCD20 rnAb. In vitro studies at our center, however, 
have so far failed to demonstrate significant upregulation of CD20 on baboon plasma 
cells by interferon-gamma therapy (Thall A, unpublished data). 
In conclusion, the above data demonstrate that baboon B cells can be efficiently 
depleted with WBI, ocCD22-IT, or ocCD20 mAb, and that medium-term (>3 months) 
depletion of B cells can be achieved with ocCD20 mAb combined with WBI. 
However, depletion ofB cells does not lead to a clinically significant reduction in the 
rate or extent of return of anti-a Gal Ab following EIA. These observations suggest 
that B cells are not the major source of anti-aGal Ab production, and that attention 
must be directed towards suppressing plasma cell and B cell blast function. We have 
demonstrated in vitro that CD38-positive cells are the major secretors of anti-aGal 
Ab. Treatment with ocCD38-IT, however, did not yield consistent results in vivo, 
possibly due to pre-existing anti-ricin rnAbs, low-affinity or slow internalization of 
the antibody, sub-optimal conjugation of ricin-A, and/or relatively low specificity of 
CD38. Nevertheless, further studies focussed on this IT or on the development of new 
and refined anti-plasma cell agents are clearly warranted and are currently in progress 
at our center. Furthennore, combinations of ocCD20 rnAb or ocCD22-IT with an 
optimized anti-plasma cell IT may be of benefit. 
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ABSTRACT 
Background. Efforts to achieve tolerance to transplanted pig organs In nonhuman 
primates by the induction of a state of mixed hematopoietic chimerism have been 
associated with disorders of 
coagulation and thrombosis. Activation of recipient vascular endothelium and platelets 
by porcine hematopoietic cells and/or activation of donor organ vascular endothelium. 
Molecular differences between species with respect to regulation of coagulation and 
hemostasis may play a role. Irradiation or drug therapy could possibly potentiate 
endothelial cell activation and/or injury. 
Methods. We have investigated parameters of coagulation and platelet activation in 
nonhuman primates following (i) a regimen aimed at inducing mixed hematopoietic 
chimerism and tolerance (NMCR that included total body irradiation, T cell depletion 
and splenectomy, (ii) pig bone marrow or pig peripheral blood mobilized progenitor cell 
transplantation (PCTx, and/or (iii) pig organ transplantation (POTx). Five experimental 
groups were studied. Baboons were the recipient subjects in all groups except Group 1. 
Group I Cynomolgus monkeys (n~6) underwent NMCR + allotransplantation of 
hematopoietic cells and a kidney or heart or NMCR + concordant xenotransplantation 
(using baboons as donors) of cells and a kidney; Group 2 Baboons (n~4) underwent 
NMCR with or without (+/-) autologous hematopoietic cell infusion; Group 3 (n~12) 
PCTx +/- NMCR; Group 4 (n~5) POTx +/- NMCR; Group 5 (n~4) NMCR + PCTx + 
POTx. Platelet counts, \\'ith plasma prothrombin time, partial thromboplastin time, 
fibrinogen levels, fibrin split products and/or D-dimer were measured. 
Results. In the absence of a discordant (porcine) cellular or organ transplant (Groups 1 
and 2), NMCR resulted in transient thrombocytopenia only, in keeping with bone 
marrow depression from irradiation. PCTx alone (Group 3) was associated with the 
rapid development of a tbrombotic thrombocytopenic (TTP)-like microangiopathic state, 
that persisted longer when PCTx was combined with NMCR. POTx (+/- NMCR) 
(Group 4) was associated with a gradual fall (over several days) in platelet counts and 
'fibrinogen with disseminated intravascular coagulation (DIC); after graft excision, the 
DIC generally resolved. When NMCR, PCTx and POTx were combined (Group 5), an 
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initial TIP-like state was superceded by a consumptive picture of DIC within the first 
week, necessitating graft removal. 
Conclusions. Both PCTx and POT x lead to profound alterations in hemostasis and 
coagulation parameters that must be overcome if discordant xenotransplantation of 
hematopoietic cells and organs is to be fully successful. Disordered thromboregulation 
could exacerbate vascular damage and potentiate activation of coagulation pathways 
following exposure to xenogeneic cells or a vascularized xenograft. 
INTRODUCTION 
The current shortage of organs for transplantation could be overcome ifpig organs could 
be transplanted successfully. However, a number of barriers have to be overcome. 
Hyperacute rejection can be prevented by various procedures, such as depletion of anti-
pig antibody (1-3) or complement (4-6) in the recipient primate or by the use of organs 
from pigs transgenic for one or more human complement regulatory proteins (7,8). 
However, even under these circumstances, a delayed fonn of rejection occurs that is 
characterized by endothelial cell activation, platelet adhesion and aggregation, with 
thrombin and fibrin deposition (9,10). Severe coagulation disturbances have been 
documented in nonhuman primates following the transplantation of pig hematopoietic 
cells andlor organs (3,11-13, and Buhler, L, et ai, manuscript submitted), Many factors 
could contribute to these disturbances, including the therapeutic interventions or 
procedures used to suppress the recipient inunune system. Activation of host vascular 
endothelium, circulating leukocytes and platelets by infused porcine hematopoietic cells 
is an additional possibility. Alternatively, the vascular endothelium within the 
transplanted porcine organ may be directly perturbed as a result of the effects of 
xenoreactive antibodies (13). 
Molecular incompatibilities may also be important factors in both situations (9,10,13-
16). Relevant examples documented include the inability of porcine tissue factor 
pathway inhibitor to adequately neutralize human factor Xa, activation of both human 
prothrombin and factor X by porcine endothelial cells, the failure of porcine 
thrombomodulin to bind human thrombin and hence activate human protein C, and the 
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enhanced potential of porcine von Willebrand factor to associate v.'ith human platelet 
GPlb (9-19). 
We have reviewed our own data in nonhuman primate auto-, allo-, and concordant xeno-
transplantation models and in the miniature swine-to-nonhuman primate discordant 
xenotransplantation model in an effort to clarify the relative roles of a regimen aimed to 
induce mixed chimerism and tolerance (tolerance-inducing regimen; NMCR), porcine 
hematopoietic cell transplantation (PCTx). and porcine organ transplantation (POTx) in 
the development of coagulation/thrombotic disturbances. Our observations indicate that 
NMCR +1- autologous, allogeneic, or concordant xenogeneic cell or organ 
transplantation have minimal disturbances in coagulation. However, in the discordant 
combination using comparable NMCR, PCTx results in a thrombotic thrombocytopenic 
microangiopathic (TTP)-like state (20, and Biihler, L., et aI, manuscript submitted), and 
the development of delayed rejection following POTx leads to disseminated 
intravascular coagulation (DIC) (3, II) which progresses unless the organ is excised. 
MATERIALS AND METHODS 
Animals 
Cynomolgus monkeys (Macaca fascicularis) (n~6) of both sexes, weighing 4-6 kg, and 
baboons (Papio anubis) (n~24) of both sexes, weighing 10-15 kg (all from Biomedical 
Resources Foundation, Houston, TX) were the recipient animals used in these studies. 
Cynomolgus monkeys, baboons or Massachusetts General Hospital rvtHC-inbred 
miniature swine (Charles River Laboratories, Wilmington, MA), weighing 9-17 kg, were 
donors of hematopoietic cells and organs. Cynomolgus monkeys and baboons were of 
AB, B or A blood type. All pigs were of 0 blood type. 
Care of animals was in accordance wit..t,. the Guide for the Care and Use of Laboratory 
Animals prepared by the National Academy of Sciences and published by the National 
Institutes of Health. Protocols were approved by the Massachusetts General Hospital 
Subcommittee on Research Animal Care. 
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Anesthesia and Surgical Procedures 
Sedation, anesthesia, intravenous line placement, splenectomy, porcine kidney and 
heterotopic heart transplantation have been described previously in baboons (1,3,21) and 
cynomolgus monkeys (22), as have the harvesting and processing of donor bone marrow 
(BM) (22,23) and the mobilization and leukapheresis of porcine peripheral blood 
progenitor cells (PBPC) (24). 
At the time of kidney transplantation, in general one native kidney was excised and the 
ureter of the remaining kidney was ligated. In the event ofDIC or rejection developing 
within three weeks, necessitating excision of the transplanted kidney, the ligature around 
the native ureter was released allowing survival of the recipient. 
Conditioning Regimen for Tolerance Induction (NMCR) 
The NMCR (See Chapter 1, figure 3) consisted of (i) non-myeloablative whole body 
irradiation in either two or three fractions (150 or 100 cGy each, respectively) on days-6 
and -5 (total dose 300 cGy); (ii) horse anti-human antithymocyte globulin (ATG) 50 
mglkg i.v. daily on days -3, -2 and -1; (iii) thymic irradiation (TI) of700 cGy on day -1; 
and (iv) splenectomy on day -8 or 0 (3,20). In baboons undergoing PCTx and/or POTx, 
extracorporeal immunoadsorption (EIA) x 3 or 4 was carried out during the previous 
week (3,25), and cobra venom factor (approximately 100 units/kg/day) was adntinistered 
(and titrated to CH50) throughout the post-transplant course (6,20). 
After hematopoietic cell and/or organ transplantation, pharmacologic 
immunosuppressive therapy varied slightly between the different experimental groups. 
All recipients received cyclosporine (CyA; Novartis, Basel, Switzerland) 10-20 
mg/kg/day i.m. from day 0 in cynomolgus monkeys or 15-20 mglkg/day by continuous 
i.v. infusion from day -5 in baboons, except where stated to the contrary. A second 
agent was added whenever xenotransplantation was being undertaken. This was either 
15-deoxyspergualin (Novartis) 6 mglkg/day i.v. on days 0-13 or mycophenolate mofetil 
(MMF) 100 mglkg/day i.v. from day -9. Baboons in Groups 3 and 5 also received 
methylprednisolone 4 mglkg/day reducing to 0.5 mglkg/day over the first four weeks. 
Two baboons receiving autologous BM transplantation received a myeloablative 
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regimen that has been described previously (26). An anti-CD40L mAb (20 mg/kg/i.v. 
on alternate days for 8 doses) was substituted for CYA in some baboons in Groups 3-5 
(20). There was no direct correlation between the immunosuppressive regimen 
administered and the changes seen in coagulation parameters. 
Extracorporeal Immunoadsorption (EIA) 
When PCTx or POTx was to be undertaken, anti-Galal-3Gal (aGal) antibody was 
depleted from the baboon's circulation by the perfusion of blood or plasma through 
immunoadsorption colunms containing synthetic Galal-3Galfil-4BGlc-X-Y (aGal type 
VI trisaccharide; Alberta Research Council, Edmonton, Alberta, Canada), as described 
previously (25). 
Supportive Therapy 
Kidney transplant recipients were monitored daily by complete blood count, serum 
creatinine, blood urea nitrogen, total protein, and electrolytes. In addition, heart 
transplant recipients were monitored by daily observation/palpation of the donor heart 
contractions. Ofloxacin (50 mg/day) or cefazolin (500 mg/day) was administered daily 
as prophylaxis against infection in all baboons of Groups 2-5. Twice weekly blood 
cultures were perfonned to detect systemic bacterial or fungal infection. To correct 
anemia, thrombocytopenia and coagulopathy, baboon ABO-matched packed red blood 
cells, platelets (collected by apheresis or by manual processing), and fresh frozen plasma 
(depleted of anti-pig antibody using adsorption colunms or pig red blood cells) were 
administered to baboons in Groups 2-5. The indication for blood transfusion was a 
hematocrit of <20%, for platelets a platelet count of <lOx !03/mm3 and/or clinical 
evidence of bleeding, and for plasma, clinical bleeding or a persistent prothrombin time 
of>35 sec. 
Measurement of Coagulation Parameters 
White blood cell and platelet counts were determined daily by standard methodology 
(Excell, Danam Electronics, TX). If the platelet count were <I 00,000/mm3, a blood 
smear was prepared, fixed with methanol, air dried, and stained with Wright Giemsa 
(Fisher Scientific, Pittsburgh, PA). Platelets were counted under oil immersion. 
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Erythrocyte morphology was also observed. Blood for special assays was collected in 
Vacutainer tubes (Becton Dickinson, Rutherford, NJ) containing 0.015 M citrate or 
heparin for plasma, and plain tubes for serum. Blood samples were centrifuged at sao g 
for 10 min. Plasma and serum samples were immediately stored at -80°C until used in 
assays. 
Prothrombin time (PT), partial thromboplastin time (PIT) and fibrinogen determinations 
were performed on plasma samples at the Hematology Laboratory at the Massachusetts 
General Hospital. PT and PTT were assayed by standard methods, and the fibrinogen 
measured by the Clauss method (27), using the MDA-lSO automated coagulation 
analyzer (Organon Teknika, Durham, NC). Fibrin split products were measured by 
standard techniques at the Massachusetts General Hospital laboratory. Ranges of D-
dimer were measured using a semiquantitative assay kit, as described in the 
manufacturer's instructions (Diagnostica Stago, Asnieres, France), supplemented by 
specific enzyme-linked immunosorbent assay (ELISA) (Gold-Dimertest, American 
Diagnostica, Greenwich, CT). 
Histopathology of Transplanted Organs or Native Organs at Autopsy 
Tissues were (i) examined by light microscopy after being formalin-fixed and 
stained with hematoxylin and eosin or periodic acid-Schiff and (ii) processed 
for immunohistology/fluorescence. To detect platelet aggregates, an indirect 
immunoperoxidase technique was applied with a murine monoclonal antibody 
directed to human CD62P (P-selectin) (Becton Dickinson, San Jose, CAl. For 
v\VF detection, a rabbit polyc1onal antibody to human vWF crossreactive with 
baboon vWF was used (DAKO, Glastrup, Denmark). For the detection ofIgG, 
IgM, C3 and fibrin deposition, frozen tissue sections were stained using direct 
immunofluorescence with FITC-conjugated rabbit polyclonal antibody to 
human IgG, IgM, C3 and fibrin (DAKO), all of which were crossreactive with 
baboon antigens. Controls consisted of tissue staining with an irrelevant 
murine monoclonal antibody or rabbit-anti-human albumin. 
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Experimental Groups 
Five experimental groups were studied (Table I). 
Group 1 (n~6). Cynomolgus monkeys received NMCR and allo (n~3) or concordant 
xeno (n~3) BM cells and kidney (n~2) or heart (n~l) transplants on day O. 
Group 2 (n~4). Baboons received either non-myeloablative NMCR alone (n~2) or 
myeloablative NMCR and autologous BM transduced -with the porcine al,3 
galactosyltransferase gene which was infused intravenously on days 0, I and 2 (n~2). 
Group 3 (n~12). PCTx+/-NMCR. Two baboons received pig PBPC (3 x 10 10 cells/kg) 
and one received pig BM (14 x 108/kg) without NMCR. Nine baboons received NMCR 
followed by PBPC (3 x 101O/kg). 
Group 4 (n~4). POTx+/-NMCR. Non-myeloablative NMCR was carried out in one 
baboon which received a pig kidney transplant. Three other baboons received kidney 
(n~2) or heterotopic heart (n~l) transplants without NMCR. 
Group 5 (n~4). NMCR+PCTx+POTx. Following non-myeloablative NMCR, 3 baboons 
received kidney transplants and one a heterotopic heart transplant. All received either 
PBPC (3 x 101O/kg) (n~l) or pig BM (8-26 x 108/kg) (n~3), the hematopoietic cell 
infusion beginning either inunediately after the organ transplant or 24 hours later (Figure 
1 ). 
RESULTS 
The results are summarized in Table 1. 
Effects ofNMCR +/- non-discordant cellular/organ Tx (Groups 1 and 2) 
Whenever NMCR was administered without PCTx or POTx, i.e. either NMCR alone or 
when accompanied by hematopoietic autologous, aIlo or concordant xeno cells and 
organs, there was a gradual decrease in platelet numbers over 7-12 days with full 
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recovery to nonnal levels between days 15-18 (Figure I). The thrombocytopenia was 
more prolonged following myeloablative NMCR (Group 2) (not shown). However, in all 
cases, PT, PTT, fibrinogen, and fibrin split products remained within the normal ranges 
or were transiently deranged to a minor extent. 
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Figure 1. 
Changes in platelet count in 2 representative recipient baboons from Group 2 that had received NMCR 
alone or NMCR and autologous hematopoietic cell transplantation. NMCR alone or NMCR + 
autologous cells resulted in a steady fall in platelet count for 10-12 days. with subsequently a rapid 
recover)' phase. 
Effects of discordant xenogeneic cellular Tx with or without NMCR (pCTx+l-
NMCR) (Group 3) 
'Whenever PCTx was carried out, a TIP-like state developed. \¥hen PCTx was carried 
out without NMCR, a rapid decrease in platelets (to <20,000 rnrn3) occurred (within 3 
days) (Figure 2) with a slight and transient prolongation ofPT «17 sec) and PTT «45 
sec) and decrease in fibrinogen level (to 30% of baseline). On blood smear, 
schistocytosis was marked (> 12 hpf) and persisted for several weeks. A massive increase 
in lactate dehydrogenase (to> 10,000 units) was seen. Fibrin split products and D-dimer 
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increased to high levels but rapidly nonnalized. Platelets recovered within 5-9 days and 
fibrinogen by day 15. In one baboon, after recovery of coagulation parameters, a second 
set ofPBPCs was infused, resulting in similar changes. 
When NMCR preceded PCTx, there was a rapid and profound fall in platelet count (to 
<20 rom3) following the first infusion of porcine cells (even after as few cells as 1 x 
10(/kg) (Figure 2). Tbrombocytopenia persisted for approximately two weeks, during 
which platelet transfusions were required. Thereafter, recovery of platelet count was 
relatively rapid. The initial rapid onset of thrombocytopenia was temporally associated 
with the PCTx. In contrast to when PCTx was carried out alone, the delayed recovery 
was associated with the effects of myelosuppression brought about by NMCR. 
Schistocytosis was again marked (>12 hpf) unless prophylactic therapy was given to 
reduce platelet and endothelial cell activation (20) and lactate dehydrogenase rose. In 
some baboons there was mild purpura, transient neurologic disorder (transient collapse, 
lethargy), or transient renal dysfunction (in one baboon). 
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Figure 2. 
Changes in platelet count in 2 representative recipient baboons in Group 3 that had received pig 
hematopoietic cells alone or following NMCR. The infusion of pig hematopoietic cells resulted in an 
immediate thrombocytopenia, which recovered quickly unless NMCR had also been administered and 
bone marrow suppression had been induced. 
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One of two baboons that received PBPC alone died after receiving a second infusion of 
PBPC. After the second PBPC infusion, severe thrombocytopenia developed, with an 
increase in LDH to >25,000 unitslL. PT, PTT and fibrinogen level remained relatively 
stable. The baboon died with features of cardiorespiratory failure within 4 days. Autopsy 
showed gross hemorrhage in the lungs and heart and in other essential organs. 
Histological examination confinned interstitial hemorrhage, particularly in the heart, the 
lungs, kidneys, and adrenal glands. Immunohistochemistry showed deposition of 
platelets in small vessels, expression of vWF on the capillary walls, with fibrin 
deposition (data not shown). 
TABLE 1 
EXPERIMENTAL GROUPS AND SUMMARY OF OBSERVED 
CHANGES IN COAGULATION PARAMETERS 
GROUPS REGIMEI' PLATELETS ..IT pn HBRNOGEN 
I (n"'6) l';1v!CR + allo or 
concordant ~ 
xeno HCs and 
organ Tx 
2(nooo4} NMCR +/. auto-
logous HCs "I<~ 
3 (n"'12) PCTx +/- NMCR ~~ , 
4 (n"'5) POTx +/- !\MCR 
" 
1'1' 
5 (n=1) NMCR +PCTx h~ H, ttt 
+POTx 
?'-lMCR '" tolerance-inducing regimen 
HCs '" hematopoietic cells (bone marrow or peripheral blood mobilized progenitor cells) 
PCTx '" porcine hematopoietic cell transplantation 
POTx = porcine organ transplantation 
Change in parameter 
Decrease ... mild, ... t modemte, Ht profound 
Increase l' mild, 1'1' moderate, t1t profound 
t 
~ 
H 
,H 
D-DTME.R 
, 
t 
tt 
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One baboon that received NMCR + PBPC died from acute cardiorespiratory failure on 
day 5 with an undetectable level of circulating platelets, despite platelet transfusion. 
There was a transient increase in PI to twice the baseline level, but this persisted for 
only 1-2 days before nonnalizing. PTT was not significantly altered. The fibrinogen 
level fell modestly 4-6 days after the initial PCTx. D-dimer levels increased between 
days 1-7, but again normalized rapidly. At autopsy, the changes were similar to those 
above. In addition, however, there was massive hemorrhage in all mesenteric lymph 
nodes. 
Effects of discordant xenogeneic organ Tx with or without NMCR (pOTx+/-
NMCR) (Group 4) 
'Whenever POIx was performed, an apparent consumptive coagulopathy and DIC 
occlllTed conclllTently with the development of delayed antibody-mediated rejection. 
When POTx was performed +/- NMCR, gradual but steady falls in both platelet count 
and fibrinogen level occlllTed. The first indication that DIe was developing was 
frequently an increase in fibrinolytic activity indicated by a rise in fibrin split products or 
D-dimer (Table 2). 
After 1-3 days, in 4 of the 5 cases there was a precipitate rise in PT (data not shown). 
Clinical bleeding occurred in 2 baboons with hematuria, and both died on day 9 with 
massive intraperitoneal hemorrhage. Rejected xenografts revealed microthrombi in 
glomeruli and microvasculature with hemorrhagic and necrotic ureters, particularly in 
the distal portion; sequential deposits of platelets (platelet microthrombi) and fibrin were 
also seen (data not shown). The changes of DIe resolved only in those baboons where 
the transplanted porcine organ was excised as an emergency procedure (Figure 3, and 
Table 2). Histopathological examination of the excised organ demonstrated variable 
features of rejection with sometimes only 20% of the organ affected by interstitial and 
deposition of platelets and fibrin. (Fibrin deposition was not seen in native organs, 
indicating a localised response.) IgM deposition was seen in the grafted organ at the time 
of excision, but IgG deposition was variable (sometimes absent or minimal) depending 
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on the pre and post-transplant therapy given. Complement deposition was frequently 
absent as a resuly of therapy with cobra venom factor. 
TABLE 2 
D-DIMER LEVELS IN TWO GROUP 4 BABOONS 
FOLLOWING PIG KIDNEY TRANSPLANTATION 
DAY 875-18 875-34 
Pre POTx 0 0.5 
Post-POTx 
<2 2-8 
2 2-8 0.5-2 
5 2-8 2-8 
AtGTx >8 >8 
48h post-GTx 0.5 0.5 
POTx = porcine organ transplantation 
GTx = graftectomy 
Effects of combined discordant xenogeneic cellular and organ Tx with NMCR 
(NMCR+PCTx+POTx) (Group 5) 
When NMCR was combined with both PCTx and POTx, all baboons developed 
immediate and profound thrombocytopenia following the first PCTx, which extended for 
12-15 days (Figure 3), and required a greater number of platelet transfusions compared 
to Group 3. This was followed by a progressive fall in fibrinogen and a prolongation of 
PT, indicating consumption of coagulation factors such as seen in DIe. As with POTx 
alone, these coagulation parameters resolved only if grafiectomy was perfonned. 
All of the transplanted organs had to be removed before day 15 to prevent worsening 
DIe. Histopathological examination of the rejected organ, however, again showed 
considerable variability in the extent of immtme injury, with patchy localized injury in 
some cases. At excision of the graft, there was variable IgM, IgG and complement 
deposition as in Group 4. When NMCR was followed by both PCTx and POTx, 
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therefore, the features seen were a combination of the thrombotic microangiopathy that 
occurred following PCTx alone and the consumptive state that occurred following POTx 
alone. 
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Figure 3. 
Changes in platelet count and plasma fibrinogen concentration in a representative recipient baboon from 
Group 5 (NMCR+PCTx+POTx). When both pig hematopoietic cel!s and a kidney were transplanted in 
combination in a baboon which had also received NMCR, there was an immediate thrombocytopenia 
which persisted for 14 days until the effects of myelosuppression had worn off. There was also a steady 
reduction in fibrinogen until the pig organ was excised (graftectomy), following which there was rapid 
recovery. 
DISCUSSION 
We have presented evidence for profound perturbations in hemostasis, coagulation and 
thromboregulation that occur consistently with the transplantation of discordant 
xenogeneic cells and/or organs in the the miniature swine-to-nonhuman primate modeL 
The coagulopathies observed after discordant organ xenotransplantation in this model 
were first documented by lerino (II) and Kozlowski (3) with their respective colleagues, 
and have also been described in the pig-to-baboon model by Meyer et al (12), The 
present study, which includes a small number of the experiments reported by lerino and 
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Kozlowski (3, II ,26), contributes additional information on this topic and further 
elucidates this important consequence of discordant xenograft rejection. 
In particular, we demonstrate that NMCR alone or when combined with autologous, alto 
or xeno hematopoietic cell transplantation +/- organ allo- or concordant xeno-
transplantation resulted in relatively minimal and transient changes in coagulation 
parameters of the recipient animal (either cynomolgus monkey or baboon). The NMCR 
utilized at our center, therefore, although prolonging the duration of thrombocytopenia 
following PCIx, would not otherwise appear to playa direct role in the development of 
either the thrombotic angiopathic state seen following PCTx or the consumptive 
coagulopathy seen after POIx. However, it is possible that whole body irradiation could 
'sensitize' the vascular endothelium making it more susceptible to activation by PBPC. 
PCIx, whether alone or in combination with NMCR, caused a profound 
thrombocytopenia, limiting the number of porcine cells that could be transfused into the 
recipient baboon. In the absence ofNMCR, recovery of platelet count following PCTx 
occurred within 5-9 days. The myelosuppression caused by NMCR delayed recovery of 
platelets for approximately two weeks. A TTP-like state developed, which has been 
investigated further and will be fully described elsewhere (Btihler, L., et a1. manuscript 
submitted). In briet~ animals rapidly became thrombocytopenic, developed schistocytes 
and demonstrated features of microangiopathy, associated \\ith a rise in lactate 
dehydrogenase. Only minor fluctuations in plasma levels of von Willebrand factor were 
seen, with transient shifts in von Willebrand factor multimeric patterns. No changes in 
von Willebrand factor-cleaving protease activity were noted (data not shown). TTP can 
progress to a state where widespread organ damage can trigger release of thromboplastin 
and a consumptive coagulopathy (DIC); this was not a feature in the present studies 
except under agonal circumstances in 2 baboons in Group 3. 
This TTP-like state is therefore comparable to that seen complicating autologous or 
allogeneic hematopoietic stem cell transplantation in humans (28). As this complication 
was seen in baboons receiving cobra venom factor (as well as in baboons receiving 
hematopoietic cells taken from pigs transgenic for human decay accelerating factor -
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data not shown), this indicates that depletion of complement factors does not preclude 
the TTP-like state. 
We are currently investigating the mechanisms whereby PBPC activate primate 
endothelial cells, lenkocytes and/or platelets. Many of the natural anticoagulants and 
complement regulators are expressed by endothelial cells and monocyte-macrophages. 
These anticoagulant proteins are largely ineffective across discordant xenogeneic species 
barriers (19). Such molecular incompatibilities may lead to activation of coagulation 
following the infusion of xenogeneic leukocytes and could result in (i) excessive fibrin 
deposition upon the infused porcine cells with consequent platelet interactions mediated 
via GPIIbIIIa or (ii) direct upregulation of adhesive proteins with cellular activation, 
predisposing to lenkocyte-platelet aggregates. 
Some of the baboons being studied, particularly in Groups 3 and 5, received therapy 
aimed at reducing the activation of the vascular endothelium and platelets of the host. 
This therapy (consisting of prostacyclin, heparin and methylprednisolone) had some 
beneficial effect in reducing the features of the TIP-like state, particularly in reducing 
the need for platelet transfusion (data not shown), but was not completely successful 
(20). 
The manifestations of TTP were quite different from the widespread coagulation 
changes seen when POTx was performed. Here coagulation-factor consumption and DIC 
developed, generally within 1-2 weeks and concurrent with the development of 
xenograft rejection. This was exemplified by a steady fall in fibrinogen and platelets and 
a late rise in PT. In some cases, after several days, PT rose acutely to a high level, 
followed by clinical hemorrhage leading to death of the recipient unless the graft was 
removed as an emergency. Following graftectomy, the coagulopathic state generally, 
but not always, rapidly resolved. "When both PCTx and POTx were combined, an initial 
TTP-like state was seen, which was exacerbated by the development of xenograft 
rejection and the evolution of DIe. The consumptive coagulopathy then became the 
predominant feature. 
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Of significance was the fact that when graftectomy was necessitated by a rapidly 
deteriorating coagulopathic state, on occasion the transplanted porcine organ looked 
relatively nonnal macroscopically, and histological examination showed only moderate 
immune injury. The extent of histopathological change in the fonn of interstitial 
hemorrhage or fibrin deposition could involve as little as 20% of the organ. We suggest, 
therefore, that the DIC may not necessarily be a result of the organ damage linked to the 
acute vascular rejection that is developing, but may be associated with factors common 
to both the development of coagulation disturbances and acute vascular rejection, such 
as vascular endothelial cell activation. 
Quiescent endothelial cells express potent thromboregula~ory factors, including the 
vascular ATP-diphosphohydrolase (or CD39), tissue factor pathway inhibitor, and 
thrombomodulin (29). In addition to heparan sulphate (30), these proteins are lost in 
association with xenograft rejection. Hence the activated endothelial cell becomes 
thrombophilic, and may initiate and perpetuate the thrombotic reactions that result in 
systemic depletion of coagulation factors seen in DIC (9,10,18,29). Tissue factor is an 
important initiating factor of coagulation and is expressed by activated endothelial 
cells and denuded vasculature. In vitro assays have ShO\\l1 that porcine endothelial 
cells stimulated by human serum are able to increase tissue factor via IL-l a. 
production and require the presence of sub-lytic complement Membrane Attack 
Complex (MAC) components (31). Despite cobra venom factor therapy in our POTx 
experiments, such sub-lytic complement activation is still likely and may have 
induced increased expression of tissue factor on the activated endothelium of the 
xenografts. In addition, porcine endothelial ceBs, including hDAF transgenic cells, 
have the capacity to upregulate tissue factor following exposure to other inflammatory 
mediators, e.g. twnor necrosis factor released by infiltrating mononuclear cells (32). 
The development of DIC in these xenografts has parallels to the consumptive 
coagulopathy seen with the Shwartzman phenomenon in antibody-mediated vascular 
injury of allografts (33). Removal of the activated endothelium (with the graft) leads to a 
greater response to therapy in the fonn of fresh frozen plasma and platelet transfusions. 
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We are not alone in identifying DIC following xenotransplantation experiments. This 
was first described in the 1960s (34,35), although there have been few reports in the 
pig-to-nonhuman primate model. In the pig-to-baboon renal transplant model, Meyer 
et al. (12) have also shown evidence for platelet activation, formation of thrombin-
antithrombin III complexes, a fall in fibrinogen, and an increase in fibrinolytic 
activity, all suggesting DIe. They also demonstrated that the transplantation of organs 
from pigs with homozygous VOn Willebrand's disease, that were severely deficient in 
von Willebrand factor, did not prevent platelet and coagulation activation. None of 
their animals, either control or with von Willebrand disease, presented with overt 
bleeding. d'Apice's group in Australia has recently observed a DIC-like state in 
unmodified (non-immunosuppressed) baboons receiving pig kidneys transgenic for 
human CD55 and CD59 (36). Other groups have not reported major coagulation 
disorders following pig-to-nonhuman primate organ transplantation. Indeed, it was 
not observed by the Cape Town and Oklahoma groups of which one of us (DKCC) 
was a member (6,37,38). 
Numerous potential differences in experimental protocols may accotu1t for this 
discrepancy, including, for example, differences in (i) the species of nonhuman 
primate used as recipient (e.g. cynomolgus monkey or baboon), (ii) the breed of 
organ-donor pig (e.g. large white or miniature swine), (iii) whether the pig has been 
genetically modified or not (e.g. the presence of hDAF on its vascular endothelium), 
(iv) the organ transplanted (kidney or heart), (v) the immunosuppressive regimen 
(where there are numerous variables, including alkylating agents at different dosages), 
and (vi) any adjunctive therapy administered (e.g. the concomitant infusion of 
hematopoietic cells or the intravenous administration of prostacyclin). However, we 
have observed DIC both in cynomolgus monkeys and baboons, after the 
transplantation of pig kidneys and hearts, when induction therapy was with whole 
body irradiation or with cyclophosphamide, and with and without cobra venom factor. 
Apart from the report from d' Apice's group mentioned above, DIC does not seem to 
have been observed by those using organs fTom pigs transgenic for one or more 
complement regulatory proteins (7,8,39). However, we have recently seen this 
complication in 2 of 3 baboons receiving hDAF kidneys at our center (Buhler, L., et 
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aI, manuscript In preparation); all 3 had received induction therapy with 
cyclophosphamide and not whole body irradiation. As we routinely adsorb out anti-
Gal antibody before the transplant, it is possible that it is the slow retwn of antibody, 
with gradual binding to the graft vascular endothelium (rather than immediate and 
massive antibody binding as occurs when antibody is not removed), that is important 
in the development of a procoagulant state. Furthermore, procedures that deplete 
antibody may also deplete or perturb labile coagulation factors. Others, however, have 
included antibody adsorption in their protocols (by similar but not identical 
techniques) but have not reported consumptive coagulopathy as a complication 
(39,40). It is therefore difficult to explain why this complication has been observed 
frequently at some laboratories but not at other centers using similar or even identical 
protocols. 
We conclude that both PCTx and POTx result in significant changes in coagulation 
that must be further investigated and overcome if discordant xenotransplantation of 
hematopoietic cells and organs is to be fully successful. The TTP-like state that 
follows PCTx limits the number of pig hematopoietic cells that can be infused and 
therefore may be a factor in the extent of pig cell chimerism that can be obtained. 
Under the circumstances of the experiments reported here, rejection of a porcine 
organ xenotransplant was consistently associated with the development of DIC, 
necessitating excision of the transplanted organ, whether it were a kidney or a heart. 
Importantly, in some cases, DIC developed before there were widespread changes of 
inununological injury to the transplanted organ. 
DIC might therefore be considered to be a surrogate marker for developing antibody-
mediated rejection. Our observations, and those of others, suggest that the discordant 
xenogeneic vasculature may be predisposed lUlder certain circumstances to initiate 
thrombotic reactions in vivo. 
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ABSTRACT 
Introduction. Attempts to induce tolerance though mixed hematopoietic chimerism 
in the discordant pig-to-baboon xenotransplantation model are complicated by a 
potentially fatal thrombotic microangiopathy in the recipient baboons. This state 
develops inunediately following the infusion of porcine mobilized peripheral blood 
leukocytes, containing progenitor cells (PBPC). In the present study, we examined the 
interaction of infused porcine PBPC with recipient platelets in vivo in baboons and 
investigated the underlying mechanisms using an in vitro model. 
Methods. Two naIve baboons and six baboons pre-conditioned with irradiation and 
inununosuppression that received porcine PBPC were evaluated in vivo. The 
interaction of porcine and baboon PBPC with baboon platelets was investigated by an 
in vitro platelet aggregation assay. Fresh and cryopreserved PBPC were evaluated as 
well as PBPC obtained from growth-factor-mobilized and unmobilized pigs. 
Furthenuore, cellular subsets of PBPC were assessed for potential to induce platelet 
aggregation. Inununohistochemical staining was performed on platelet-leukocyte 
aggregates and potential inhibition of aggregation with anti-P-selectin and anti-
CDIS4 mAbs, or eptifibatide (a GPIIb/IlIa receptor antagonist), was tested. 
Results. All baboons that received porcine PBPC rapidly developed marked 
tbrombocytopenia «20,OOO/).lI), elevated serum lactate dehydrogenase (>l,SOOU/I), 
schistocytosis, and platelet aggregates on blood smear. Three baboons died (two 
untreated and one pre-conditioned), and substantive platelet aggregates containing 
porcine leukocytes were observed in the microvasculature of lungs and kidneys. h! 
vitro, porcine, but not baboon, PBPC induced aggregation of baboon platelets in a 
dose-dependent manner. lnununohistological examination of these aggregates 
confinued the incorporation of porcine leukocytes. Cryopreserved PBPC caused less 
aggregation than fresh PBPC, and growth-factor-mobilized PBPC induced less 
aggregation than unmobilized PBPC. Aggregation was fully abrogated by the addition 
of eptifibatide, and modulated by anti-P-selectin and anti-CD1S4 monoclonal 
antibodies that recognize adhesion receptors on activated platelets. Purified fractions 
(granulocytes, CD2+, and CD2" cells) of porcine PBPC did not initiate aggregation, 
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whereas addition of exogenous porcine PBPC membranes (erythrocytes, dead cells, 
and/or platelets) to the purified fractions exacerbated the aggregation response. 
Conclusions. These data indicate that porcine PBPC mediate aggregation of baboon 
platelets. This process likely contributes to the thrombotic microangiopathy observed 
following PBPC transplantation in the pig-to-baboon model. Eptifibatide can fully 
abrogate platelet aggregation induced by porcine PBPC in vitro. Purification of the 
precursors from porcine PBPC and/or treatment of baboons with eptifibatide may be 
beneficial. 
INTRODUCTION 
The use of porcine xenografts as an alternative for human cadaveric organs is viewed 
by many as a potential solution to the increasing shortage of allografts (1,2). Although 
many advances have recently been made with respect to understanding the 
immunological basis of rejection of highly disparate organs when transplanted into 
nonhuman primates, xenografts generally do not survive beyond approximately one 
month (3,4). This process is, at least in part, related to host immunological responses 
to the xenograft. 
In our efforts to induce tolerance to porcine organs transplanted to nonhuman 
primates, we have attempted to induce a state of mixed hematopoietic chimerism (5). 
Such an approach has been successful, without· major complications, in rodent 
allogeneic and xenogeneic transplantation models, and also in swine and primate 
allogeneic models. In these models, immunological tolerance is associated with 
indefinite survival of the grafts (6, 7, 8, 9). When extending this approach to the 
discordant pig-to-baboon model, using large numbers of mobilized porcine 
leukocytes, containing approximately 2% progenitor cells (PBPC), however, a 
thrombotic microangiopathy has been observed (10). This phenomenon did not occur 
when smaller numbers of porcine bone marrow cells were transplanted into baboons 
(11) and, importantly, when a comparable number of cells were transplanted in a 
swine allotransplantation model (8). The clinicopathological entity included 
neurological and renal disturbances with fever, immediate thrombocytopenia, 
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markedly elevated serum lactate dehydrogenase levels, schistocytosis on blood smear, 
with microvascular thrombosis of lungs, heart, and IGdneys on autopsy (12). 
Thrombotic microangiopathy has also been observed following clinical autologous 
and allogeneic bone marrow transplantation. Here the underlying pathophysiology is 
thought to be widespread endothelial cell damage associated with several factors, 
including inflammation, cyclosporine, or graft-versus-host disease (13). This state, 
however, does not generally develop before the transplanted marrow has engrafted, 
whereas the thrombotic microangiopathy in our studies developed rapidly after 
porcine PBPC (PPBPC) transplantation. We therefore postulated that the etiology of 
these two pathologic states may differ, in that porcine leukocytes may be directly 
interacting with baboon platelets in vivo. This process may be accentuated by the 
existence of molecular incompatibilities that would facilitate these interactions (14). 
We have therefore evaluated such interactions in pre-conditioned and unconditioned 
baboons receiving large numbers ofpPBPC (1-3xlO IO cells/kg) in vivo, and correlated 
these observations with pPBPC-platelet interactions in vitro. Furthermore, several 
agents aimed at preventing these interactions were studied in vitro. Effects of these 
individual components of the conditioning regimen on platelet aggregation are 
discussed elsewhere (Appel JZ III, et aI., manuscript in preparation). 
MATERIAL AND METHODS 
In vivo experiments 
Animals 
Naive baboons (Papio anubis, n=8, Biomedical Resources Foundation, Houston, TX), 
of known ABO blood group and weighing 9-15 kg, were used as recipients ofpPBPC, 
as donors of platelet-rich plasma (PRP), or as donors of baboon PBPC. 
Massachusetts General Hospital MHC-inbred miniature swine (n=6, Charles River 
Laboratories, Wilmington, MA), of blood group 0 and weighing 18-40 kg, served as 
donors of pPBPC. All experiments were performed in accordance with the Guide for 
the Care and Use of Laboratory Animals prepared by the National Academy of 
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Sciences and published by the National Institutes of Health. Protocols were approved 
by the Massachusetts General Hospital Subcommittee on Research Animal Care. 
Surgical procedures 
Details of anesthesia, intravenous (iv) catheter placement in pigs and baboons, and 
intra-arterial line placement, splenectomy, and extracorporeal immunoadsorptions of 
anti-aGal antibodies in baboons have been described elsewhere (15, 16, 17). 
Non-myeloablative conditioning regimen (NMCR) 
This regimen has been described previously (18) and consists of -induction therapy 
with splenectomy, whole body irradiation, thymic irradiation, anti-thymocyte 
globulin, and multiple extracorporeal immunoadsorptions of anti-a Gal antibodies. 
Maintenance therapy consists of anti-CD154 monoclonal antibody (mAb) +1-
cyclosporine, mycophenolate mofetil, cobra venom factor, prost acyl in, heparin, and 
methylprednisolone. Porcine growth factors (IL-3 and stem cell factor) were 
administered to promote pig cell engraftment. 
Mobilization and leukapheresis of P BPC in pigs and baboon 
This procedure was performed as previously described (19). In summary, pigs were 
treated with recombinant hematopoietic growth factors before and during the period 
of collection of PBPC. Leukapheresis was carried out on days 5-9 and 12-16 
following commencement of growth factor mobilization using a Cobe Spectra 
apheresis machine (Cobe, Lakewood, CO). Baboons were treated with recombinant 
hematopoietic growth factors (as for the pigs) and leukapheresis was carried out on 
day 7 alone. Plasma was removed from the product by centrifugation at 920 g for 7 
minutes. The collected cells were washed and used for in vitro assays, or frozen and 
stored in 5% DMSO until transplantation or until used for in vitro assays. 
Preparation of pPBPCfor transplantation 
Cryopreserved PBPC were thawed by immersion in a 37 - 40° C water bath with 
gentle agitation for 1 - 2 minutes, washed twice with calcium-, magnesium, and 
phenol red-free Hanks' balanced salt solution (HBSS. Mediatech, Herndon, VA), and 
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resuspended in the same solution for immediate transplantation to the recipient 
baboon. Viability was assessed with trypan blue staining. 
Hematologic and serum chemistry parameters 
Daily blood samples were taken for measurement of platelet count (Excell, Danam 
Electronics, Dallas, TX), and prothrombin time (PT), partial thromboplastin time 
(PTT), fibrinogen, and fibrinogen degradation products (Hematology Laboratory, 
Massachusetts General Hospital). Blood smears were also prepared on a daily basis, 
fixed with methanol, air dried, and stained with Wright Giemsa (Fisher Scientific, 
Pittsburgh, PA). Platelets were counted under oil immersion, and erythrocyte 
morphology was observed. Daily serum samples were obtained for the measurement 
of lactate dehydrogenase levels (Chemistry Laboratory, Massachusetts General 
Hospital). 
Immunopathology 
Tissues were (i) formalin-fixed, stained with hematoxylin and eosin for evaluation by 
light microscopy, or (ii) processed for immunohistology using standard methodology. 
Baboon platelets and porcme cells were detected by standard indirect 
irnmunoperoxidase technique, using the murine anti-CD62 (P-selectin) mAb cross-
reactive with baboon (Becton Dickinson, San Jose, CA) and the porcine pan-
leukocyte mAb (I 030H-I-19), respectively. 
In vitro experiments 
Preparation of platelet-rich plasma (P RP) and platelet-poor plasma 
Blood was drawn from naIve baboons (lO mI), citrated, and centrifuged at 280 g for 
15 minutes at 22°C. The supernatant, consisting of PRP containing approximately 
lxl08 platelets/ml (as measured with a Coulter counter, Beckman Coulter, Inc., 
Fullerton, CA), was transferred in 400 ).11 aliquots to siliconized glass cuvettes and 
used as experimental samples. The remaining pellet was further centrifuged at 2,400g 
for 2 minutes at 22°C, the resulting supernatant, platelet-poor plasma (containing less 
than Ixl03 platelets/ml), was transferred in a 400 fll aliquot to a siliconized glass 
cuvette and used as reference sample. 
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Preparation of peripheral blood progenitor cells (PEPC) 
Fresh pPBPC, and frozen baboon or pPBPC, were processed as described above. The 
cells were resuspended in HBSS to reach a final concentration of approximately I xl 04 
cells/fll. 
Cell sorting 
A MoFlo Cytomation High Speed Cell Sorter (Cytomation, Fort Collins, CO) was 
used to purify and sort fractions of fresh or cryopreserved pPBPC. The product was 
washed twice in phosphate buffered saline containing 2% fetal bovine serum, but 
without calcium or magnesium, and lx108 cells were resuspended at lx107/ml. The 
cells were then incubated with the murine biotinylated anti-porcine CD2 (MSA4) 
mAb, and subsequently labeled with streptavidin phycoerythrin, Cells were then 
washed, resuspended at 5xl07/ml and run through the cell sorter. The pPBPC product 
was sorted for CD2+ and CD2- cells based on lymphocyte and fluorescence gating. 
Sorting of granulocytes and exogenous membranes (debris, consisting of erythrocytes, 
platelets, or dead cells) was based on forward-side scatter. Approximately 2xl06 
CD2+ and CDT cells, 2xl05 granulocytes, and 2xl06 exogenous membrane fragments 
(as measured per event) were used for each assay. Data acquisition and analysis were 
performed with Cyclops Summit software (Cytomation, CO), 
Platelet aggregation assay 
Platelet aggregation in PRP was measured in a platelet aggregometer (two-sample, 
four-channel, model 560 Ca Lumi-aggregometer, Chronolog Corp., Havertown, PAl, 
according to the manufacturer's specifications, as a percentage change in light optical 
density from baseline (set to 0%) as compared to a reference sample. The maximum 
platelet aggregation induced by a potential stimulator was detennined after 6 minutes. 
Fresh pPBPC, cryopreserved pPBPC, or cryopreserved baboon PBPC were added to 
the baboon PRP in increasing quantities, ranging from lxl05 - Ixl07 cells, and 
platelet aggregation was measured. VYhen PBPC were added, an initial increase in 
optical density was observed dependent on the final number of particles in solution. 
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Baseline aggregation was then reset at 0%. In other experiments, pPBPC (1xl06 -
lxl07) from growth factor-mobilized and unmobilized miniature swine, or individual 
and combined fractions ofpPBPC (2xl05 - 2xl06, as described above), were added to 
the PRP. Positive controls of aggregation were baboon PRP to which exogenous 
collagen (5 !J.glml) was added. Negative controls consisted of experimental samples of 
baboon PRP alone, or to which HBSS was added. Continuous stirring of the sample 
with a magnet prevented sedimentation of cells during the assay. 
Competitive blocking experiments were perfonned by incubating baboon PRP with an 
anti-human P-selectin mAb (R&D Systems) (2.5 - 5.0 f!g/ml), an anti-CDl54 mAb 
(100 - 300 f!g/rnl) that would recognize adhesion receptors linked to platelet-cellular 
interactions (ref), or eptifibatide (GPIIb/IIIa receptor antagonist) (0.5 - 5.0 ).lg/ml), at 
room temperature for 15 minutes. Following this incubation, the extent of baboon 
platelet aggregation in the presence of pPBPC was measured. 
Immunohistology 
The experimental samples, obtained after platelet aggregation assays with baboon or 
pPBPC, were centrifuged at room temperature for 10 seconds. The pellet was 
resuspended in 20 III supernatant, and snap-frozen in isopentane embedded in TBS 
tissue freezing medium (Triangle Biomedical Sciences, Durham, NC). Five J-lm 
sections were prepared and stained with standard immunohistochemical staining 
techniques using the murine anti-CD62 rnAb (P-selectin, Becton-Dickinson), or the 
murine anti-GPIIbIIIa (CD3Ia, R&D Systems, both cross-reactive with baboon), and 
porcine pan-leukocyte mAb (l030H-I-19), as well as with a hematoxylin 
counterstain. 
RESULTS 
In vivo experiments 
Approximately 70-80% of PBPC remained viable after the freezing/thawing process. 
All baboons developed a marked thrombocytopenia «20,000/f!1) almost immediately 
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following transplantation of pPBPC that necessitated platelet transfusions on several 
occasions. In baboons that received pPBPC only, platelet recovery was observed 
within 5 - 9 days (data not shown), whereas pPBPC transplantation with the NMCR 
resulted in sustained thrombocytopenia for 2 - 3 weeks (Fig. I - top left). These 
differences were in keeping, at least in part, with the myelosuppression associated 
with whole body irradiation. All baboons developed an increase in serum lactate 
dehydrogenase level, which was more marked in the baboons receiving pPBPC alone 
than in those receiving pPBPC with the NMCR (>!O,OOOU/I and <1,700U/l, 
respectively, data not shown). Components of the NMCR (Le. heparin, prostacyclin, 
and methylprednisolone) appear responsible for this protective effect (Appel JZ III, 
manuscript in preparation). Increases in schistocytes and platelet aggregates on blood 
smear were also observed (Fig. 1 - top right). These features were consistent with a 
thrombotic microangiopathy. In the three baboons that died, microvascular 
thrombosis and interstitial hemorrhage was observed in lungs, kidneys, heart, and 
other organs. Immunohistochemical examination revealed deposition of platelets 
closely associated with porcine cells (Fig. 1 - bottom). 
In vitro experiments 
The addition of baboon PBPC (lxl05 - 2xI0') did not result in measurable 
aggregation of baboon platelets as assayed by light aggregometry (Fig. 2 - left). 
Increased baseline optical density was, however, observed depending on the number 
of baboon PBPC added. The more sensitive immunohistochemical examination of 
sedimented samples demonstrated small baboon platelet aggregates in conjilllction 
with Ix I 06 baboon PBPC (Fig. 2 - right). Examination of baboon platelets alone, or 
platelets plus HBSS (data not shown), did not demonstrate any aggregates. These data 
indicate that minimal platelet aggregates are observed in conjunction with baboon 
PBPC. These are most likely due to limited interaction between the baboon PBPC 
products and platelets under shear stress. 
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Top left. Immediate thrombocytopenia following pPBPC infusion in baboons receiving NMCR. The 
platelet counts (x 1 x I 0·3/1l1) are plotted against time . Porcine PBPC (total 3x 1 01Q ce lls!kg) were infused 
on days 0, I, and 2 (depicted by arrows). Note the rapid fall in platelet count to <100,000/111 
immediately after the first pPBPC are infused. The thrombocytopenia is sustained around 10,000 -
20 ,OOOljll for approximately 14 days, in keeping at least in part with bone marrow depression resulting 
from whole body irradiation, during which platelet transfusions are required (not shown). Recovery of 
platelets to pre-PBPe infusion levels generally took place within 3 - 4 weeks. t signifies the demise of 
baboon 869-360 from thrombotic complications. 
Top right. Platelet aggregates and schistocytes on blood smear from a representative baboon that 
underwent the NMCR and pPBPC transplantation (3xlO ' O !kg). The horizontal arrow indicates baboon 
platelet aggregates. The 2 vertica l arrows indicate typical schistocytes. 
Bottom. Immunohistochemical examination of frozen lung tissue obtained at autopsy from 869-360 on 
day 9 (see Fig. 1 - top left) . The two photomicrographs are serial sections (note the blood vessel in the 
lower left comer) at I OOx magnification. 
Left. Stained with an anti-CD62 (P-selectin) mAb. Arrow depicts conglomerate of baboon platelets in 
microvasculature. 
Right. Stained with anti-l 030H 1-19 (pan-pig leukocyte) mAb. Arrow depicts porcine leukocytes in 
identical location as baboon platelet aggregate. 
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Left . Graphs depicting the effect of baboon (allo) PBPC on baboon platelet aggregation as measured by 
li ght aggregometry. The percentage aggregation is calculated by subtract ing the optical density 
observed immediately after the PBPC have been added (set to 0%) from the optical densiry observed 
after 6 minutes. Baboon PBPC are added in increasing numbers. The addition of I x I 05 (I), I x I 06 (2), 
or 2x I 06 (3) baboon PBPC did not cause macroscopic aggregat ion of baboon platelets. 
Right. Immunohi stochemical examination of experimental sample from Fig. 2 - left - 2 ( I x I 06 baboon 
PBPe + PRP). Specific staining of platelets was perfonned with an ami-CD62 mAb and leukocytes 
were visua lized by hematoxylin counterstain. The horizontal arrow indicates several aggregated 
platelets around an activated baboon leukocyte. 
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Figure 3. 
Left. Graphs depicting the effect of porcine (xeno) PBPC on baboon platelet aggregation as measured 
by light aggregometry. Porcine PBPC were added in increasing numbers. The add ition of Ixl05 (I), 
lxlO6 (2), or 2xl06 (3) pPBPC induced 17%, 26%, and 35% aggregation of baboon plate lets. 
respectively. 
Right. Immunohistochemical examination of experimental sample from Fig. 3 - left - 2 ( I x I 06 pPBPC 
+ PRP). Specific staining of baboon platelets was perfonned with an anti-CD62 mAb and of porcine 
leukocytes with ami- 1030H 1-1 9 mAb. Note the extensive platelet conglomerates incorporating porcine 
leukocytes as indi cated by the horizontal arrow. 
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Addition of cryopreserved pPBPC (lxl05 - 2xl06) led to marked aggregation of 
baboon platelets that was further determined to be dose-dependent (Fig. 3 - left). 
Platelet aggregation approximated 17%,26%, and 35% with addition of lxl05, lxl06, 
and 2xl06 pPBPC, respectively. Furthermore, in these samples increased optical 
density was observed that was dependent on the number of pPBPC added. Variations 
in platelet aggregation could be observed depending On the pPBPC product and the 
source of the PRP. In 5 assays, lxl06 pPBPC induced 14% - 63% baboon platelet 
aggregation, with a mean of28% (data not ShO\\ll1). 
Immunohistochemistry demonstrated mUltiple large platelet aggregates in conjunction 
with 1 x 1 06 pPBPC (Fig. 3 - right), when compared to baboon PBPC. 
Fresh pPBPC induced more platelet aggregation than cryopreserved PBPC (Fig. 4). In 
4 assays, lxl06 fresh pPBPC induced 30 - 79% (mean 48%) platelet aggregation. 
Fresh pPBPC contained more granulocytes and platelets than cryopreserved pPBPC, 
whereas the latter contained more dead cells (data not shown). The highest percentage 
of platelet aggregation (79%) was observed with fresh pPBPC that were obtained 
from a pig that had not been mobilized with porcine growth factors. The main 
difference found between umnobilized and mobilized pPBPC was the higher 
proportion of monocytes in mobilized pPBPC that increased relative to the duration of 
growth factor-mobilization (data not shown). 
Fresh or cryopreserved porcine granulocytes, CD2+ cells, CDT cells in isolation, or 
porcine membranes alone were not able to induce aggregation of baboon platelets 
(Table 1). When all subsets of fresh or cryopreserved pPBPC including the 
membranes were combined, however, 48% and 14% platelet aggregation was 
induced, respectively. The omission of exogenous porcine membranes from the 
preparation consistently failed to induce aggregation. Unsorted fresh or cryopreserved 
PBPC resulted in 52% and 22% aggregation, respectively. 
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Figure 4. 
Graphs comparing the effect of lxlO6 fresh and cryopreserved pPBPC (from the same leukapheresis 
product) on platelet aggregation as measured by light aggregometry. Representative experiments are 
shovro. Fresh pPBPC induced 32% platelet aggregation, whereas cryopreserved pPBPC induced only 
21 % aggregation. Note that the increase in optical density following the addition of frozen/thawed 
pPBPC is less than that following the addition of fresh pPBPC, suggesting less exogenous particulate 
matter in the cryopreserved product. 
Pre-incubation of PRP with anti-P-selectin mAb led to a 60% inhibition of platelet 
aggregation when lxl05 cryopreserved pPBPC were added, when compared to 
aggregation in the absence of P-selectin (Table 2). Pre-incubation of PRP with anti-
CD154 rnAb or eptifibatide resulted in 51% and 93% inhibition of platelet 
aggregation, respectively, after 1x106 cryopreserved pPBPC were added (Table 2), 
when compared to controls. 
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TABLE 1 
BABOON PLATELET AGGREGATION RESPONSES ARE NOT INDUCED BY PURIFIED 
FRACTIONS OF PORCINE PBPC 
Fractions of pPBPC I Cryopreserved aggregation Fresh aggregation , 
response (%) response (%) 
CD2+ I 2 
, CDr 4 I 
Granulocytes * 2 0 
Exogenous membranes 2 2 
Combined fractions ** 48 14 , 
Combined fractions wlo membranes 4 
, 
0 
Total product pre~cell sorting 52 22 
Fractions of pPBPC were obtained by cell sorting (as described). 
2xl06 cells/fractions are used in all assays except when otherwise noted. 
2xl05 cells were used in this assay as fewer could be obtained. 
** Combination of all fractions of pPBPC in equal percentages. 
DISCUSSION 
Thrombotic microangiopathy in baboons following the transplantation of large 
numbers of pPBPC is a serious and potential fatal complication. Furthennore, it also 
limits the number of pPBPC that could be transplanted, thereby decreasing the 
possibility of induction of mixed hematopoietic chimerism and anticipated 
immunologic tolerance. In contrast to the thrombotic microangiopathy following 
autologous or allogeneic bone marrow transplantation, the onset of thrombocytopenia 
and other thrombotic events was directly related to the infusion of pPBPC to the 
baboon, suggesting a direct interaction between pPBPC and baboon platelets. This 
was confinned in the baboons that died, where, at autopsy, baboon platelets were 
demonstrated in close proximity to porcine leukocytes in the microvasculature of 
lungs and kidneys. 
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TABLE 2 
THE INDUCTION OF BABOON PLATELET AGGREGA nON RESPONSES BY 
CRYOPRESERVED PORCINE PBPC IS MODULATED BY ANTI-P-SELECTIN AND ANTl-
CDI54 MONOCLONAL ANTIBODIES AND FULLY ABROGATED BY EPTIFIBATIDE 
pPBPC Aggregation response (%) Decrease from baseline (%) 
Anti-P-selectin mAb * 8 60 
Anti-CD154 rnAb ** 22 51 
Eptifibatide *** 3 93 
lxl06 cells are used in all assays except when otherwise noted. 
Baseline aggregation response is obtained in the absence of blocking agents (anti-P-selectin mAb, 
anti-CD154 rnAb, or eptifibatide). 
Blocking agents were pre-incubated with PRP for 15 minutes at room temperature. 
lxlOS cells were used in this assay (for baseline as well as blocking experiment) 
as fewer could be obtained. Concentration of anti-P-selectin rnAb was 5.0 ).lg/ml. 
** Concentration of anti-CD154 mAb was 300 fig/mi. 
*** Concentration of eptifibatide was 5.0 jlg/ml. 
In our in vitro studies, porcine PBPC, but not baboon PBPC were able to induce 
baboon platelet aggregation in a dose-dependent manner. Immunohistological 
examination demonstrated incorporation of porcine leukocytes into baboon platelet 
aggregates. Further analysis of the pPBPC product revealed that heightened 
aggregation was initiated by fresh rather than frozen pPBPC. Fragmented porcine 
erythrocytes, dead cells, and/or platelets also appeared to contribute to this process. 
Based on these data, we have hypothesized several mechanisms that may contribute to 
this thrombotic microangiopathy. Firstly, dead cells and platelets present in the 
pPBPC preparations could provide a greater number of xenogeneic membranes, and 
thereby potentiate complement activation (20). Although suppression of complement 
activity in baboons undergoing our NMCR is attempted by administering cobra 
venom factor, we realize that the complement depletion may be incomplete, and, due 
to the mechanism of action of cobra venom factor, residual complement components 
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may be in an activated state. Complement activation has been shovvn to induce and 
increase the conversion of prothrombin to thrombin, that can subsequently induce 
platelet aggregation (14, 21, 22, 23) and result in the described thrombotic 
complications. Secondly, complement has been demonstrated to be associated with 
the adhesion of human leukocytes to porcine aortic endothelial cells through P-
selectin (24). These interactions may be relevant to om model. As adhesion through 
selectin molecules is conserved across mammals (25), porcine leukocytes may 
interact with baboon platelets via such adhesion molecules. We have presented further 
evidence to this effect by decreasing the induction of pPBPC-mediated baboon 
platelet interactions with an anti-P-selectin mAb. Furthermore, since the activation of 
complement can lead to upregulation of P-selectin (26) and ~2-integrin (27), porcine 
leukocytes may thus adhere to baboon platelets (28, 29). Aggregation of these 
activated platelets, initiated by GPlIbIlla cross-linking, could then result. A third 
possibility is that porcine monocytes become activated and upregulate adhesion 
molecules in the absence of overt complement activation or in the presence of sub-
lytic levels of complement. Inflammatory cytokines, such as those released from dead 
cells, are associated with an increased expression of adhesion molecules (30). These 
cytokines (such as tumor necrosis factor-a) may activate leukocytes, increase the 
expression of adhesion molecules (such as P-selectin and ~-integrins) on the cell 
surface, consequently activate platelets and induce aggregation responses. These 
potential mechanisms and others need to be further elucidated. 
We have demonstrated that a thrombotic microangiopathy occurs following the 
transplantation of pPBPC in nonhwnan primates, and that this is associated with 
porcine leukocyte - baboon platelet interaction. We can now present evidence that 
pPBPC can directly induce the aggregation of baboon platelets in vitro. Aggregation 
responses can be modulated by anti-CD154 and anti-P-selectin mAbs, and are fully 
abrogated by eptifibatide (a potent GPlIbIlla antagonist). The severe thrombotic 
microangiopathy that is associated with the transplantation of pPBPC into baboons 
may therefore be ameliorated by stringent pmification of the pPBPC product and/or 
including eptifibatide to the conditioning regimen. Such an approach may allow for 
the transplantation of larger numbers of pPBPC and facilitate the induction of mixed 
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chimerism and immunological tolerance. These studies are currently W1derway in our 
laboratory. 
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ABSTRACT 
Introduction. The induction of tolerance to pig antigens in primates should facilitate 
the development of successful clinical xenotransplantation protocols. The infusion of 
mobilized porcine peripheral blood leukocytes (PBPC) into splenectomized pre-
conditioned baboons, intended to induce mixed hematopoietic cell chimerism, however, 
results in thrombocytopenia and a severe thrombotic microangiopathy (TM). As the 
mechanisms responsible for this phenomenon are unclear, we have explored the effects 
of individual components of the conditioning regimen, of therapeutic adjuncts and of 
PBPCs on platelet aggregation. 
Methods. Groups of splenectomized baboons (n=2 in each group) were treated with 
single components of the conditioning regimen - whole body irradiation (\VBI), anti-
thymocyte globulin (ATG), extracorporeal irnmunoadsorption (EIA), mycophenolate 
mofetil (MMF), anti-CD40L mAb, cobra venom factor (CVF), pig hematopoietic 
growth factors (interleukin-3 (pIL3) and stem cell factor (PSCF» - or with potential 
adjuncts, cyclophosphamide (CPP), prostacyclin (PGI2), heparin, methylprednisolone, 
and eptifibatide. Blood samples were collected and platelet-rich plasma (PRP) was 
prepared. Using light transmission aggregometry, the extent of aggregation induced by 
platelet agonists (Thrombin, adenosine diphosphate (ADP), collagen, ristocetin, and 
arachidonic acid) was detennined in vitro. PRP was also prepared from untreated 
baboons and baboons receiving either eptifibatide (a GPIIb/IIIa antagonist) or CPP and 
PBPC were added and platelet aggregation was measured in the absence of exogenous 
platelet agonists. 
Results, WEI, ATG, MMF, anti-CD40L mAb, CVF, pIL3 + pSCF, and PGI2 had no 
effect on purified baboon platelet aggregation profiles in vitro. CPP or eptifibatide 
markedly inhibited platelet aggregation induced by all standard agonists. Thrombin-
induced platelet aggregation was inhibited by EIA or heparin, and ADP-induced 
aggregation was inhibited to some extent by methylprednisolone. In vitro addition of 
PBPC to PRP stimulated platelet aggregation in the absence of any agonists. Prior 
treatment of baboons with eptifibatide or CPP, however, inhibited this effect by 70-80% 
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and 55%, respectively. TM was not evident in baboons receiving a conditioning 
regimen that included CPP instead of WBI. 
Conclusions. Aggregation of baboon platelets and TM is directly induced by PBPC. 
but not by individual components of the conditioning regimen. CPP has direct anti-
aggregatory properties and may provide an alternative strategy to WBI. GPilb/IIla 
antagonists, such as eptifibatide, interfere directly with xenogeneic PBPC-platelet 
interactions and may further ameliorate TM in the pig-to-primate modeL 
INTRODUCTION 
Because of the limited availability of suitable human organ donors, 
xenotransplantation has received considerable attention in recent years. For several 
reasons, the pig is considered the best candidate for this purpose (1-3). However, the 
transplantation of porcine tissue into humans or non-human primates elicits a severe 
and rapid rejection response, resulting in graft loss, even when intensive 
immunosuppressive therapy is administered (4). 
One approach that would overcome the pig-to-primate xenogeneic barrier is the 
development of donor-specific unresponsiveness, or transplantation tolerance (5). 
Tolerance has been induced in several allogeneic models using a variety of 
approaches. Of these, perhaps the most successful protocols are those that establish 
mixed hematopoietic cell chimerism by infusing donor bone marrow or hematopoietic 
progenitor cells into conditioned recipients (6). 
Our center has infused porcine hematopoietic progenitor cells into conditioned 
primates in an attempt to induce a state of pig-primate mixed chimerism to promote 
xenogeneic tolerance (5). Leukocytes are mobilized from porcine bone marrow ill 
vivo using pig-specific hematopoietic groVvih factors (7-9). These mobilized 
peripheral blood leukocytes (PBPC), that contain approximately 2% hematopoietic 
progenitor cells, are collected by leukapheresis (9). The PBPC are then infused into 
baboons that have undergone a conditioning regimen modified from those that have 
met with success in allogeneic models (See Chapter I. Figure 3). This preparative 
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regimen entails thymic irradiation and non-lethal myelosuppression in the form of 
whole body irradiation (WEI). Baboons receive anti-thymocyte globulin (ATG) and 
undergo a process of extracorporeal immunoadsorption (EIA) of anti-Gal (al-3) Gal 
(Gal) natural antibodies. Baboons also receive immunosuppression, in the fonn of 
mycophenolate mofetil (MMF) and anti-CD40L mAb, cobra venom factor (CVF), and 
pig-specific hematopoietic growth factors, pig interleukin-3 (pIL3) and pig stem cell 
factor (PSCF) (10). Once this regimen has been completed, large numbers of porcine 
PBPC (2-4 x 101O/kg) are infused intravenously. 
Although transient engraftment of pig hematopoietic progenitor cells (detectable in 
the blood by pol)'lllerase chain reaction and by flow-activated cell sorting) has been 
achieved in two of eight baboons receiving this regimen, a severe thrombotic 
microangiopathy (TM) inevitably develops shortly after the infusion of PBPC (7). 
This is manifest by pronounced thrombocytopenia (platelet count < 20,000) (See 
Chapter 5, Figure 2), schistocytosis, and elevation of lactate dehydrogenase. In many 
regards, this syndrome resembles the TM observed in approximately 14% of bone 
marrow transplant recipients (11) but, in the xenogeneic combination, develops much 
earlier (i.e. long before, not after, engraftment). Prothrombin time (PT), partial 
thromboplastin time (PTT), and fibrinogen levels, although transiently disturbed by 
EIA, typically remain unaffected. The condition can be fatal in experimental animals, 
and autopsies reveal microvascular thrombosis and vascular injury in several major 
organs, including the heart, lungs, and kidneys (Figure I) (7). 
TM represents a considerable barrier to the achievement of xenotransplantation 
tolerance in this model because it may be associated with significant morbidity and it 
limits the total number of PBPC that can be infused, therefore reducing the likelihood 
of establishing mixed hematopoietic cell chimerism. Thus, an improved 
understanding of the mechanisms underlying the platelet activatioillaggregation 
observed in baboons receiving \VBI and PBPC may suggest ways of preventing these 
sequelae, thereby facilitating mixed chimerism and the induction of 
xenotransplantation tolerance. 
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Figure I. 
Baboons receiving WBI develop thrombotic microangiopathy after infusion of pig PBPC. 
Microvascular thrombi with platelet sequestration develop in organs such as the kidney (stained for P-
selectin). 
Cyclophosphamide (CPP) has been used as an alternative to irradiation in some 
instances prior to clinical bone marrow transplantaion (12). A prodrug, CPP is 
biotransformed by a microsomal oxidase system in the liver to active metabolites. 
Some of these species inhibit the growth of rapidly proliferat ing celis, most likely by 
cross-linking DNA, thereby exerting an immunosuppressive and, possibly, 
myelosuppressive effect. Additionally, the administration of CPP to some patients 
with TM of various etiologies has proved therapeutic (13-16). Thus, CPP may be a 
favorable alternative to WBI in this pig-to-primate model of mixed chimerism and 
tolerance induction. 
In this study, standard light transmission aggregometry was utilized to assess the 
effects of the individual components of this complex conditioning regimen and of 
PBPC on platelet aggregation in vitro. Furthermore, the anti-thrombotic properties of 
c pp and of several potential adjuncts to the current conditioning regimen, including 
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PGI2, heparin, methylprednisolone, and eptifibatide (a GPIIb/IIIa platelet receptor 
antagonist) were examined. 
MATERIAL & METHODS 
Animals 
Baboons (Papio anubis, n=12, Biomedical Resources Foundation, Houston, TX), 
weighing 9-13 kg, were used to test experimental agents in vivo and as a source of 
platelets for in vitro experiments. All animals had been previously splenectomized 
through a midline laparotomy. Normal platelet counts and coagulation parameters 
were present in all baboons at the onset of the present study. All experiments were 
performed in accordance with the Guide for the Care and Use of Laboratory Animals 
prepared by the National Academy of Sciences and published by the National 
Institutes of Health. Protocols were approved by the Massachusetts General Hospital 
Subcommittee on Research Animal Care. 
Surgical Cannulation of Vessels 
Baboons were anesthetized and the carotid artery and internal jugular vein were 
cannulated with silastic catheters as described previously (17). A jacket and tethering 
system was utilized, which allowed continuous or intermittent administration of 
intravenous (IV) fluids and/or drugs, withdrawal of blood, monitoring of arterial 
blood pressure, and sedation (as needed) for the baboon. Cefazolin sodium (500 mg 
IV) was given daily as prophylaxis against infection. 
Individual Components of the Conditioning Regimen 
All immunomodulatory procedures, agents, or combinations of agents, were tested in 
vivo in at least two baboons (Table 1). Serial blood samples were taken in order to 
monitor platelet count, PT, PTT, fibrinogen, fibrinogen degradation products, white 
blood cell counts, and hematocrit (Hematology Laboratory, Massachusetts General 
Hospital). Seven baboons were used to test more than one agent, but platelet 
aggregation and coagulation parameters were allowed to return to baseline before 
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subsequent drugs were administered. Most agents were infused continuously 
although bolus injections were used in some instances, as indicated in Table 1. 
Collection of Mobilized Peripheral Blood Leukocytes (PBPC) 
PBPC were collected from miniature swine using a 16-day leukapheresis protocol 
described previously (9). Pigs were treated with recombinant hematopoietic growth 
factors (8-10) before and during the period of leukapheresis. On days 0-15, pIU and 
pSCF were administered daily by subcutaneous injection, each at a dose of 100 
r;g/kg/d. Human granulocyte colony stimulating factor (Arngen, Thousand Oaks, CAl 
was administered subcutaneously at 10 J..Lglkgld on the evening before each 
leukapheresis procedure. Leukapheresis was performed on days 5-9 and 12-16 using 
a Cobe Spectra apheresis machine (Cobe, Lakewood, CO). This leukapheresis 
product was washed and, following lysis of red blood cells, the remaining PBPC were 
frozen in 5% dimethylsulfoxide. 
Platelet Aggregation Assay 
At intervals before, during and after the administration of each agent, or before and 
after a procedure (e.g. EIA, WBI), 10 ml citrated blood was drawn from the baboon 
and centrifuged at 280 g for 15 minutes at 22°C. The supernatant, consisting of 
platelet-rich plasma (PRP), was removed and the remaining pellet was centrifuged at 
2,400 g for 2 minutes at 22 'C to obtain platelet-poor plasma. The final PRP was 
transferred in 400 IJ.I aliquots to siliconized glass cuvettes, comprising the 
experimental samples. A 400-)11 aliquot of platelet-poor plasma was used as a 
reference sample, to which platelet aggregation in PRP samples could be compared. 
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TABLE I 
AGENTS I PROCEDURES ADMINISTERED TO BABOONS 
AgentJProcedure Dose Administered References Suggesting 
Tested Pro~/Anti~ Thrombotic 
i 
i Properties 
! Whole body irradiation i 150 cGy/d x 2d 18-21 
Anti~thymocyte globulin 50 mg/kg/d elv x 3d 22 
: Extracorporeallmmunoadsorption i Daily x 3d 23,24 
i. Mycophenolate mofetil llO mg/kgld CIY 22,25 
Anti-CD40L mAb 40 mg/kg xl I 26-29 
i Cobra venom factor I 100-200 Ulkgld x 3d I 30-32 
: :ecombinant pIL3 200 !J.g/kg bolus, I 
400 ~glkg/d CIY x 2d 
, 
, 
I Recombinant pSCF , 1 mg/kg bolus, 
2 mg/kg/d elv x 2d 
Cyclophosphamide I 40 mg/kg/d x 3d 12-16,33,34 
Prostacyclin (PGI2) 20-30 ng/kg/min CIV x 3d 35-37 
Heparin sodium 10 50 Vlkg/hr CIV x 5d 38,39 
Methylprednisolone 2 mg/kg twice daily x 3d 40 
Eptifibatide (GPllb/Ula 180 ).Lg/kg bolus, 41,42 
! antagonist) 2.0-7.5 ).Lglkg/min CIV x Id 
pIL3 = porcine interleukin 3, pSCF = porcine stem cell factor, CIY = continuous intravenous infusion 
Four of five standard platelet agonists (thrombin (1.25 Ulml), adenosine diphosphate 
(ADP) (20 ).LM), collagen (10 ).Lg/ml), and ristocetin (1.25 ).Lg/ml)) were added to the 
experimental samples, and the extent of aggregation over a period of six minutes was 
measured using a platelet aggregometer (two-sample, four-charmel, model 560 Ca 
Lumi-aggregometer, Chronolog Corp., Havertown, PA). Because ristocetin (which 
acts via GPIb receptors in association with v\VF) was found to be a less potent 
agonist, arachidonic acid (which is converted into pro-aggregatory metabolites PGH2 
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and TXA2) (1.2 mM) was used in some instances. By adding a small rotating magnet 
to each sample, shear stress was created in order to simulate intravascular flow 
conditions. 
VVhenever PBPC were to be added to baboon platelets in vitro, blood was drawn from 
untreated baboons and, in the manner described above, PRP was prepared. 
Immediately prior to use, PBPC were rapidly thawed in a water bath at 37°C and 
were washed twice with calcium-, magnesium-, and phenol red-free Hanks balanced 
salt solution. In the absence of any agonists, increasing numbers of PBPC (1 x 105, 2 
x 105, 1 x 106, and 2 x 106 ) were added to separate PRP samples and aggregation was 
measured. 
Immunohistochemical Staining of PBPC-stimulated Aggregates 
Experimental PRP samples to which PBPC had been added were centrifuged at 
10,000 rpm for 20 seconds. The supernatant was aspirated from these and the 
remaining pellet was resuspended in 20 /.11 supernatant, and frozen in TBS tissue 
freezing medium (American Mater-Tech Scientific, Lodi, CA). From these frozen 
samples, 5 )..tm-thick sections were prepared and subsequently stained with anti-P-
selectin or 1 030H-l-19, a pan-pig monoclonal antibody developed by our laboratory. 
RESULTS 
Effects of Individual Components of the Conditioning Regimen on Platelet 
Aggregation 
Table 2 summarizes platelet aggregation (relative to baseline) measured in PRP 
prepared from baboons treated with each of the individual components of the 
conditioning regimen. A change in platelet aggregation was considered to be 
substantial if it differed by more than 20% from baseline measurements and occurred 
in both baboons tested. 
Exposure to \VBI did not affect platelet aggregation, which was assessed 48 hours 
following the second fractionated dose. Following WEI, platelet counts in both 
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baboons decreased gradually, reaching values approximating 20% of baseline 
measurements after 8 and 10 days, respectively. Coagulation parameters and 
hematocrit remained stable during this period. Administration of CPP on three 
consecutive days (a total dose of 120 mg/kg), however, resulted in a progressive 
inhibition of agonist-stimulated platelet aggregation that was most pronounced after 
approximately 6-8 days (Figure 2). Aggregation induced by thrombin, ADP, collagen, 
and arachidonic acid was decreased from baseline by as much as 62%, 85%, 84%, and 
95% respectively, in one baboon and by 74%, 98%, 83%, and 98% in another. 
Fourteen days after administration of the drug, platelet aggregation returned to pre-
treatment levels in both baboons. Coagulation parameters were not altered 
significantly during the experiment. CPP-treated baboons experienced a progressive, 
but transient, decrease of white blood cells (from approximately 9,000/f'l to 900/f'I 
and from 12,000/f'l to 800/f'I over 7 days) and of platelets (from approximately 
310,000/f'l to 66,000/1-'1 and from 300,000/1-'1 to 170,000/f'l over 11 days), which 
returned to pre-treatment values 16 days following administration of the drug. 
To verify that the reduction in platelet aggregation was independent of platelet count, 
PRP was prepared from untreated baboons. Baseline platelet aggregation induced by 
thrombin, ADP, collagen, and arachidonic acid was 27%, 30%, 62%, and 20%, 
respectively. When diluted (from an initial count of 540,000 platelets/f'l) as much as 
eight-fold with calcium-, magnesium-, and phenol red-free Hanks balanced salt 
solution, platelet aggregation induced by thrombin, ADP, and collagen was unaffected 
(22%, 33%, and 65%, respectively). Similar results were obtained when PRP was 
diluted with platelet-poor plasma. 
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Effect of the in vivo administration of cyclophosphamide (total dose 120 mgikg) on in vitro baboon 
platelet aggregation. Platelet aggregation by all agonists was partially inhibited 6-! I days after 
cyclophosphamide administration. ADP = adenosine diphosphate. 
The process of EIA had a transient inhibitory effect on thrombin-induced platelet 
aggregation (by 98%) (Table 2). Coagulation parameters. measured at the same time, 
were prolonged (PT >30 s, PTT > 80 s) but recovered over a period of 12-18 hours. 
Administration of ATG, MMF, anti-CD40L mAb, or CVF to individual baboons, 
however, had no substantial effects on the aggregation of baboon platelets. As 
anticipated, baboons receiving ATG developed leukopenia, but no thrombocytopenia, 
and this was rapidly reversed upon discontinuation of treatment. Laboratory 
parameters were otherwise unchanged in these baboons. 
Inconsistent effects on platelet aggregation were observed in baboons receiving either 
hematopoietic growth factors (pIL3 + pSCFl or PGI2. Ristocetin-induced platelet 
aggregation was slightly increased (by 25%) in one baboon receiving pIL3 and pSCF. 
Platelet aggregation was unaffected in baboons receiving PGI2 20 ng/kg/min, 
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although ADP- and collagen-induced platelet aggregation was inhibited by 24% and 
23%, respectively, in one baboon receiving 30 nglkglmin. No disturbances of vital 
signs, coagulation parameters, or other adverse effects were noted in these baboons. 
As predicted, heparin reduced thrombin-induced platelet aggregation In a dose-
dependent manner. Little effect on global platelet parameters and aggregation 
responses was apparent in baboons maintained on a continuous infusion of 10 
Ulkg/hour. However, considerable inhibition of thrombin-induced aggregation (by 
90%) was evident at 50 Ulkglhr. PTT was prolonged to > 150 seconds in contrast to 
baseline parameters of < 30 seconds. 
In both baboons that received methylprednisolone, platelet aggregation induced by 
ADP was inhibited (by 43% and by 50%). Arachidonic acid-induced platelet 
aggregation was inhibited in one baboon by up to 93% on two separate days, but was 
unaffected in a second baboon. 
The administration of eptifibatide resulted in potent and global inhibition of platelet 
aggregation (Figure 3). This was dose-dependent, such that continuous infusion at 2.0 
)lglkglmin had little effect (0-48% inhibition), whereas 7.5 )lglkglmin inhibited 
aggregation induced by all agonists tested (by 84 - 99%). The onset of this effect was 
rapid, evident as early as 30 minutes after initiation of the drug infusion and was 
rapidly reversible, platelet aggregation returning to baseline levels within two hours 
after discontinuation of therapy. 
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Effect of the in vivo administration of eptifibatide on in vitro baboon platelet aggregation. Eptifibatide 
inhibited platelet aggregation induced by all agonists, and had an increasing inhibitory effect at higher 
dosages. ADP = adenosine diphosphate. 
Vital signs, coagulation, and other laboratory parameters were unaffected at all doses 
tested, and bleeding episodes or other adverse effects were not observed. 
Effect of PBPC on Platelet Aggregation 
In vitro, the addition of porcine PBPC to PRP from untreated baboons stimulated 
platelet aggregation in the absence of any agonist. and increased with the number of 
PBPC added (Figure 4A & B). Although no aggregation was detected when I x 105 
cells were added, the addition of 2 x 105, I X 106, and 2 x 106 PBPC induced 
aggregation by as much as 17%, 26%, and 35%, respectively, in one baboon. This 
trend was apparent in a total of four experiments using PBPC and PRP from different 
pigs and baboons. Immunocytochemistry using anti-P-selectin and/or the pan-pig 
preparation, 1030H-I-19, demonstrated the aggregation of baboon platelets around 
porcine leukocytes (See Chapter 6, Figure 3). When PBPC were added in vitro to 
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PRP prepared from baboons treated with eptifibatide (7.5 ).lg/kg/min IV), platelet 
aggregation was prevented by > 70% (Figure 4C). Similarly, PBPC-induced platelet 
aggregation was inhibited by 55% in PRP prepared from a baboon 6 days after the 
administration ofCPP (120 mg/kg total dose) (Figure 4D). In baboons treated with a 
CPP-based conditioning regimen instead of \VBI, TM was not evident following the 
infusion of PBPC. Although platelet counts in CPP-treated baboons decreased to 
some extent, the profound thrombocytopenia and thrombotic complications 
characteristic of VYBI-treated baboons did not develop and platelet counts recovered 
earlier (Figure 5 - Top). Schistocytosis was not detected and lactate dehydrogenase 
levels were unaffected in these CPP-treated baboons (Figure 5 - Bottom). 
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Platelet aggregation curves of nai've baboons obtained after in vitro addition of porcine PBPC. 
(A) Addition of Ix105 porcine PBPC to baboon PRP containing approxiamte[y lxl08 platelets led to 
11% aggregation. (8) Addition of 2 x 106 PBPC resulted in 22% platelet aggregation. (C) When 
platelets were prepared from the same baboon after treatment with eptifibatide, platelet aggregation 
induced by 2 x 106 PBPC was inhibited by > 70% (to 5%). CD) Platelet aggregation induced by 2 x 106 
PBPC was inhibited by 55% (to 10%) in PRP prepared from the same baboon 6 days after treatment 
with C?P. 
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TABLE 2 
EFFECT OF VARIOUS IN VIVO AGENTS/PROCEDURES ON IN VITRO BABOON 
PLATELET AGGREGATION 
Platelet Agonist 
Agent/Procedure c c c :c • ~ 5 .. " Tested N Q ~ v 0 E 
-
~ "0 
.c U ~ ... 
i 
WBI 2 
-
-
-
-
Anti·thymocyte globulin 2 -
- -It -, 
i EIA 2 ... - - -
Mycophenolate mofetil 2 - -It - -
Anti·CD40L mAb 2 -
- i - -
Cobra venom factor 2 
-
-
i 
-It -
pIL3 + Pscf 2 - - I - -It 
Cyclophosphamide 2 ... ... 
I 
... NA 
PGI2 (20 ng/kg/min) 2 - -
-
NA 
PGI2 (30 nglkglm;n) 2 
- -It I -It NA 
Heparin 2 ... - I - NA 
Methylprednisolone 2 - ... i - NA 
Eptifibatide 2 + + + NA 
,} or t indicates a change in platelet aggregation >20% from baseline. 
- indicates a change of <20%. NA indicates agonist not used in corresponding experiment. 
WBI = whole body irradiation, EIA = extracorporeal immunoadsorption, pIU = porcine 
interleukin 3, pSCF = porcine stem cell factor, PGI2 = prostacyclin, ADP = adenosine 
diphosphate. 
:s 
v 
~ 
v 
'= 0 
:s 
.c 
v 
• 
-
~ 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
... 
-
-
-
-It 
+ 
169 
I 
Section IV - Chapter 7 
700. ~Cyclophosphamide 
~-WBI 
600~ 
500' 
400 
300 
200 
100~ 
O-------c----c~~~~~~~~--~~~cc 
-10 -5 0 5 10 15 20 25 
WBI 111 DAYS 
or mPL 
Cyclophosphamide 
w 
2000- ~Cyclophosphamide 
i --WBi ~ 
Z 
W 
(!) 
o 
0:: 
1600j 
o ::i' 1200 
>--:r:::> 
W::::. 
Cl 
W 
f-
~ () 
« 
-' 
Figure 5. 
800 
400l 
O~i---c--~----~--~~~~~~~ 
-10 -5 2115 10 15 20 25 
WBI I DAYS 
or mPL 
Cyclophosphamide 
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cyclophosp:1amide-based conditioning regimens. (Top) Thrombocytopenia is much less pronounced 
and (Bottom) lactate dehydrogenase levels are more stable in baboons receiving cyclophosphamide 
than in those undergoing WBf. 
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DISCUSSION 
Substantial advances in xenotransplantation have enabled hyperacute rejection to be 
overcome (4). The onset of acute vascular rejection to be delayed in part by the 
administration of intensive immunosuppressive therapy. However, even if acute 
vascular rejection (delayed xenograft rejection) can be prevented, the acute cellular 
response is likely to be strong. Long-term survival of discordant xenografts may 
therefore depend on the successful induction of transplantation tolerance. 
By infusing donor hematopoietic progenitor cells into recipients this way, and 
inducing a state of mixed hematopoietic cell chimerism, tolerance has been achieved 
in allogeneic animal models (6) and, recently, in a human renal allograft recipient 
(43). Using a complex conditioning regimen (as described above) (4, 7), transient 
bone marrow engraftment of pig progenitor cells has been achieved in some baboons 
pretreated with \VBI and thymic irradiation. However, baboons undergoing VVBI 
exhibit a severe TM immediately after the infusion of PBPC (7). 
The current study investigated the roles of the individual components of the 
conditioning regimen, and of PBPC, in the aggregation of baboon platelets. 
Furthermore, it assessed the anti-thrombotic properties ofCPP, an alternative to \VBI, 
and of several potential adjuvants, including PGI2, heparin, methylprednisolone, and 
eptifibatide, a GPIIb/IHa platelet receptor antagonist. 
\\!hen administered individually to baboons, no single component of the VVBI-based 
conditioning regimen increased platelet aggregation. Porcine PBPC, when added to 
baboon platelets in vitro, initiated aggregation in the absence of any platelet agonists. 
Immunocytochemistry, using anti-human P-selectin and 1030H-1-19 (a pig-specific 
stain), confirmed the formation of PBPC-platelet aggregates. This phenomen 
increased with larger numbers of PBPC and suggests that they playa primary role in 
the fonnation of platelet microthrombi in vivo. It is likely that the aggregation of 
platelets and the sequestration in the microvasculature contribute to the 
thrombocytopenia and TM observed in conditioned baboons after PBPC infusion. 
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The observation that \VBI had no effect on platelet aggregation is of interest as the 
formation of platelet microthrombi can occur following irradiation in vivo (20, 21). 
The detrimental effects of irradiation on the vascular endothelium are well 
documented (18, 19) and include endothelial cell activation (indicated by upregulation 
of ICAM-l and P-selectin), vacuolization, and separation from the basement 
membrane (20). As WBI does not affect the inherent tendency of platelets to 
aggregate, as indicated by the results of this study, the formation of microthrombi in 
irradiated patients may depend largely on endothelial damage. In contrast to the TM 
observed in baboon recipients of porcine PBPC, the clinical sequelae of bone marrow 
allotransplantation typically require several days as opposed to hours to become 
manifest (11). Although irradiation may inflict endothelial damage in the baboons in 
our studies, which may lead to the formation of rnicrothrombi in some instances, it is 
unlikely that this contributes primarily to the TM observed immediately following the 
administration of PBPC. 
Vlhen administered to baboons, CPP inhibited platelet aggregation induced by all 
agonists. This effect may explain why treatment with CPP instead of \VBI prior to the 
infusion of PBPC protected baboons against TM. In contrast to \VB1-treated baboons, 
those receiving CPP appeared to tolerate the infusion of PBPC without major 
complications and with only a minor reduction in platelet count (Figure 5 - Top). 
However, engraftment may be compromised as it was not observed in baboons 
receiving CPP. CPP may be a less effective mode of myelosuppression in this model, 
or it may not create the bone marrow "space" necessary for PBPC engraftment. 
However, the use of CPP as an alternative, or in combination with a lower dose of 
\VBl, may yield certain advantages. 
Although not reported here, the infusion of PBPC into baboons in the absence of the 
conditioning regimen initiated a state nearly identical to the TM seen in baboons 
receiving the full regimen, confirming the primary role of PBPC in this syndrome 
(See Section 4, Chapters 5 & 6). This finding also supports the conclusion that CPP is 
protective against TM, since this syndrome develops in baboons (with or without 
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\VBl), but is not evident in those receiving CPP. This also demonstrates that \VBI is 
not necessary for the initiation of TM, although it may exacerbate this state by 
delaying marrow regeneration. Moreover, additional effects of WBI, such as 
endothelial cell damage, may also contribute to the formation of microthrombi. 
The inhibition of platelet aggregation by CPP was not apparent until approximately 
one week after infusion of the drug. Thus, the direct actions of one or several 
metabolites of CPP on platelets could contribute. Two of these, 4-hydroxy-CPP and 
acrolein, have been implicated in at least one other report (17). Data from preliminary 
experiments in our laboratory suggest that the effects of CPP on baboon platelets 
result from the modification of signal transduction pathways that are involved in 
normal aggregation (data not shown). 
Because the cytotoxic effect of CPP metabolites has been attributed to their ability to 
cross-link DNA nuc1eotides, our laboratory has hypothesized that such complexes 
could bind purinergic receptors resulting in blockade at the platelet surface. However, 
using serotonin and epinepherine, which would bypass purinergic receptor blockade, 
indicate that this is not the case (data not sho\VIl). 
The maximal CPP-induced inhibition of platelet aggregation was apparent on days 
when platelet counts approached their nadirs (66,OOO/f'1 and 170,OOO/f'I, respectively). 
Previous reports have indicated that ADP- or collagen-induced platelet aggregation is 
sustained at platelet counts as low as 50,OOO/f'1 (44). Our control studies, in which 
PRP (with an initial platelet count of 540,OOO/f'I) was diluted as much as eight- to 
twelve-fold, confirmed these findings for ADP and collagen, as well as for thrombin. 
Thus, a low platelet count alone would not account for this decrease in platelet 
aggregation. It is possible that this decrease in platelet count reflects CPP-induced 
megakaryocyte depletion or inhibition, resulting in temporarily diminished platelet 
regeneration. Subsequent recovery of megakaryocyte function and production of new 
platelets would account for the concomitant increase in platelet count and return of 
platelet aggregation to baseline. 
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The EIA of anti-Gal antibodies transiently prevented thrombin-induced platelet 
aggregation. The activation of platelets and coagulation factors by circulation through 
the irnmunoadsorption apparatus could contribute to this effect. This may have been 
exacerbated further, however, by the high concentration of citrate used as an 
anticoagulant during EIA, which may have had marginal effects on blood coagulation 
and platelet activation (45, 46). 
Of the potential therapeutic agents administered to baboons, eptifibatide was the most 
effective platelet antagonist, inhibiting platelet aggregation by all agonists tested. 
This effect was related to the dose of the drug administered (0-48% iuhibition at 2.0 
fLglkg/min. and 84-99% iuhibition at 7.5 fLg/kg/min.). The effect was rapidly induced, 
requiring administration for only 30 minutes, and readily reversible, returning to near-
baseline values within 2 hours after cessation. As expected, heparin inhibited the 
aggregation of baboon platelets by thrombin alone, as heparin catalyzes thrombin 
degradation by associating with anti-thrombin. Methylprednisolon.e inhibited ADP-
induced platelet aggregation by as much as 55%, an effect that, to our knowledge, has 
not been reported previously, but that could relate to membrane stabilization and the 
inhibition of phospholipases (40). In contrast to results in other animal models (36, 
37), PGI2 did not iuhibit platelet aggregation substantially. This may indicate that 
this preparation ofPGI2 is less effective in baboons than in humans. Alternatively, as 
PGI2 also acts on the endothelium, the antiplatelet properties of this compound may 
require the presence of a functioning endothelium and thus may not be apparent in 
this model of platelet aggregation. 
When PRP was prepared from baboons treated with eptifibatide, PBPC-induced in 
vitro platelet aggregation was inhibited by > 70%. This suggests that eptifibatide, or 
other GPIIb/IIIa antagonists, would be beneficial adjuncts to the conditioning regimen 
currently used. For this reason, trials investigating the role of eptifibatide in baboons 
receiving porcine PBPC have begun. Furthermore, PBPC-induced platelet 
aggregation was also iuhibited (by 55%) in PRP prepared from a baboon 6 days after 
administration of CPP. The ability of CPP to abrogate PBPC-induced platelet 
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aggregation provides further evidence that CPP may protect baboons receiving PBPC 
against TM. 
The experimental model of platelet aggregation used in the present study provides 
considerable information on the ability of various agents to alter the threshold for 
platelet activation and aggregation in baboons. Most molecular interactions would 
continue to occur in vivo after the administration of each agent or procedure prior to 
withdrawal of blood samples. Additionally, since the PRP subsequently prepared 
contains most of the components of blood, many molecular interactions would also 
occur during in vitro assays. By inducing an element of low shear stress, the platelet 
aggregometer mimics flow conditions in the venous (but not the arterial) vasculature 
to some extent. However, this model is limited in that it does not account for the 
contributions imparted by the endothelium (whether intact and functional or in a 
pathological state) including cell-cell interactions, the release of soluble mediators, 
and vasoconstrictive/vasodilatory responses. Thus, in future endeavors, it would be 
useful to utilize assays that better assess the role of the endothelium, such as intravital 
video microscopy. 
Althougb this study demonstrates that porcine PBPC initiate the fonnation of baboon 
platelet aggregates in vitro, resulting in thrombocytopenia when infused in vivo, it 
does not elucidate which component of the leukapheresis product is primarily 
responsible. Flow-activated cell sorting studies demonstrate that the PBPC 
leukapheresis product (after one freezing/thawing cycle) contains approximately 30% 
T cells, 45% B cells and monocytes, 20% debris (e.g. dead cells and cellular 
fragments), and <1 % granulocytes. Any of these cellular subsets, or even soluble 
factors that they have released, could contribute to this phenomenon. To determine 
whether or not specific cellular subsets of porcine PBPC are responsible for TM, in 
vitro studies have begun to assess which, if any, specific fractions induce platelet 
aggregation and/or endothelial cell activation. It may be that aggregation is induced 
by a fraction that is unnecessary for the engraftment of porcine hematopoietic 
progenitor cells, in which case the removal of this subset from PBPC may eliminate 
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the morbidity currently associated with PBPC infusion and facilitate mixed 
chimerism. 
Substantial PBPC-induced platelet aggregation has only been observed between 
discordant species in our laboratory. The addition of baboon PBPC to baboon PRP, 
for example, does not result in substantial platelet aggregation (see Chapter 6). Thus, 
it will be important to determine if immunological factors or molecular barriers 
contribute. It is unlikely that aggregation is mediated by baboon complement since 
the depletion of complement by CVF has no effect on the course of TM. Likewise, it 
is improbable that preformed xenoreactive antibodies play a major role since the 
depletion of anti-Gal (by >95%) by EIA does not affect PBPC-induced platelet 
aggregation (Appel, J.Z., et a!. - unpublished observations). It may be that specific 
porcine PBPCHbaboon platelet ligands interact more extensively than species-specific 
ligands and therefore result in more substantial platelet aggregation. Specific 
inhibition of these interactions (e.g. by CPP or GPIIb/IIIa antagonists) may abrogate 
this syudrome. 
Nevertheless, it is likely that the TM observed in baboons receiving PBPC results 
from a multifactorial process. It is possible that the combination of some components 
of the conditioning regimen exacerbate TM in baboons. Although platelet 
aggregation is not increased after treatment with the full \VBIHbased conditioning 
regimen (without PBPC) (Alwayn, I.P.J. - unpublished observations), these baboons 
may exhibit a dysfunction in platelet-endothelial interactions not detected in this in 
vitro model. Furthermore, it is likely that the mechanisms involved in TM extend 
beyond simple platelet-platelet and platelet-leukocyte interactions. It will be 
important to assess the tendency of porcine PBPC and of PBPC-induced platelet 
aggregates to activate primate endothelial cells and studies to invesTigate this have 
already been initiated. 
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ABSTRACT 
Introduction. Activation of endothelial cells and platelet sequestration playa major 
role in rejection of xenografts. The histopathology of both hyperacute and acute 
vascular or delayed rejection of vascularized discordant xenografts is characterized by 
interstitial hemorrhage and intravascular thrombosis. Agents that prevent platelet 
activation and consequent microthrombus formation have proven beneficial in 
xenograft rejection but do not fully preclude vascular thrombosis. Recently, several 
new anti platelet therapies have undergone extensive clinical testing for atherosclerotic 
thrombotic vascular disorders; other putative therapies are undergoing preclinical 
evaluation. We have investigated the effect of several of these novel agents on platelet 
aggregation in baboons in order to screen for future potential in xenograft rejection 
models. 
Methods. Drugs tested in these experiments were aurintricarboxylic acid (ATA, von 
Willebrand Factor-GPIb inhibitor). fucoidin (selectin-inhibitor), l-benzylimidazole 
(1-BI, thromboxane synthase antagonist), prostacyclin (POI,. endothelial stabilizer), 
heparin (thrombin antagonist), nitroprusside sodium or nicotinamide (NPN or NA, 
both NO-donors). and eptifibatide (EFT, GPIIb/lIIa receptor antagonist). These were 
infused intravenously to 9 baboons. Coagulation parameters and platelet counts were 
monitored and baboons were observed for adverse side effects. Ihe efficacy of these 
agents in inhibiting platelet aggregation was assayed in a platelet aggregometer. 
Results. Treatment with ATA and fucoidin resulted in complete inhibition of platelet 
aggregation but also in major perturbation of coagulation parameters. 1-BI and PGI2 
had no effect when administered alone, but in combination resulted in moderate 
inhibition of aggregation without disturbance in PI or PTT. NPN and NA had no 
substantive effects on platelet aggregation. Heparin resulted in specific inhibition of 
thrombin-induced platelet aggregation and, as anticipated, was associated with 
moderate prolongation of PIT. Importantly, EFT caused complete inhibition of 
platelet aggregation without changes in coagulation. Platelet counts, fibrinogen levels, 
and fibrinogen degradation products remained within the normal ranges in all 
experiments. 
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Conclusions. Although excellent inhibition of platelet activation was obtained with 
AT A and fucoidin, clinical use may be precluded by concomitant disturbances of 
coagulation. Combinations of heparin and EFT may prove beneficial in preventing the 
thrombotic disorders associated with xenograft rejection while maintaining adequate 
hemostatic responses. These agents are to be evaluated in our pig-to-primate 
xenotransplantation models. 
INTRODUCTION 
Transplantation of vascularized porcine organs in untreated primates results in 
hyperacute rejection within minutes to hours after reperfusion (1,2,3). "When 
hyperacute rejection is averted, either by depletion of xenoreactive antibodies or 
complement or by using donors transgenic for human complement-regulatory 
proteins, rejection usually occurs within days to weeks and is termed acute vascular or 
delayed xenograft rejection (4,5,6,7). All fonus of rejection <ire associated with 
vascular il~ury resulting at least in part from platelet activation (8,9,10,11,12). 
Rejected xenografts invariably demonstrate intravascular thrombosis and interstitial 
hemorrhage (2,3,4,13,14). In addition, following miniature swine-to-baboon kidney 
transplantation, disseminated intravascular coagulation has developed within 6-10 
days. This process had been manifest by steadily decreasing fibrinogen and platelet 
counts, with increased prothrombin time (PT) and fibrinogen degradation products 
(15,16,17). This state has developed before histopathological evidence of rejection 
was advanced (17). 
In our attempts to induce immunological tolerance in the miniature swine-to-baboon 
model by achieving mixed hematopoietic chimerism, a thrombotic microangiopathic 
state has been observed after the systemic infusion of mobilized porcine peripheral 
blood progenitor cells. Thrombocytopenia, high levels of lactate dehydrogenase, and 
erythrocyte schistocytosis have been observed (17,18). 
The potential benefit of antithrombotic agents in the treatment of transplantation 
rejection is well recognized, and has been the subject of investigation for numerous 
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years (9,19,20,21,22), Inhibition of platelet activation, recruitment, and sequestration 
might inhibit development of the thrombotic microangiopathy and/or of the 
disseminated intravascular coagulation. There have been major advances in 
understanding mechanisms of platelet activation that have resulted in the development 
of new therapeutic strategies to block the formation of platelet microthrombi (9,23). 
We have therefore investigated the effect of various agents on platelet aggregation. 
Eight drugs were selected and then administered to baboons by intravenous (iv) 
infusion; the effect of each agent on platelet aggregation was tested in vitro. 
MATERIALS AND METHODS 
Animals 
Baboons (Papio Anubis, n=9, Biomedical Resources Foundation, Houston, TX), 
weighing approximately 9-15 kg, were used for testing the experimental agents. All 
animals had been previously splenectomized through a midline laparotomy. Five 
baboons had previously been treated with a regimen aimed at inducing immunological 
tolerance, either with or without infusion of mobilized porcine peripheral blood 
progenitor cells> 4 months prior to the current experiments (15). Three baboons had 
previously (>3 months) received pharmacologic immunosuppressive therapy. Each 
baboon was administered at least two of the agents tested, but coagulation parameters 
and platelet aggregation were allowed to return to baseline before a second drug was 
tested. 
All experiments were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals prepared by the National Academy of Sciences and published by 
the National Institutes of Health. Protocols were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care. 
Surgical Procedures 
Baboons were given atropine (0.05 mg/kg im) and ketamine (10 mg/kg im) as 
premedication, and were intubated and ventilated through a closed circuit with oxygen 
(1-2 Limin), nitrous oxide (2-4 Llmin), and isoflurane (0.5-3.0 %). The baboon's 
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carotid artery and internal jugular vein were cannulated, the cannulae were tunneled 
subcutaneously towards the scapula, and brought out through a jacket and tethering 
system. This allowed monitoring of arterial blood pressure, access to blood 
withdrawal, and continuous or intermittent iv administration of fluids and/or drugs. 
Cefazolin (500 mg iv daily) was given as prophylaxis against infection. 
Experimental Agents 
All agents, or combination of agents, were tested in at least two baboons, and were 
administered through continuous iv infusion unless otherwise described. Bolus 
injections are specified when used. 
Aurintricarboxylic acid (ATA, Sigma-Alldrich, St. Louis, MO), administered at 0.5-
8.0 mg/kgihour, is kuown to inhibit binding of von Willebrand factor (vWF) to 
platelet glycoprotein Ib (GP Ib) in vitro and has been shov.TI to significantly inhibit 
platelet adhesion and platelet aggregation in several small animal models (24,25,26). 
The observed anti thrombotic activity possibly arises from inhibitory effects on 
thrombin activity and the vWF-GPlb pathway. 
Fucoidin (Fluka Chemie AG, Buchs, Switzerland), administered at 0.5 - 1.0 
mg/kglhour, is a non-toxic sulfated fucose oligosaccharide derived from seaweed that 
blocks platelet (P)-selectin and may prevent platelet adhesion and associated 
aggregation responses (27,28,29,30). Selectins are adhesion molecules found on 
leukocytes (L-selectin), endothelium (P- and E-selectin), and platelets (P-selectin) that 
bind to oligosaccharide ligands containing fucose and sialic acid to mediate leukocyte 
rolling on, and platelet adhesion to, the endothelium. Inhibition of these selectins may 
result in reduced platelet adhesion andlor aggregation (29,30). 
Thromboxane A2, an enzymatic product of arachidonic acid, has been implicated in 
platelet aggregation and the initiation of vasoconstriction in various organ systems 
(31,32). Selective inhibition of thromboxane synthase, which converts prostaglandin 
H2 to fhromboxane A2, using l-benzylimidazole (I-BI, Cayman Chemical Company, 
AIm Arbor, MI) has been shown to reduce thromboxane A2 concentration in vivo in 
183 
Section IV - Chapter 8 
rat brains (33). l-BI was administered at 10 - 40 Ilg/kg/hour as a single agent or in 
conjunction with POh (see below). 
Prostacyclin (PGI" Glaxo Wellcome Inc, Research Triangle Park, NC) is an 
endothelial-derived vasodilator with reported anti-thrombotic effects (34). It has been 
documented to inhibit platelet aggregation in vitrQ in small animal models (35,36). 
PGh was administered at 20 - 40 ng/kg/min as a single agent, and in conjunction with 
l-BI at 30 ng/kg/min. 
Heparin has well-known actions in potentiating antithrombin III and thereby 
influencing thrombin-mediated platelet aggregation (37,38). Thrombin catalyzes the 
formation of fibrin from fibrinogen, reSUlting in thrombus formation, and strongly 
induces platelet activation and recruitment (39). Furthermore, thrombin promotes 
chemotaxis by monocytes, and stimulates P-selectin activity in endothelial cells (40). 
Heparin sodium (Heparin, Elkins-Sinn, Inc., Cherry Hill, NJ) was administered at 10 
- 50 Units/kglhour. 
Nitroprusside sodium (NPN, Ohrneda PPD Inc., Liberty Comer, NJ), administered at 
1.0 - 10 Ilg/kg/min, is a well-<lescribed nitric oxide (NO)-donor that may also have 
an inhibitory effect on platelet aggregation. NO, formally referred to as the 
endothelium-derived relaxation factor, is a potent vasodilator that maintains 
endothelial integrity (41,42). It has also been described to have anti-platelet effects 
through increasing the intracellular cyclic guanidine monophosphate in platelets (43). 
Nicotinamide (NA, Sigma Chemical Co., St, Louis, MO), administered at 0.25 - 0.5 
mg/kglhour, is a B-complex vitamin that is also associated with increased NO 
production and vasodilatation (44). NA may therefore be effective in inhibiting 
platelet aggregation for the same reasons as NPN. 
Eptifibatide (EFT, Cor Therapeutics, Inc., South San Francisco, CAl was 
administered as a bolus infusion of 180 Jlglkg iv followed by continuous iv infusion at 
2.0 - 7.5 Ilg/kg/min. EFT is a synthetic GP Ilb/Illa receptor antagonist currently used 
in the treatment of acute myocardial infarction and for post-angioplasty restenosis 
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(45,46). By preventing GP lIb/IlIa receptor binding to fibrinogen, crosslinking of 
platelets is precluded and aggregation is specifically inhibited. 
Coagulation Parameters 
Serial blood samples were taken for measurement of platelet count, prothrombin time 
(PT), partial thromboplastin time (PTT), fibrinogen, and fibrinogen degradation 
products (FDP) (Hematology Laboratory, Massachusetts General Hospital). 
Platelet Aggregation Assay (Figure 1) 
Ten milliliters citrated blood were drawn from the baboon and centrifuged at 280g for 
15 minutes at 22°C. The supernatant, consisting of platelet-rich plasma, was 
transferred in 400 J.lI aliquots to siliconized glass cuvettes, and formed the 
experimental samples. The platelets were counted in a Coulter counter (Beckman 
Coulter, Inc., Fullerton, CA) and, if necessary, the experimental samples were diluted 
to a final concentration of lxl08 platelets/ml with a calcium-, magnesium-, and 
phenol red-free Hanks buffer solution (Mediatech, Inc., Herndon, V A). The reference 
sample, consisting of platelet-poor plasma, was used to set the baseline level of 
aggregation to 0%. This was obtained by further centrifuging the remaining pellet at 
2,400g for 2 minutes at 22°C. 
Different platelet agonists/stimulators (agents that are known to initiate platelet 
aggregation) were added to the experimental samples in the platelet aggregometer 
(two-sample, four-channel, model 560 Ca Lumi-aggregorneter, Chronolog Corp., 
Havertown, PA) at set concentrations, and aggregation was induced with a magnet 
causing shear stress. The agonists used were thrombin (1 - 5 U/ml, causing platelet 
activation and aggregation by binding to platelet GP Ib and cleaving platelet GP V), 
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Figure I. 
Citra ted blood 
n 280g for 15 minutes 
Platelet-rich plasma = 
n 2,400g for 2 minutes 
Experimental samples 
Platelet-poor plasma 
(reference sample) 
= Aggregometer 
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Addition of platelet ~ ~ .•.... 
agoDlsts ~ ~ 
Aggregation profiles 
Platelet aggregation assay. Citrated blood collected from baboons was centrifuged for 15 minutes at 
280g at room temperature. The supernatant, platelet-rich plasma, was then used as experimental 
samples. Changes in optical density after adding platelet agonists (thrombin, collagen, ADP, ristocetin, 
and arachidonic acid) were measured in the aggregometer against the optical density reference sample, 
platelet-poor plasma (see methods). 
adenosine diphosphate (ADP) (5 - 20 flM, inducing platelet shape change and 
aggregation by binding to multiple high-affinity ADP-specific receptors on platelets), 
collagen (5 - 10 )..tg/ml, inducing platelet aggregation by interacting with multiple 
platelet receptors such as GP Ib and fibronectin), ristocetin (1.25 ).lg/ml, initiating 
platelet aggregation by interacting with the GP Jb-vWF binding site). Arachidonic 
acid (1.2 rnJ\1) was substituted for ristocetin when an agent was tested that was not 
expected to interact with the GP Ib receptor. Platelet aggregation was measured as a 
percentage change in light optical density from baseline (with baseline being the 
measurement obtained in the experimental sample in the absence of the platelet 
aggregation agonist when compared with the reference sample (see Fig. 1)). Typical 
aggregation curves obtained from a naIve, untreated baboon are depicted in Fig. 2. 
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A B 
c D 
Figure 2. 
Control baboon platelet aggregation curves. Agonists were added to platelet-rich plasma in the 
aggregometer. Results are from a representative experiment. Initial increase in percentage aggregation 
is due to shape changes of activated platelets. 
A. Addition of thrombin resulted in 68% aggregation. 
S. Addition of collagen led to 48% aggregation. 
C. Addition of ADP led to 53% aggregation. 
D. Addition ofristocetin resulted in 68% aggregation. 
RESULTS 
The clinical results and in vitro assays are summarized in Table 1. Coagulation 
parameters (PT, PTT, fibrinogen, and circulating FDP levels), platelet count and 
aggregation profiles were all within normal ranges at the onset of each experiment, 
and none of the agents tested induced any changes in platelet count, fibrino gen, or 
FDP levels. 
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Aurintricarboxylic acid (AT A) 
ATA was administered in increasing doses from 0.5- 8.0 mg/kglhour iv. At a 
cumulative dose of 15 mg/kg, vomiting was observed as well as an increased heart 
rate to >200 bpm with a simultaneous drop in blood pressure to 65/35 mmHg. 
Cessation of the drug resulted in rapid recovery. When re-administered after an 
interval of several days at 0.5 mg/kglhour, no effect on platelet aggregation or 
changes in coagulation were observed (data not sho\Vll). Increasing the dose to 1.0 
mg/kg/hour resulted in decreased platelet aggregation induced by ristocetin (Fig. 3 -
left). This was accompanied by a prolongation in PT from 14.0 to >50 seconds (Fig. 3 
- right). Discontinuing the drug resulted in recovery of the coagulation parameters 
within 3 days, but one baboon died from intrawabdominal bleeding 2 days after 
cessation of the drug. Infusion of ATA at 2.0 mg/kglhour completely abrogated 
aggregation induced by ristocetin (Table I). The other agonists (i.e. thrombin, 
collagen, and ADP) were not influenced by ATA therapy. 
Fucoidin 
Fucoidin at 0.5 ~glkg/hour did not alter the platelet aggregation or coagulation 
profile. At 1 !-lg/kg/hour for 4 hours, nearwcomplete inhibition of aggregation induced 
by all agonists was achieved (Table 1). This also resulted in an increase in PT from 18 
to 65 seconds. No other side effects were documented and recovery of coagulation 
parameters occurred rapidly following discontinuation of the drug. 
I-benzylimidazole (I-BI) 
I-BJ at 20 or 40)lg/kglhour did not substantively change platelet aggregation induced 
by any of the platelet agonists (Table I). Coagulation parameters remained 
unchanged, and there were no untoward side effects. 
Prostacyclin (PGI,) 
Inconsistent changes III platelet aggregation were observed with this agent. The 
maximum inhibition of aggregation obtained with PGh was 40 and 70% for ADP and 
arachidonic acid, respectively (Table 1). No changes in coagulation parameters and no 
additional toxic effects were observed at doses between 10- 50 ng/kg/min. 
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CHANGE IN PLATELET AGGREGATION AND COAGULATION PARAMETERS IN BABOONS 
Number Inhibition of Platelet Disturbance of Comments 
of Baboons Aggregation Coagulation 
Thrombin ADP Collagen Ristocetin Arach Parameters 
acid 
-,---
- ~------- Clinical bleeding, major ATA 2 + + ++ +++ N/A Yes 
increase in PT. 
--~--
Fucoidin 2 +++ +++ +++ ++ N/A Yes Major increase in PT. 
---------
J-BI 4 - - - - N/A No -
-
------------
PGI2 2 - - - N/A ++ No -
l-BI + PGI, 2 + - - - N/A No Moderate inhibition of platelet 
aggregation. 
-----
Heparin 2 +++ - - - N/A Yes Anticipated increase in PTT. 
--
-------
NPN 2 + - - N/A + No -
f-= .... ---------
NA 2 - - - N/A + No -
EFT 2 +++ +++ +++ N/A +++ No Dose-dependent inhibition of 
platelet aggregation by all 
I agonists. 
Average percentage inhibition of platelet aggregation: - = 0-20; + = 20-50; ++ = 50-80; +++ = >80. N/A: nol applicable 
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Figure 3. 
Aurintricarboxylic acid (AT A) 
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Left. Administration of AT A at 1.0 mg/kg/h and 2.0 mg/kglh by continuous iv infusion. A dose-
dependent inhibition of aggregation induced by ristocetin and, to a Jess extent, by collagen was 
achieved, with little response to ADP and thrombin. 
Right. At an AT A infusion of 2.0 mglkglh, an increase in PT and PIT to >50 and >150 seconds, 
respectively, was observed. Cessation of AT A led to recovery of coagulation parameters. 
I-benzylimidazole (I-BI) and prostacyclin (PGI,) 
The combination of I-BI (at 10 j.lglkglhour) with PGI, (at 30 ng/kg/min) in one 
baboon resulted in progressive blockade of platelet aggregation induced by thrombin. 
Increasing I-BJ to 20 j.lg/kglhour led to complete inhibition of aggregation induced by 
thrombin. Aggregation induced by other agonists was not significantly changed 
(Table I). A further increase of I-BJ to 40 j.lglkglhour in a second baboon, however, 
resulted in only minimal inhibition of platelet aggregation. In combination, the two 
agents did not result in any substantial changes in coagulation parameters. 
Heparin 
Heparin at 10 U/kg/hour led to a predicted increase in PIT from 29 seconds to 100 
seconds in one baboon, and was associated with complete inhibition of platelet 
aggregation induced by thrombin (Table I). Aggregation profiles induced by collagen, 
ristocetin, and ADP remained unchanged. In a second baboon, however, heparin at 10 
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U/kg/hour did not alter the coagulation parameters nor inhibited platelet aggregation. 
At an incremented dose of 50 U/kglhour, an increase in PTT to 100 seconds was 
observed. This was accompanied by inhibition of aggregation induced by thrombin. 
No clinical signs of bleeding or other side effects were observed at this time and 
heparin dosage. 
Nitroprusside sodium (NPN) 
NPN (at 1.0 - 15 ~g/kg/min) resulted in a modest decrease in platelet aggregation 
induced by thrombin and arachidonic acid in one baboon, but did not affect 
aggregation in a second baboon, suggesting individual sensitivity (Table 1). At doses 
higher than 10 J..lglkglmin, vomiting was observed without changes in blood pressure 
or coagulation parameters. 
Nicotinamide (NA) 
NA (at 0.25 - 0.5 mg/kglhr) did not cause significant inhibition of platelet 
aggregation although aggregation induced by arachidonic acid was decreased to some 
extent (Table 1). No other effects of the drug were noted. 
Eptifibatide (EFT) 
EFT was administered as an iv bolus of 180 J..lglkg followed by continuous infusions 
at dosages ranging from 2.0 -7.5 ~g/kglmin. Platelet aggregation induced by all 
agonists used (i.e., thrombin, ADP, collagen, and arachidonic acid) was effectively 
inhibited with increasing dosages of EFT (Table 1 and Fig. 4). EFT at 2.0 f!g/kg/min 
had no effect on aggregation. Increasing the dose to 5.0 and 7.5 f!g/kg/min led to a 
dose-dependent complete inhibition of aggregation induced by ADP (Fig. 5) and by 
other agonists. Cessation of the drug led to full recovery of platelet aggregation within 
2 ~ 4 hours. During treatment with EFT, no side effects were noted, and no changes in 
coagulation parameters were observed. 
191 
Section IV - Chapter 8 
OThrombin 
!l!IADP 
OColiagen 
"",IO,'m'" mo,,,,,",,, 
Agent {dosol 
Figure 4. 
Eptifibatide (EFT). EFT effectively inhibited platelet aggregation in a dose-dependent manner. At 2 
).1glkglmin, no response was noted (data not shown). At 5 !Jog/kg/min, aggregation responses induced by 
thrombin, ADP, collagen, and arachidonic acid decreased markedly. EFT when administered at 7.5 
).1g/kg/min resulted in a further, near-complete decrease in aggregation induced by all agonists. Two 
hours following discontinuation of EFT, aggregation returned to baseline levels. 
DISCUSSION 
There are two major reasons related to xenotransplantation why we have investigated 
drugs that inhibit platelet aggregation. 
Firstly, in our experience, the histopathological features of hyperacute and acute 
vascular rejection of vascularized xenografts in the pig-to-nonhuman primate model 
invariably demonstrate intravascular thrombosis and interstitial hemorrhage. 
Miniature swine kidney transplants into baboon recipients frequently show features of 
disseminated intravascular coagulation, even before rejection is histopathologically 
advanced (15,16,17). We believe that activation of recipient platelets and/or donor 
vascular endothelium play major roles. Prevention of these thrombotic events may 
extend xenograft survival by preserving adequate perfusion and maintaining 
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oxygenation of the graft even though the underlying inflammatory mechanisms may 
not be fully prevented. 
Secondly, the transplantation of mobilized porcine peripheral blood progenitor cells to 
baboons in an attempt to induce immunological tolerance through mixed 
hematopoietic chimerism has been associated with a thrombotic microangiopathy, 
characterized by thrombocytopenia (platelet count < 20,000/f!1), elevated lactate 
dehydrogenase, and erythrocyte schistocytosis (18). In our laboratory, we have 
observed the formation of baboon platelet aggregates in the presence of mobilized 
porcine peripheral blood progenitor cells in vitro (Alwayn IPJ, et aI., unpublished 
data). Drugs that modulate formation of these aggregates may allow the infusion of 
more porcine progenitor celis, thus facilitating engraftment of these cells and the 
development of mixed hematopoietic chimerism. 
It has become clear that the binding of agonists/stimulators to receptors on the platelet 
surface plays a central role in inducing platelet activation. Platelet adhesion to 
subendothelium leads to activation of the platelets) after which platelet sequestration 
and formation of aggregates can occur. VVhen circulating platelets come into contact 
with exposed subendothelium (i.e. after endothelial cell retraction), adhesion occurs 
through binding of subendothelial platelet agonists, such as vWF, to platelet GP Ib 
under shear stress (47,48). This results in activation of platelets with 
release/generation of more platelet mediators, such as thrombin, ADP, and 
arachidonic acid (a precursor of thromboxane A2). These agonists generally have 
their own specific receptors on platelets and cause the platelets to change shape, form 
pseudopodia, and activate the GPIIb/IIIa receptor on the platelet surface. Cross-
linking of these receptors with fibrinogen or soluble vWF results in platelet 
aggregation (49,50). Recent data suggest that platelets may also bind directly to 
endothelial cells and subsequently become activated (51). Other platelet receptors 
include a2pl integrin, GP IV, and GP VI (all receptors for collagen). Although there 
are many diverse substances that can activate platelets, our interest was in testing 
agents that interact with platelets at different points of application. 
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Although treatment with AT A or fucoidin was very effective at inhibiting platelet 
aggregation, both gave rise to severe disturbances of coagulation parameters, which 
may preclude their use in a clinical setting. The effects of AT A and fucoidin on 
coagulation parameters were not anticipated and could not directly be explained by 
the mechanisms by which these agents interact with platelets. It is, however, possible 
that, in addition to inhibiting receptors on platelets, they interact with other 
components of the coagulation pathway that have not yet been delineated. 
I-BI was brought to our attention by Pierson and his colleagues, who have used 
thromboxane synthase inhibitors in a pig-to-human xenoperfusion model in an effort 
to prevent pulmonary vasoconstriction (52). This agent has also been sho\Vtl to 
improve perfusion in a rat cerebrovascular ischaemia model by preventing the 
production ofthromboxane A2, a potent platelet agonist (35). When administered to a 
baboon, we observed no significant changes in platelet aggregation even when 
dosages in excess of those recommended in other experimental models were used. It 
is possible, though unlikely, that therapeutic levels of I-BI necessary to effectively 
inhibit platelet aggregation were not achieved. In these experimental settings, no 
changes in PT or PTT were observed. 
PGh, a metabolite of arachidonic acid, has potent vasodilatory effects on pulmonary 
and systemic arterial beds (53,54) and has been reported to be an inhibitor of platelet 
aggregation in humans (55). We administered this drug in doses exceeding those 
recommended for humans without any significant change in blood pressure, heart rate 
or coagulation parameters. In contrast to the human data, no suppression of platelet 
aggregation in vitro could be obtained. When PGI2 was combined with a high dose of 
1-BI, however, moderate inhibition of platelet aggregation induced by thrombin was 
obtained, unaccompanied by changes in PT or PTT. 
Heparin has been used in several models in an attempt to prolong survival of 
transplanted allo- or xeno-grafts, with varying results (21,56,57). In the latter two 
experiments, heparin was effective in preventing platelet aggregation induced by 
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thrombin in vitro. This effect was only observed when the PTT had reached a 
therapeutic level of> 1 00 seconds, and was not associated with clinical bleeding. 
It has been sho\\11 that NO has protective effects on the endothelium (43,44,45) and 
can prevent platelet aggregation by increasing intracellular cyclic guanidine 
monophosphate (cGMP) levels in platelets. In our model, however, NPN, an NO-
donor, did not lead to any substantive decrease in aggregation. One explanation may 
be that insufficient levels of NO were obtained in our dosing regimen, as no 
associated vasodilatory effects, such as hypotension, were noted. Furthermore, since 
NO has both inflammatory oxidant-mediated effects (58) as well as platelet 
aggregation inhibitory potential (45), titrating towards a therapeutic dose will be 
challenging. Additionally, exogenous NO may exacerbate inflammation through 
synthesis of platelet-activating factor and mobilization of P-selectin (59). NA, also 
associated with increased NO production and vasodilatation, may have a similar mode 
of action as NO-donors (46). However, we observed no inhibitory effect on platelet 
aggregation in the studies presented here. It is possible that endothelial cells may be 
more susceptible to NO protection than platelets and that these potentially beneficial 
effects of NO may be more apparent in an in vitro model of platelet-endothelium 
interaction. 
The last and most promising agent tested was EFT. This agent is a synthetic OP 
lIb/IlIa receptor antagonist that has been sho\\Tl to have potent inhibitory effects on 
platelet aggregation in humans (47,48). We were able to confirm these results in 
baboons. EFT was studied instead of the monoclonal antibody abciximab, which also 
targets the OP lIb/IlIa receptor, because of the lower incidence of intracerebral 
hemorrhage, decreased potential for Fe-interactions, and absent risk for cross-
immunization associated with treatment with EFT. No side effects were noted at the 
dosages administered. The complete inhibition of platelet aggregation in the absence 
of any changes of coagulation parameters may be of benefit in preventing the 
thrombotic disorders associated with the transplantation of porcine vascularized 
organs or hematopoietic progenitor cells. In the discordant guinea pig-to-rat cardiac 
xenograft model Candinas et aL demonstrated prolonged xenograft survival and 
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diminution of intragraft platelet micro thrombi using the GPUb/lIla antagonist GPI 
562. These results were not confinned in a recent ex vivo discordant perfusion model 
of a porcine kidney with human blood using the GPIIb/IIIa antagonist abciximab (60). 
In this model, however, as no measures were undertaken to prevent hyperacute 
rejection, the effect of inhibition of platelet aggregation post-hyperacute rejection was 
not addressed. 
We recently administered EFT as an initial iv bolus of 180 f.lglkg, followed by 
continuous iv infusion at 7.5 ).lg/kg/min, to one baboon receiving our conditioning 
regimen aimed at inducing immunological tolerance. This non-myeloablative regimen 
has been described elsewhere (15), and consists of splenectomy, whole body (300 
cGy) and thymic (700 cGy) irradiation, multiple extracorporeal irnmunoadsorptions of 
anti-aGal antibodies, T cell depletion, phannacological immunosuppressive therapy, 
and costimulatory blockade, prior to the infusion of large numbers of mobilized 
porcine peripheral blood progenitor cells. The infusion of pig cells is always followed 
by an immediate and profound thrombocytopenia that can be ameliorated by steroids, 
PGI" and heparin. When EFT was infused, in the absence of heparin, the onset of 
thrombocytopenia was delayed by one day, but not prevented. These data suggest 
that, although inhibition of platelet-platelet aggregates may provide some benefit, 
other factors (e.g. platelet-leukocyte, or platelet-(sub)endothelial interactions) 
contribute to these thrombotic complications, and that receptors other than GPIIb/IIla 
may also be involved. 
In the context of solid vascularized organ xenotransplantation, in one experiment in 
our pig-to-baboon model, the combined administration of heparin and EFT appeared 
to reverse the early features of disseminated intravascular coagulation (increasing 
thrombocytopenia and steadily falling fibrinogen levels) (data not shown). 
Other platelet-inhibitors have been described and remam under experimental 
evaluation in other models. The vascular NTP-diphosphohydrolase (CD39) is another 
candidate for study, as are ADP-receptor antagonists, such as ticlopidine. The lack of 
a fully active truncated form of CD39 has delayed testing of this agent, and ADP-
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receptor antagonists have been implicated in the initiation of thrombotic 
thrombocytopenic ptrrpura (61). 
These data lead us to conclude that, although AT A and fucoidin are potent inhibitors 
of platelet aggregation, the experimental use of these agents in baboons may be 
prohibited by an associated high risk of bleeding. The combination of l-BJ and PGJ, 
results in moderate inhibition of platelet aggregation, without changes in coagulation 
or other side effects, but its effect may be insufficient to be of clinical value. Heparin 
leads to good inhibition of thrombin-induced platelet aggregation at doses that cause 
only minor prolongation of PTT, allowing for its use in xenotransplantation models. 
NPN and NA do not appear to effectively inhibit platelet aggregation in these studies. 
EFT clearly was efficient in inhibiting platelet aggregation without any untoward side 
effects and will be considered for incorporation into our pig-to-primate transplantation 
model for further study. 
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GENERAL DISCUSSION 
The potential clinical implementation of xenotransplantation, or the transplantation of 
tissues and/or organs between species, has received considerable attention from both 
governmental institutions and media in numerous countries over the last few years. 
Renewed interest in xenotransplantation research has been fuelled by an increasing 
shortage of donor organs and mortality of patients awaiting a donor organ. The 
measures that have been undertaken to increase the donor-pool have thusfar not been 
successful, and alternatives to xenotransplantation - i.e. the use of bioartificial organs. 
stem cells, or gene therapy for organ failure - are still in early development. 
Most investigators believe that, if xenotransplantation is to become a clinical reality, 
the pig will be the most suitable source of organs for a number of reasons (1). 
However, xenografts between widely disparate species i.e. discordant xenografis, 
such as pig-to-primate, are rapidly rejected within minutes to hours by a humoraL 
complement-dependent, mechanism, known as hyperacute rejection. Once hyperacute 
rejection is averted, the rejection responses that follow are also thought to be 
antibody-mediated, but most likely complement-independent, and may involve 
cellular mechanisms (2). Although much progress has been made in overcoming some 
of the immunological hurdles associated with pig-to-nonhuman primate 
xenotransplantation, porcine organs do not routinely survive beyond three months in 
nonhuman primates (3). As current evidence suggests that suppression of both the 
humoral and cellular response to a discordant xenograft will require extremely intensive 
immunosuppressive therapy, with its associated increased risks, it seems likely that 
xenotransplantation will only prove successful if immunologic tolerance to the 
transplanted pig organs can be achieved (4). 
This dissertation describes our attempts at inducing immunological tolerance in the 
pig-to-baboon xenotransplantation model through mixed chimerism. The condition 
regimen we used was modified from others that have proven successful in various 
models of allotransplantation and concordant xenotransplantation. The importance of 
preformed, xenoreactive antibodies in these experiments is emphasized, and several 
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methods of depleting, or suppressing the production of, these antibodies are discussed 
in detail. Furthermore, thrombotic complications were observed in baboons that 
received porcine cells or organs. Additional experiments were designed to address 
these complications; these are also included in this dissertation. 
An introduction to xenotransplantation is presented in Chapter 1. The needs for 
xenotransplantation, as well as the current understanding of the rejection responses 
and potential modulation of these responses are discussed in detaiL From this chapter 
we conclude that the discussed therapeutic modalities alone will not be able to 
achieve long tenn, clinically relevant survival of xenografts. In this context, the 
phenomenon of accomodation deserves some more attention. Although this state has 
been described in sensitized humans receiving kidney allotransplants (5), as well as in 
various small animal xenotransplantation combinations (6), it has to date not been 
described in a pig-to-nonhuman primate xenotransplantation modeL In fact, with our 
conditioning regimen aimed at inducing immunological tolerance, we have created an 
environment that theoretically would be ideal to induce a state of accommodation. 
The baboon recipients in these experiments are temporarily depleted of anti-Gal 
antibodies and of terminal complement components when a porcine kidney is 
transplanted. The returning anti-Gal antibodies, especially IgM, however, remain 
capable of mediating graft rejection (Buhler et a!., submitted for publication). It 
appears that the porcine endothelial cells, rather than becoming accommodated, 
become activated by the induced antibody response and that accommodation may not 
be achieved in pig-to-primate xenotransplantation. We therefore believe that 
combinations of current therapies, further refinement of these therapies, and new 
technologies designed to prevent or treat rejection (especially those aimed at inducing 
immunological tolerance), need to be explored and developed. 
Our protocol aimed at achieving mixed hematopoietic chimerism and thereby 
inducing immunological tolerance in the pig-to-baboon model is presented in 
Chapter 2. This protocol consists of induction therapy with splenectomy, whole body 
irradiation, thymic irradiation, anti-thymocyte globulin, and multiple extracorporeal 
immunoadsorptions of anti-Gal antibodies. The maintenance therapy consists of 
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treatment with anti-CD154 mAb +/- cyclosporine, mycophenolate mofetil, and cobra 
venom factor, after which a large number of grmvth factor-mobilized porcine leukocytes 
(1 x 10 10 cellslkg) are infused into recipient baboons on each of 3 consecutive days (total 
3 x 1010 cellslkg). In this chapter we present, for the first time in a large animal model, 
successful depletion of baboon macrophages using medronate liposomes. The distinct 
dimensions and properties of these liposomes render them susceptible to phagocytosis 
by macrophages. Once phagocytosed, medronate interferes with the cell's metabolism 
and causes cell death. When macrophage depletion is added to our conditioning 
regimen for tolerance induction, significantly higher levels of porcine chimerism are 
achieved in the recipient baboons, underlining the importance of recipient 
macrophages in the clearance of donor porcine hematopoietic cells and the high 
potential of medronate liposomes for other experimental xenotransplantation 
protocols. 
In addition, observations from other experiments suggest that an absence of anti-Gal 
IgG may also be an important factor in allowing the development of chimerism, as 
these antibodies are able to destroy target cells by antibody-dependent cell-mediated 
cytotoxicity, independent of complement. Although anti-Gal antibodies are effectively 
depleted from circulation by multiple extracorporeal immunoadsorptions, the return of 
anti-Gal antibodies cannot be prevented, thereby reducing the possibility of achieving 
mixed hematopoietic chimerism and immunological tolerance. The importance of 
anti-Gal antibodies in mixed chimerism protocols and vascularized organ 
xenotransplantation, as well as current methods for depleting, or suppressing the 
function of these antibodies are described in Chapter 3. We conclude, based on a 
comprehensive review of the literature, as well as on our own experience, that, 
although anti-Gal antibodies may be successfully but temporarily depleted by 
extracorporeal immunoadsorption, none of the immunosuppressive agents currently 
employed are significantly successful at preventing their return following depletion. 
However, the ability of anti-CD 154 mAb to prevent the induced antibody response to 
pig cells does represent a significant step in overcoming the immunologic barriers to 
xenotransplantation, and will undoubtedly facilitate the survival of transplanted pig 
organs in primates and the induction of tolerance. 
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Some of the future studies described in chapter 3 with respect to the development of 
specific anti-B cell or anti-plasma cell antibodies in an effort to prevent the 
production of anti-Gal antibodies are explored in Chapter 4. In extensive in vivo and 
in vitro experiments, we demonstrated that baboon B cells can be efficiently depleted 
with whole body irradiation or with specific anti-B cell mAbs or irnmunotoxins. 
Additionally, combining irradiation with a rnAb directed against the B cell-specific 
CD20 determinant led to depletion of B cells for > 3 months. However, this does not 
lead to a clinically significant reduction in the rate or extent of return of anti-Gal 
antibodies following immunoadsorption. These observations suggest that B cells are 
not the major source of anti-Gal antibody production in baboons, and that attention 
must be directed towards suppressing plasma cell and B cell blast function. This was 
confirmed by our findings that the major secretors of anti-Gal antibodies in baboons 
are CD38-positive cells, or plasma cells. Unfortunately, the anti-CD38 irnrnunotoxin 
we studied was not effective in vivo, potentially due to various reasons, including 
suboptimal conjugation of the rnAb to the toxin. 
The next chapters focus on the thrombotic complications that are associated with pig-
to-baboon xenotransplantation. There are historical precedents for the development of 
coagulation abnormalities and thrombocytopenia in association with solid organ 
xenograft rejection, and these data are confirmed by the studies described in Chapter 
5. In this chapter, we also demonstrate that the infusion of porcine hematopoietic cells 
is associated with vvidespread thrombotic vascular injury with deleterious 
consequences for the recipient. The mechanisms underlying the thrombotic 
complications in these settings are still unclear. It is possible that varying levels of 
immune mediators within the vascularized xenograft could promote vascular 
thrombosis, as a component of the inflammatory response ab initio with endothelial 
cell activation. With respect to porcine hematopoietic cell transplantation, we 
hypothesized that these cells directly induce platelet aggregation and subsequent 
sequestration of platelets in the microvasculature of recipient baboons, or that the 
conditioning regimen aimed at inducing mixed chimerism contains components that 
may initiate platelet aggregation and thrombocytopenia. 
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In Chapter 6 we demonstrate that porcine hematopoietic cells mediate aggregation of 
baboon platelets. Furthermore, we present evidence that eptifibatide, a substance that 
prevents the GPIIb/lIIa platelet-receptor from binding to fibrinogen, thereby 
precluding crosslinking of platelets, can fully abrogate platelet aggregation induced 
by these cells in vitro. Purification of the precursors from porcine PBPC and/or 
treatment of baboons with eptifibatide may be beneficial in preventing these sequelae. 
These findings are confirmed in Chapter 7 where, in addition, each of the individual 
components of the conditioning regimen are assessed for their ability to induce 
platelet aggregation in baboons. Interestingly, none of the components of the 
conditioning regimen are found to be pro-aggregatory, but cyclophosphamide appears 
to have protective, anti-aggregatory properties and may therefore provide an 
alternative strategy to whole body irradiation in our attempts to achieve mixed 
hematopoietic chimerism and the induction of tolerance. 
Finally, in Chapter 8 other pharmacologic agents aimed at preventing platelet 
aggregation III baboons are examined. We demonstrate that, although 
aurintricarboxylic acid and fucoidin are potent inhibitors of platelet aggregation, the 
experimental use of these agents in baboons may be prohibited by an associated high 
risk of bleeding. Heparin leads to good inhibition of thrombin-induced platelet 
aggregation at doses that cause only minor prolongation of the partial thromboplastin 
time, allowing for its use in xenotransplantation models. Eptifibatide leads to 
excellent inhibition of platelet aggregation without any untoward side effects and is 
therefore a good candidate to be incorporated into Oill future pig-to-nonhuman 
primate studies. 
The successful induction of stable immunological tolerance in pig-to-baboon 
xenotransplantation will, beyond any doubt, pave the way to clinical 
xenotransplantation. The above discussion deady points out that many factors, both 
immunological and not, stand in the way of mixed chimerism and tolerance. Based on 
the previous studies, it has become evident that anti-Gal antibodies remain a major 
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problem in xenotransplantation. Recent experiments perfonned at our own laboratory 
(not included in this dissertation) with in vivo depletion of anti-Gal antibodies by 
infusion of bovine serum albumin conjugated to Gal (BSA-Gal) to naIve baboons, 
baboons undergoing our tolerance induction protocol, or baboons receiving porcine 
kidney xenografts (in conjunction with extracorporeal immunoadsorption and 
costimulatory blockade with an anti-CD154 mAb), demonstrated complete or near 
complete depletion of anti-Gal antibodies sustained for periods of up to 30 days 
(Teranishi and Gollackner, unpublished data). The return of anti-Gal antibodies 
following cessation of the BSA-Gal was more delayed than observed in controls that 
did not receive BSA-Gal. In addition to neutralizing anti-Gal antibodies, this agent 
may, therefore, possibly tolerize anti-Gal antibody-producing cells by binding to their 
antigen receptors. We therefore believe that future studies must focus on the 
refinement of BSA-Gal, as well as on the development of agents that prevent the 
production of anti-Gal antibodies, such as efficient anti-plasma cell immunotoxins. 
Additionally, the potential of macrophage depletion in pig-to-nonhuman primate 
tolerance induction needs to be further explored and possibly implemented in refined 
protocols, Furthennore, the etiology of the associated thrombotic complications must 
be elucidated. 
In conclusion, this dissertation discusses some of the major immunological hurdles 
that preclude clinical implementation of xenotransplantation, and offers insight into 
current attempts at inducing immunological tolerance through mixed hematopoietic 
chimerism. The problem of anti-pig antibodies is addressed, as well as associated 
thrombotic disorders, and current and novel therapeutic modalities are presented. 
Based on the results presented in this dissertation, the addition of a specific and 
effective anti-plasma cell immunotoxin, macrophage depletion with medronate 
liposomes, and prevention of platelet aggregation with eptifibatide, to the standard 
conditioning regimen as discussed in Chapter 2, may facilitate the induction of mixed 
chimerism and immunological tolerance. Further refinement of BSA-Gal, to achieve 
in vivo depletion of anti-Gal antibodies, as well as using composite thymo-organs for 
T cell tolerance may also be beneficial. The author hopes that the experiments and 
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findings described will be of benefit to the future of xenotransplantation, and that this 
exciting field will eventually become a part of clinical medicine. 
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D1SCUSSIE 
Het begrip xenotransplantatie, ofwel het transplanteren van weefsel eulof organen 
tussen diersoorten, is de laatste jaren onderwerp van discussie geweest op nationaal en 
internationaal niveau, zowel bij overheidsinstanties als in de publieke media. 
Vanwege het steeds groter wordend tekort aan orgaandonoren, met daarbij een 
stijgende mortaliteit van patienten met tenninaal orgaanfalen die op de wachtlijst 
staan voer een donororgaan, is hemieuwde belangstelling voor xenotransplantatie-
onderzoek ontstaan. De huidige maatregelen welke getroffen zijn am het aantal 
donoren te vergroten schieten helaas tekort, en altematieven voor transplantatie -
zoals het gebruik van bioartificiele organen, stamcellen, of gentherapie bij 
orgaanfalen - zijn nog niet voldoende ontwikkeld. 
Het varken wordt door veel wetenschappers gezien als de ideale leverancier voor 
donororganen (1). Het transplanteren van organen tussen diersoorten die fylogenetisch 
ver van elkaar zijn verwijderd, zoals van het varken naar de primaat, gaat echter 
gepaard met een zeer snelle en heftige afstotingsreactie. Deze afstoting, ook wei 
hyperacute afstoting genoernd, is antilichaam-gemedieerd en cornplement-afhankelijk, 
en treedt binnen enkele minuten tot uren na transplantatie op. Indien het lukt deze 
afstotingsvorm af te wenden, bijvoorbeeld door antilichaam of complement depletie 
of door varkens te gebruiken die transgeen zijn voor humaan complement regulerende 
eiwitten, treden andere afstotingsverschijnselen op. Deze zijn eveneens antilichaam-
gernedieerd maar waarschijnlijk cornplement-onafuankelijk, en bevatten daarnaast 
cellulaire cornponenten (2). Hoewel veel vooruitgang is geboekt in het begrijpen en 
behandelen van sommige van deze immunologische barrieres, lukt het niet 
routinernatig overleving van meer dan drie maanden te verkrijgen van varkensorganen 
in primaten (3). De huidige bewijslast suggereert dat de humorale en cellulaire 
afstotingsresponsen tegen xenotransplantaten in het varken-naar-prirnaat model 
dennate hevig zullen zijn dat deze aileen te behandelen zullen zijn met bijzonder hoge 
doseringen immuunsuppressiva, hetgeen gepaard zal gaan met onaanvaardbaar hoge 
risico's op infecties en rnaligniteiten. Het verkrijgen van immunologische tolerantie in 
dit model, waarbij een specifieke hyporesponsiviteit voor varkensantigenen in de 
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primaat-ontvanger optreedt, is derhalve essentieel voordat xenotransplantatie klinisch 
gelmp1ementeerd zal worden (4). 
Dit proefschrift beschrijft onze pogingen immunologische tolerantie te induceren in 
het varken-naar-baviaan xenotransplantatie model via het verkrijgen van gemengd 
hematopoietisch chimerisme. Het gebruikte conditioneringsprotocol is gemodelleerd 
naar succesvolle protocollen binnen allotransplantatie en concordante 
xenotransplantatie. Het belang van voorgevormde, xenoreactieve antilichamen in deze 
experimenten wordt benadrukt en diverse methoden van depleteren of onderdrukken 
van de produktie van deze antilichamen worden in detail besproken. Hiemaast worden 
de thrombotische complicaties welke ZIJn gesignaleerd In bavianen die 
varkensorganen of hematopoietische cellen ontvangen gepresenteerd. T evens worden 
de aanvullende experimenten die zijn uitgevoerd om deze complicaties te analyseren 
en beperken beschreven. 
Een introductie tot xenotransplantatie wordt gegeven in Hoofdstuk 1. Het belang en 
de noodzaak van deze vorm van transplantatie, alsmede het huidig begrip en de 
behandelingsmogelijkbeden van de afstotingsverschijnselen, worden in detail 
besproken. Wij concluderen uit dit hoofdstuk dat de huidige therapie op zichzelf 
ontoereikend is om langdurige, klinisch relevante overleving van xenotransplantaten 
te verkrijgen. In dit verband verdient het begrip accommodatie enige toelichting. Het 
houdt in dat de getransplanteerde organen overleven ondanks de aanwezigheid van 
antilichamen gericht tegen antigenen van deze transplantaten. Accommodatie is 
beschreven bij gesensitiseerde patienten die een niertransplantatie ondergaan (5) 
alsmede in verscheidene kleine proefdiermodellen van xenotransplantatie (6). Tot 
heden is dit fenomeen echter niet aangetoond in het varken-naar-primaat 
xenotransplantatie model. In het door ons bestudeerde tolerantie-inductie protocol 
wordt een cmgeving gecreeerd welke theoretisch ideaal zou zijn voor het optreden 
van accommodatie. Irnmers, de bavianen in deze experimenten zijn gedepleteerd van 
anti-Gal antilichamen en terminale complement componenten op het moment dat een 
varkensnier wordt getransplanteerd. De anti-Gal antilichamen welke terugkeren na 
depletie, in het bijzonder IgM antilichamen, blijven echter in staat afstoting te 
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veroorzaken (Buhler et al., ingestuurd v~~r publikatie). Kennelijk ondergaan de 
varkensendotheelcellen in plaats van accommodatie, activatie door de geYnduceerde 
antilichaamrespons in dit model en is het mogelijk dat accommodatie niet te 
verkrijgen zal zijn in varken-naar-primaat xenotransplantatie. Wij denken derhalve dat 
wellicht combinaties van therapieen, verdere verfijning van bestaande behandelingen 
en het ontwikkelen van nieuwe strategieen gericht op het voork6men danwel 
behandelen van afstoting dienen te worden ontwikkeld. In het bijzonder dient de 
inductie van immW1oiogische tolerantie aandacht te krijgen. 
Het protocol gericht op het verkrijgen van gemengd hematopoietisch chimerisme met 
hierbij de inductie van immunologische tolerantie in het varken-naar-baviaan model 
wordt gepresenteerd in Hoofdstuk 2. Dit protocol bestaat uit inductietherapie van de 
baviaan met behulp van splenectomie, totale lichaams- en thymus bestraling, het 
toedienen van anti-thymocyten globuline, en multipele extracorporele 
immunoadsorpties van anti-Gal antilicharnen. De onderhoudsbehandeling bestaat uit 
het toedienen van anti-CD154 monoklonale antilichamen +/- cyclosporine, 
mycofenolaat mofetil en cobra gif, waama verspreid over drie dagen een grote 
hoeveelheid groeifactor-gernobiliscerde varkens lcukocyten (totaal 3 x 1010 cellenlkg) 
wordt toegediend aan de baviaan. Hier presenteren wij voor de eerste keer in een grote 
proefdieren model succesvolle depletie van bavianen macrofagen met behulp van 
medronaatliposomen. Deze liposomen hebben specifieke kenmerken en afrnetingen 
welke ze ontvankelijk rnaken voor fagocytose door macrofagen. Het gefagocyteerde 
medronaat verstoort vervolgens het rnetabolisme van de cel en leidt tot celdood. 
Wanneer macrofaagdepletie wordt toegevoegd aan het basis-conditionerings protocol 
zoals hierboven uiteengezet worden beduidend hogere waarden van varkenschimerisrne 
in de ontvangende bavianen aangetoond. Hiennee wordt het belang van macrofagen in 
het wegvangen van varkenscellen uit de circulatie van bavianen onderstreept en lijkt het 
interessant macrofaagdepletie ook in andere xenotransplantatiemodellen te bestuderen. 
Belangrijk voor het verkrijgen van gemengd hematopoietisch chimerisme is de 
afwezigheid van anti-Gal antilicharnen, in het bijzonder anti-Gal IgG. Uit eerdere 
studies is gebleken dat deze antilichamen cellen kunnen destrueren middels 
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antilichaam-afhankelijke cel-gemedieerde cytotoxiciteit, onatbankelijk van 
complement. Anti~Gal antilichamen kunnen effectief worden verwijderd uit de 
circulatie middels achtereenvolgende extracorporele immunoadsorpties. De terugkeer 
van anti-Gal antilichamen wordt hiennee echter niet voorkomen waardoor de kans op 
het verkijgen van chimerisme en irnmunologische tolerantie wordt venninderd. Het 
belang van anti-Gal antilichamen in gemengd-chimerisme protocollen en 
xenotransplantatie van gevasculariseerde organen, alsmede huidige 
behandelingsmethoden voor het depieteren of venninderen van de functie van deze 
antilichamen worden beschreven in Hoofdstuk 3. Wij concluderen, gebaseerd op de 
meest recente literatuur en onze eigen ervaring dat, hoewel tijdelijke depietie van anti-
Gal antilichamen zeer goed mogelijk is middels extracorporele irnmunoadsorptie, niet 
een van de gangbare immmllsuppressiva de terugkeer van antilichamen na depletie 
kan voorkomen. Het vennogen van het anti-CD 154 antilichaam om de gei'nduceerde 
antilichaamrespons tegen varkenscellen te voorkomen is echter weI een significante 
bevinding en zal zeker de overleving van varkensorganen in primaten verbeteren en 
de inductie van tolerantie vergemakkelijken. 
Sommige van de in hoofdstuk 3 beschreven vervolgstudies met betrekking tot het 
ontwikkelen van specifieke anti-B eel of anti-plasmacel antilichamen met als doel 
anti~Gal antilichaamproduktie te voorkomen, worden bestudeerd in Hoofdstuk 4. In 
uitgebreide in vivo en in vitro experimenten demonstreren wij dat B cellen in 
bavianen efficient kunnen worden gedepleteerd middels totale lichaamsbestraling of 
door toediening van specifieke anti-B eel monoclonale antilichamen of 
immunotoxines. De combinatie van bestraling met een monoclonaal antilichaam 
gericht tegen de B cel-specifieke detenninant CD20 resulteert in depletie van B cellen 
voor meer dan 3 maanden. Dit leidt echter niet tot vennindering van anti~Gal 
antilichaamproduktie. Deze observaties suggereren dat B cellen niet de voomaamst 
verantwoordelijke cellen zijn voor antilichaam produktie in bavianen en dat aandacht 
dient te worden besteed aan het onderdrukken van de [unktie van plasmacellen. Dit 
blijkt ook uit in vitro experimenten waarin het merendeel van anti-Gal antilichaam 
secreterende cellen CD38-positief zijn, een marker voor plasmacellen. Helaas was het 
anti-CD38 immunotoxine dat wij hanteerden in onze in vivo experimenten niet 
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effectief, onder andere vanwege een suboptimale conjugatie van het antilichaam met 
het toxine. 
In de volgende hoofdstukken wordt aandacht besteed aan de thrombotische 
complicaties die geassocieerd worden met varken-naar-baviaan xenotransplantatie. 
Het ontstaan van stollingsstoomissen en thrombocytopenie samenhangend met de 
xenotransplantatie van gevasculariseerde organen is in het verleden reeds beschreven 
en wordt door ooze onderzoeksresultaten bevestigd in Hoofdstuk 5. In dit hoofdstuk 
demonstreren wij ook dat het transplanteren van varkenshematopoietische cellen 
geassocieerd is met indrukwekkende thrombotische vasculaire schade met schadelijke 
gevolgen voor de ontvanger. Het hieraan ten grondslag liggend mechanisme is 
onduidelijk. Mogelijk spelen immuunmediatoren binnen het xenotransplantaat een rol. 
Deze zouden bijvoorbeeld thrombose kunnen bevorderen als onderdeel van een 
inflarnmatoire reactie welke optreedt na endotheelcelactivatie. In het geval van 
hematopoietische celtransplantatie IS het mogelijk dat deze cellen direct 
bloedplaatjesaggregatie veroorzaken met een hieropvolgende sequestratie van 
bloedplaatjes in de microcirculatie van de baviaan ontvangers. Ook kunnen 
individuele componenten van het conditioneringsregime bloedplaatjesaggregatie met 
thrombocytopenie veroorzaken. 
In Hoofdstuk 6 tonen wij dat varkenshematopoietische cellen aggregatie kunnen 
medieren van bavianenbloedplaa~es. Tevens presenteren Vvij dat eptifibatide, een 
GPIIb/IIIa receptor antagonist, deze aggregatie in vitro volledig kan voorkomen. Het 
venvijderen van debris uit het varkenshematopoietische stamcellen produkt en/of het 
behandelen van bavianen met eptifibatide kan helpen deze complicaties te 
voorkomen. 
Deze bevindingen worden nogmaals bevestigd in Hoofdstuk 7. T evens worden de 
individuele componenten van het conditioneringsregime beoordeeld op hun vermogen 
thrombocyten aggregatie te induceren in bavianen. Naast het feit dat geen van de 
componenten inductie van aggregatie veroorzaakt, wordt aangetoond dat 
cyclofosfamide beschermende, anti-aggregatoire eigenschappen bezit. Dit middel kan 
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derhalve in onze pogingen gemengd hematopoietisch chimerisme te bereiken een 
alternatief betekenen voor totale Iichaamsbestraling. 
Tenslotte worden in Hoofdstuk 8 andere fannacologische middelen getest op hun 
vennogen thrombocytenaggregatie te remmen in bavianen. Middelen als 
aurintricarboxylzuur en fucoidin blijken krachtige remmers van aggregatie te zijn. Het 
gebruik hiervan wordt echter verhinderd door een onaanvaardbaar hoog risico op 
bloedingscomplicaties. Heparine is een bekende remmer van thrombine-geinduceerde 
bloedplaatjesaggregatie en kan worden gebruikt in doseringen die slechts een kleine 
verlenging van geactiveerde partiele thromboplastinetijd veroorzaken. Eptifibatide 
leidt tot een zeer goede inhibitie van thrombocytenaggregatie zonder duidelijke 
bijwerkingen en is hierdoor een goede kandidaat om te gebruiken binnen onze 
toekomstige xenotransplantatieprotocollen. 
De succesvolle inductie van stabiele immunologische tolerantie in varken-naar-
baviaan xenotransplantatie zal ongetwijfeld de voorv.raarde scheppen voor klinische 
xenotransplantatie. Het bovenstaande illustreert dat vele factoren, zowel 
immunologische als andere, in de weg staan van gemengd chimerisme en tolerantie 
voor varkensorganen. Gebaseerd op voorgaande studies is duidelijk geworden dat 
anti-Gal antilichamen een groot probleem vonnen in xenotransplantatie. Wij hebben 
recent experimenten uitgevoerd (niet beschreven in dit proefschrift) om in vivo 
depletie van anti-Gal antilichamen te verkrijgen in naIve bavianen, in bavianen die 
ons tolerantie-inductieprotocol ondergaan en In bavianen die 
varkensniertransplantaten ontvangen, door albumine van kalveren geconjugeerd met 
Gal (BSA-Gal) toe te dienen. Met dit middel wordt (bijna) complete depletie van anti-
Gal antiliehamen verkregen tot 30 dagen (Teranishi and Gollaekner, ruet 
gepubliceerde data) na toediening. De terugkeer van anti-Gal antilichamen, nadat 
behandeling met BSA-Gal is gestaakt, verloopt vervolgens langzarner dan bij 
bavianen die niet met BSA-Gal worden behandeld. Naast het vermogen van BSA-Gal 
om anti-Gal antilichamen te neutralizeren, kan het waarschijnlijk ook anti-Gal 
antilichaamproducerende cellen tolerizeren door hun antigeenreceptoren te binden. 
Wij vinden derhalve dat, naast de al eerder genoemde studies gericht op het 
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ontwikkelen van middelen die de produktie van anti-Gal antilichamen kunnen 
remmen. zoals efficiente anti-plasmacel immunotoxinen, toekomstige studies gericht 
moeten zijn op het verfljnen van het gebruik van BSA-GaL 
Tevens dient het potentieel van macrofaagdepletie in varken-naar-primaat tolerantie-
inductie modellen nader onderzocht te worden en zo mogelijk gelmplementeerd te 
worden in verbeterde protocollen. Ook zal de etiologie van het v66rkomen van 
thrombotische complicaties in deze modellen bestudeerd moeten worden. 
Sarnenvattend kan worden gesteld dat in dit proefschrift een aantal van de 
belangrijkste immunologische obstakels voor klinische impiementatie van 
xenotransplantatie wordt besproken. T evens wordt inzicht gegeven in de huidige 
mogelijkheden om immunologische tolerantie te verkijgen in het pre-klinische 
varken-naar-baviaan gemengd-chimerisme model. Het probleem van anti-varkens 
antilichamen wordt toegelicht, begeleidende thrombotische complicaties worden 
beschreven en huidige en nieuwe behandelingsmogelijkheden hiervan worden 
voorgesteld. Op grond van de resultaten beschreven in dit proefschrift zal een 
protocol dat, naast de componenten van het conditioneringsregime zoals beschreven 
in Hoofdstuk 2. tevens een specifieke en effectieve anti-plasmacel immunotoxine, 
medronaatliposomen v~~r macrofaagdepletie, alsmede eptifibatide ter voorkoming 
van thrombocytenaggregatie, bevat, moge1ijk de inductie van gemengd chimerisme en 
immunologische tolerantie faciliteren. De auteur hoopt dat de experimenten en 
resultaten welke beschreven worden in dit proefschrift, van belang zijn voor de 
toekomst van xenotransplantatie en dat dit boeiende vakgebied deel zal gaan uitmaken 
van de tmnsplantatiegeneeskunde. 
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LIST OF ABBREVIATIONS 
I-BI 
3H-Leu 
aGal 
o::CD20mAb 
o::CD22-IT 
o::CD2S-lT 
ocCD38 mAb 
ocCD38-lT 
ADP 
Anti-aGal Ab: 
ATA 
ATG 
AVR 
BM 
cpp 
CVF 
dg 
DIC 
EFT 
EIA 
FDP 
GP 
HAR 
HBSS 
IT 
1. v. 
IVIg 
LDH 
LN 
I-benzylimidazole 
3H-Leucine 
galal-3Gal epitope 
anti-CD20 monoclonal antibody Rituximab 
anti-CD22-ricin A immunotoxin 
anti-CD25-ricin A irnmunotoxin 
anti-CD38 monoclonal antibody OKTI 0 
anti-CD38-ricin A immunotoxin 
adenosine diphosphate 
anti-Gala 1-3Gal antibodies 
aillintricarboxylic acid 
antithyrnocyie globulin 
acute vascular rejection 
bone marrow 
cyclophosphamide 
cobra venom factor 
deglycosylated 
disseminated intravascular coagulation 
eptifibatide 
extracorporeal immunoadsorption 
fibrinogen degradation products 
glycoprotein 
hyperacute rejection 
Hank's balanced salt solution 
irnmunotoxin 
intravenous 
intravenous immunoglobulin 
lactate dehydrogenase 
lymph node 
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mAb 
ML 
MPS 
NA 
NMCR 
NO 
NPN 
PCIx 
PGJ, 
pIL3 
POIx 
pPBPC 
PRP 
pSCF 
PI 
PTI 
ricin A 
SFU 
IM 
TIP 
vWF 
WBI 
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monoclonal antibody 
medronate liposomes 
mononuclear phagocyte system 
nicotinamide 
non-myeloablative conditioning regimen 
nitric oxide 
nitroprusside sodium 
pig cell transplantation 
prostacyclin 
porcine interleukin 3 
pig organ (kidney or heart) transplantation 
porcine hematopoietic progenitor cells 
baboon platelet-rich plasma 
porcine stem cell factor 
prothrombin time 
partial thromboplastin time 
RIA 
spot forming units 
thrombotic microangiopathy 
thrombotic thrombocytopenic purpura (rnicroangiopathy) 
von Willebrand factor 
whole body irradiation 
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